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Summary
The mortality associated with colorectal cancer is extremely high, however if the disease 
is caught at the earliest stage then there is a 95% 5 year survival. An improved screening 
technique which is less invasive than current methods may increase uptake by the public. 
Also, an increase in knowledge of the different genetic pathways of colorectal 
carcinogenesis may help to tailor treatments to individual patients.
The experiments in this thesis address these aims by searching for possible biomarkers 
which may be detectable in stool samples and by looking for early genetic alterations at 
the molecular, gene expression and chromosomal levels. This thesis also explored various 
different techniques such as single stranded conformation polymorphism, fragment 
analysis, sequencing, cDNA arrays and fluorescent in situ hybridisation (FISH).
The findings of these experiments include mitochondrial DNA mutations occurring 
frequently in late stage colorectal carcinogenesis. These mutations predominantly 
occurred in microsatellites within the mitochondrial genome. Nuclear microsatellite 
instability (MSI) levels within the South Wales population studied are within the levels 
found in the rest of the Western world. There was no correlation found between 
mitochondrial and nuclear MSI suggesting the presence of separate mismatch repair 
systems. Various genes were found down-regulated in the early stages of colorectal 
cancer, including PTEN, TGF-6RII and p21. These genes may be key to the early stage 
development of a significant proportion of colorectal cancers. I developed a FISH probe 
for p21 which was simple to make and apply, as well as being cost effective. 
Chromosome 6 aberrations were detected in an increasing frequency in samples with 
increasingly developed tumours. A large variation was found in chromosome 6 copy 
number within different regions of an individual tumour. This variation shows how 
essential it is that research and diagnostic tests are based on either large portions of a 
tumour or from multiple smaller biopsies.
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Chapter 1 
General Introduction
1.1 General introduction to cancer
Cancer is a worldwide disease. In the UK alone there are over V* million cases diagnosed 
every year, approximately 1 in every 3 of us will develop a form of cancer and 
approximately 50% of those with the disease will die as a result. In terms of financial 
cost, the annual NHS hospital costs for diagnosis, surgery, chemotherapy and other 
treatments and support for sufferers are greater than £1 billion (Department of Health 
statistics, 2005).
Cancer is defined as any malignant neoplasm; an uncontrolled growth of cells that 
exhibits invasiveness and remote growth, these neoplasms seem to evade the normal 
control from nerves or hormones (Strachan and Read, 1998). Gene expression patterns 
are different to those of normal tissue, for example, tumour suppressor genes (which are 
discussed further in section 1.1.1.5) are frequently down regulated in tumour cells 
(Kitahara et a l, 2001). There are many forms of the disease as virtually any cell type can 
become cancerous and grow in an uncontrolled manner. For example, a breast cell that 
eludes normal regulation and divides out of control may form a breast cancer tumour. If 
cells from this then grow and spread into the bloodstream or lymphatic system then the 
cancer can spread to neighbouring tissues and via the circulatory system throughout the 
body causing secondary cancerous growths. The spread of cancer cells beyond the 
original site is known as metastasis. Cancers can also form in the blood; leukaemia is a 
form of cancer in which the white blood cells proliferate. Because of the nature of the cell 
type solid tumours are not formed however the cancerous cells circulate through the body 
where they may grow in other tissues. The chance of cancer detection depends on the 
location of the neoplastic growth. For example, skin cancers are often detected at early 
stages of cancer progression as the skin is easily monitored for any signs of cell change. 
The success rate of treatment depends upon the tissue type affected and the stage of
1
progression at which the cancer has been detected at as well as the form of treatment 
selected. The incidence of the most common forms o f cancer in the UK can be seen in 
Figure 1.1.
UK Incidence 2001 : Cancers which contribute one percent or more to total
cancer burden
4 l.oec <I5%I
Lung 37,450' <14-41
M l u r g e  b o n a 34,540 03% )
|  Prostate 30,140 <11%)
Bladder 10660 <4%)
M H H H B M M  Non-Hodgkin's lymphoma 9,230' <3%l
Stomach 9.100 <3M
9 I H I S S H  Head and neck 7,820' (3%l
V S M m  O esophagus 7,480 (3%)
■ H H H I  Metanoma 7.320 (3%)
■ ■ ■ ■ ■  Pancreas 6.520 <3%l
■ ■ ■ ■  Ovary 6 8 8 0 <3%j
I H  Leukaemia 6,?eo <2%l
■ ■ ■  Kidney 5,160' <2^ 41
Lnerus 5.650 <2%l
■ H  & a n  and cen tra  nervous system 4,470 <2%)
M i Multiple myeloma 3.570 (1%)
Ml Cervix 2.540 (1%J
■  Liver 2,560 (1%)
Mesothelioma 2,060 (1%)
Other 27 940 (10%)
Persons all malKjnant neoplasms excluding non-mefanoma skin cancer 270.700 (100%)
Figure 1.1
This graph illustrates the frequency of various cancer types in the UK in 2001. From 
www.cancerresearchuk.org
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There are many factors that influence an individual’s risk of developing cancer such as 
age and, for various cancer types, sex. Lifestyle also is highly important; whilst smoking 
increases the risk of many different forms of cancer, eating a diet high in fruits and 
vegetables can lower the risk. The risk factors for colorectal cancer are discussed in 
Section 1.2.1.
1.1.1 Basic genetics of cancer
All cancer cells share a common cause, mutations or disruption to the gene expression of 
the genes which regulate cell growth, apoptosis or DNA repair (Bertram, 2001). In a 
normal cell there are highly developed systems to repair damage to the DNA of the cell, 
regulate cell growth and cell death through either necrosis or apoptosis. Tumours develop 
by the accumulation of damage to these genes and a multistep hypothesis suggests that 
for a tissue to become cancerous between 3-6 mutations are required to these growth 
control and/or repair genes (Vogelstein and Kinzler, 1993). Genomic instability is 
required to allow a sufficient amount of genetic change to accumulate to permit the 
neoplastic phenotype to develop.
1.1.1.1 Cell cycle
Cells are required to replicate in order for organisms to grow and also to replace cells 
which die either from age or as a result of cellular damage. This occurs through a process 
known as the cell cycle. The cell cycle is divided into four phases, first growth or gap 
phase (Gi), synthesis (S), second growth or gap phase (G2) and mitotic phase (M). The 
mitotic phase consists of prophase, metaphase, anaphase and telophase. These can be 
seen in Figure 1.2. The length of time taken for the cell to complete a cycle varies from 
type to type with skin cells dividing approximately every 12 hours and liver cells dividing 
every 2 years. This variation occurs when cells are not dividing and are said to be in G0 
phase (Lodish etal., 1995). Throughout the cell cycle there are checkpoints which control 
the progression through the cycle, these checkpoints are detailed in Table 1.1. The cell 
cycle is carefully regulated by cyclin dependant kinases (CDKs) which are activated by
3
cyclins and inhibited by CDK inhibitors (Grana and Reddy, 1995). The genes which code 
for these proteins are frequently mutated in cancer cells which results in uncontrolled cell 
division. The regulation of cell cycle is further discussed in Chapter 6, Section 6.1.6.1.1 
when relevant to specific parts of my thesis.
DNA
replication
Synthesis
p h a S e
£ Growth 
and 
preparation 
for mitosis
Figure 1.2
This diagram shows the phases of the cell cycle. The cycle is not shown to time scale as 
the size of each section is not representative of the time taken to complete each stage. The 
average period o f time taken to complete the cell cycle is generally considered to be 
around 16 hours. Mitosis is a short stage lasting around 1 hour with interphase lasting for 
the remaining 15 hours (Lodish etal., 1995). From www.bmb.psu.edu.
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Phase Events
Gi
Cell grows and produces RNA and synthesizes proteins
The interval between the completion of mitosis and DNA 
synthesis
Gi Checkpoint
checks if the cell is large enough and the environmental factors are
favourable
Interphase S
DNA synthesis.
The cell’s DNA is duplicated prior to cell division
g 2
Cell starts to produce proteins required for cell division
Mitochondria are duplicated to meet the increased energy 
demands of the cell
In the late G2 condensation of chromatin starts
G2 Checkpoint
assesses integrity of DNA and also checks if the cell is large enough and if 
the environmental factors are favourable
Prophase
Chromosomes condense
Centrioles move to opposite poles of the cell
Pro­
metaphase
Nuclear membrane is broken down 
Kinetochores begin to form on each chromosome
Mitosis Metaphase
Spindle fibres connect centrioles to centromere 
Chromosomes align along equator of cell
Metaphase Checkpoint 
checks the chromosomes are aligned on spindles
Anaphase
Centromeres spilt
Chromatids separate and move to opposite poles
Telophase
Spindle fibres disperse
Nuclear membranes form around each set of chromosomes
Cytokinesis
A ring of actin filaments form around the equator of the cell 
and tightens to form a cleavage furrow
The cell is divided into two daughter cells
Table 1.1
This table details the stages and checkpoints of the cell cycle
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1.1.1.2 Mutagenesis
A mutation is a change to the nucleotide sequence and can be in the form of a single base 
change or deletions or insertions to the sequence. Depending upon where in the DNA 
sequence the mutation occurs the affect of the mutation can vary from mutations in non­
coding regions which have little or no effect on the cell function to frameshift mutations 
(Strachan and Read, 1998). These latter mutation types may create a stop codon and lead 
to the production of a truncated protein with significant loss of function. For example, the 
adenomatous polyposis coli (APC) gene is frequently mutated in colorectal cancers. This 
in turn leads to the production of truncated protein and the tumour suppressor function of 
wild type APC is lost (Feamhead etal, 2001).
Single base substitutions are the most common form of mutation. These can be either 
transition or transversion mutations. Transition mutations are changes from one purine to 
another e.g., A -> G or pyrimidine to pyrimidine such as T C. Transversion mutations 
are changes from purine to pyrimidine and vice versa such as A -> T mutations. 
Transition mutations often form due to transient tautomers forming non-standard base 
pairs within the double helix. These tautomers are the rare forms of bases where, for 
example, the amino group (-NH2) on an adenosine base can tautomerize to an imino form 
(=NH) which allows the pairing of this form of adenosine to pair with cytosine (Stryer, 
1995). If not repaired, in further rounds of replication the daughter strands created would 
consist of one normal sequence of DNA and one mutated strand. Transversion mutations 
can occur as a result of damage to the bases such as an incorporation of an oxygen atom 
onto the purine guanine base. This gives rise to 8-hydroxy-2'-deoxyguanosine which can 
mispair with the purine adenosine (Grollman and Moriya, 1993). This is further discussed 
in Chapter 3, section 3.1.1.4.
1.1.13 Repair
DNA is damaged by environmental factors such as mutagenic chemicals and radiation as 
well as intrinsic factors such as oxidative damage. During DNA replication the wrong 
base is sometimes incorporated by the DNA polymerase causing point mutations or
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strand slippage can occur giving either deletion or insertion mutations. This mutational 
load would be too great for cell survival if left unchecked and so systems have evolved to 
repair the damage. There are three types of DNA repair, base excision (BER), nucleotide 
excision (NER) and mismatch repair (MMR).
BER removes defective DNA bases such as those damaged by reactive oxygen species 
(Nilsen and Krokan, 2001). Damaged bases are repaired by BER where the base is 
removed by DNA glycosylase to leave an abasic site also known as an AP site. This is 
then recognised by AP endonuclease which removes the AP site and neighbouring 
nucleotides. The resulting gap is then filled by DNA polymerase I and DNA ligase. 
Biallelic mutations in the BER DNA glycosylase gene MutYH have been found to lead to 
adenomatous colorectal polyposis and a greatly increased risk of colorectal cancer 
(Cheadle and Sampson, 2003).
NER removes bulky DNA lesions such as adducts produced by chemical carcinogens or 
UV-induced lesions (Benhamou and Sarasin, 2000). These lesions distort the DNA 
double helix which is detected and repaired by NER. During this process the 
oligonucleotide containing the lesion is excised from the DNA by endonuclease and the 
resulting single-stranded gap is then filled in by DNA polymerase I and then DNA ligase 
(Voet and Voet, 1995). Xeroderma pigmentosa (XP) is a heritable disease where patients 
have genetically defective NER. Exposure to UV irradiation from sources such as 
sunlight causes the patient’s skin to develop erythematous patches which later develop 
into skin keratoses (Komberg and Baker, 1992).
MMR repairs the DNA where errors have occurred during DNA synthesis, recombination 
or chemical damage (Kolodner, 1996). In order to establish which base is incorrect from 
a base pair the system has to be able to distinguish between the template strand and the 
newly synthesised strand. The template strand is methylated whereas the newly 
synthesised strand is not at this stage and so the strands can be differentiated. The 
incorrect bases are then excised and the gap filled by DNA polymerase DI and DNA 
ligase (Lodish et al, 1995). Mutations to the genes involved in this pathway such as
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hMSH2 and hMLHl are mutated in hereditary non-polyposis colorectal cancer (HNPCC) 
which is further discussed in section 1.3.1.
1.1.1.4 Proto-oncogenes
Proto-oncogenes are generally involved in the control of cell proliferation which, if over 
expressed, can contribute to the transformation of a normal cell into a tumour cell. Once 
activated these genes are known as oncogenes, this can occur by mutation, 
hypomethylation or by larger scale genetic damage such as gene amplification or 
chromosomal translocations or rearrangements (Laird et al, 1995; Fearon, 1996). 
Examples of these genes are K-ras which is mutated in 60% of late colorectal adenomas 
(Weinberg, 1991) and bcl-2 the over expression of which makes cells resistant to 
apoptosis (Vaux etal, 1988).
1.1.1.5 Tumour suppressor genes
Tumour suppressors are genes which in normal circumstances negatively regulate cell 
proliferation, but when mutated or down-regulated the cell can over proliferate and 
become cancerous (Collins eta l, 1997). These genes are often involved in the checkpoint 
controls of cell cycle such as p53 which when the DNA is damaged promotes either 
apoptosis or halts the cell cycle at Gi checkpoint in order for repair to occur prior to cell 
division (Lane, 1993). Hypermethylation is responsible for the inactivation of some 
tumour suppressor genes such as the mismatch repair gene hMLHl (Herman eta l, 1998; 
Cunningham etal, 1998).
1.2 Colorectal cancer
As the second most common cause of cancer related death (see Figure 1.3), colorectal 
cancer has received attention from many research groups around the world. In the UK 
over 31,000 people develop colorectal cancer annually, 13% of all new cancers 
diagnosed. Despite advances in medicine, with surgery as the main form of treatment, 
there is 70% mortality, largely due to patients initially presenting with later stages of 
colorectal cancers (Mella et al, 1997). Over 50% of Westerners develop a colorectal
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tumour by the age of 70. 1 in 10 of these will progress to malignancy (Navaratnam et al,
1999). In Wales, figures from 1994 show that there are around 2000 cases of colon 
cancer per year. Worldwide, in 1990 there were approaching 800,000 new cases 
diagnosed and 400,000 deaths with the number having risen rapidly over the last 25yrs. 
Colorectal cancer rates are lower in Africa and Asia. This is likely to be due to 
environmental and lifestyle factors such as diet, as opposed to genetic background 
because migrating populations develop similar relative risks as to the area to which they 
have migrated (Haenszel and Kurihara, 1968).
UK Mortality 2002 Cancers which contribute one per cent 
or more to total cancer mortality
Lung 33.600 (22°°)
Bowel 16.220 (10°o)
Breast 12.930 (8%)
■ ■ ■ ■ H  Prostate 9.940 (6%)
0 m i  Oesophagus 7,250 (5%)
■ ■ ■ ■  Pancreas 6.880 (4*0)
■ ■ ■ H  Stomach 6.360 (4%)
Bladder 4.910 (3%)
Non-Hodgkin s lymphoma 4,750 (3%)
Ovary 4.690 (3%)
■ H  Leukaemia 4.310 (3%)
■ ■  Brain and CNS 3,370 (2%)
Kidney 3.360 (2%)
Head and neck 3.000 (2%)
jHI Multiple myeloma 2,600 (2%)
■ 1  Liver 2,510 (2%)
Mesothelioma 1,760 (1%)
If Malignant melanoma 1,640 (1%)
|  Cervix 1,120 (1%)
1  Body ot Uterus 1,070 (1%)
Other 22.910 (15%)
Persons: all mahanant neoplasms 155.180 (100%)
Figure 1.3
This graph illustrates the mortality of cancers in the UK as surveyed in 2002. It can be 
seen that colorectal cancer is the second most common cause of cancer related death with 
10% of cancer deaths resulting from this type. From www.cancerresearchuk.org
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In Western countries approximately 60% of primary colorectal cancers arise within either 
the rectum or sigmoid and around 20% are located in the caecum (Houlston, 2001); more 
details of the proportion of colorectal cancers within each region o f the colorectum can be 
seen in Figure 1.4. Cancers of the colorectum are known, as with other cancers of 
epithelial tissue, as carcinomas.
Hepatic 
flexure 3%
Ascending 
colon 5%
Descending 
colon 5%
Sigmoid colon 
20-25%
Caecum
10- 20%
Recto-sigmoid 
5 -10%
Rectum
35-40%
Transverse 
colon 5%
Splenic flexure
3%
Figure 1.4
This diagram shows the regions of the colorectum and also the proportion of colorectal 
cancers which occur in each region. Adapted from www.hokins-gi.org and Mel la et al., 
1997.
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Although there are some similarities in the gastrointestinal epithelium of both the small 
intestine and the colon the rates of cancer incidence are very different with less than 1% 
of cancers occurring in the small intestine (Cancer Research UK, 
www.cancerresearchuk.org). There are several possible explanations for this including a 
lower rate of spontaneous apoptosis in the proliferative region of the large intestine in 
comparison to the small intestine. The rate is approximately 10 times lower in the colon, 
with an apoptotic cell occurring in around 0.1% of colonic crypt cells and proportionally 
fewer of these are in the stem cell region of the crypt (Hall et al., 1994). This reduced 
ability for the colon to remove excess stem cells may result in hyperplastic colonic 
crypts, which may become targets for carcinogenesis (Potten etal., 1997).
1.2.1 Clinical aspects of colorectal cancer
Colonic tumours may be asymptomatic or the patient may present with changes in bowel 
habit, constipation, diarrhoea, narrow stools, passage of blood or mucous par rectum, 
obstruction or rectal pain. The symptoms may also be more general such as abdominal 
discomfort including frequent gas pains, bloating, fullness and cramps. The symptoms 
also vary on the location of the lesion with the right-sided lesions resulting in weight loss 
and iron deficiency anaemia secondary to chronic occult blood loss (Petersen and 
Shepherd, 2000). The symptoms however are frequently ignored until the cancer has 
progressed to later stages. The delay in patients presenting to their doctor or delays in 
treatment are likely to be responsible for the lower survival rates in England and Wales 
compared to the rest of Western Europe.
Colorectal cancers in the UK are classified by Dukes’ staging according to how far the 
cancer has progressed (Dukes and Bussey, 1958). This classification system uses the 
letters A-D where Dukes’ A is cancer of only superficial layers of cells through to Dukes’ 
D which is metastatic disease where the cancer has spread to distant organs. These stages 
are represented and explained in Figure 1.5. Dukes’ A and B stage colon cancer have
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very high cure rates, 95% and 80% estimated 5-year survival rate respectively (Rhodes,
2000). However only around a third of new cases are diagnosed at these stages, the 
remainder are diagnosed with stage C and D colon cancer. For these later stages the 
survival rates drop to 50% for stage C and only 3-5% for stage D (Rhodes, 2000). For the 
earlier stage the usual treatment is surgery, whereas the later stages C and D are usually 
treated with a combination of surgery and chemotherapy and for rectal tumours 
sometimes radiation is used, see Figure 1.5.
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Figure 1.5
This figure shows the progression of colorectal cancer as well as the likely treatments, 
patient survival and the percent of patients that present at these stages. From 
http://www.exactsciences.com/pregen26/professionals/about_hnpcc/.
Current recommendations suggest that to detect colon cancer in these early stages, when 
the chance o f survival is highest, everyone over the age of 55 should have bi-annual
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endoscopic examinations of the colon (Winawer et al, 1997; Rex et a l , 2000). This 
comes with risks connected to the procedure itself with 1 in every 2000 colonoscopic 
examinations having complications including problems associated with sedation and 
perforation of the bowel, which can, in extreme circumstances, result in death. Screening 
using faecal occult blood tests (FOBTs) is currently being used across the UK as studies 
in other European countries and the US have shown these tests could reduce mortality by 
50% (Hobbs, 2000). A 5 year survival rate for patients with colorectal cancer should be 
achievable as this relatively recent screening programme becomes established. Although 
FOBTs are inexpensive they also have a high number of false positives which may cause 
unnecessary alarm. Only between 2-18% of those with a positive result will actually have 
cancer or large polyps (Ransohoff and Lang, 1997). As a result, FOBTs do not prevent 
unnecessary colonoscopies which are both expensive and come with the aforementioned 
risks. Barium enemas can be used to detect growths and abnormal masses and although 
uncomfortable, no sedation is required and there is no risk of bowel perforation. 
However, further examination is required in the form of a colonoscopy if anything 
abnormal is discovered and also smaller polyps or flat adenomas may be missed using 
this procedure (Winawer et al, 2000). The proportion of cancers within reach of 
sigmoidoscope has fallen to <50% within the last 20 years with tumours now tending to 
have a more proximal location (Spence and Johnston, 2001). This trend could have 
serious implications as a sigmoidoscope is often the first diagnostic test carried out and if 
cancers are being missed at this stage there is the possibility of patients being 
misdiagnosed. This shows the urgent need for a non-intrusive test such as the FOBT but 
with lower levels of both false positive and negative results.
Early colorectal lesions may be evident as simple polypoid lesions, flat adenomas or 
depressed lesions. Tumour progression is not inevitable but the factors that govern this 
are not fully understood. Cancer of the colon is mainly sporadic or non-familial with 
around 5% due to inherited syndromes such as familial adenomatous polyposis (FAP) 
and hereditary non-polyposis colorectal cancer (HNPCC), which are both discussed later. 
The adenoma-carcinoma pathway is not the only route to colorectal cancer; in ulcerative 
colitis associated neoplasm (UCAN), carcinomas arise in the absence of adenomas.
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1.2.2 Risk Factors for colorectal cancer
Over 90% of colorectal cancers occur in patients over 50 years o f age with the peak age 
of incidence occurring with people in their 70’s, as can be seen in Figure 1.6 (Ionov et 
al., 1993; Thibodeau et al., 1993). Only 1-2% of sporadic colorectal cancer patients are 
under 36 but these patients may require more drastic surgical measures, such as total 
colectomy, than older patients as the chance of a later second colorectal cancer is much 
greater. Genetic testing for MMR gene mutations and genetic counselling for the patient 
and family are also particularly important in this subset of patients (Liu et al., 1995a). 
Both males and females are almost equally at risk from this disease however recta! cancer 
is marginally more common in men (Hayne et al, 2001).
Number of new cases diagnosed and age-specific rates per 100,000 population, 
colorectal cancer, by sex, UK 2000
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Figure 1.6
Graph showing the number of new cases and cancer rates of colorectal cancer in the UK. 
From www.cacnerresearchuk.org.
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Studies have shown a positive correlation between mortality and deprivation (Boyle and 
Langman, 2000). In the United Kingdom the rates are highest in Scotland where the diet 
is generally higher in animal fats and red meats, which have been shown to increase the 
risk of colorectal cancer (Giovannucci and Willett, 1994; Sandhu, 2001). Lifestyle risk 
factors such as smoking and alcohol consumption have also been linked to a higher risk 
of developing carcinomas of the colon, whereas diets high in fibre, fruit, vegetables, 
calcium and folate help to lower that risk (Michels et al., 2000; Lipkin et al., 1999; 
Giovannucci et al., 1998). Hormone replacement therapy (HRT) in postmenopausal 
women can also reduce colorectal cancer risk (Grodstein eta l, 1998). Fibre is thought to 
reduce colorectal cancer risk by diluting any carcinogens within the stools and by 
reducing the transit time in which they travel through the colon (Burkitt, 1971). Diet is 
thought to responsible for up to 80% of colorectal cancer (Bingham, 2000).
A study feeding rats and mice a Westem-style diet for 12 weeks showed that a diet of low 
calcium and vitamin D as well as an increase in fat and phosphate cause colonic 
hyperplasia and hyperproliferation. These diets were devised by nutrient density 
equivalent to the dietary intakes of the U.S. population and were administered to the 
rodents without any additional carcinogen. As the study saw these changes in the colonic 
mucosa after such a short duration it is reasonable to consider that hyperplasia and 
hyperproliferation may be factors in tumour promotion and, based on epidemiological 
data, may contribute to eventual colonic neoplasia (Newmark et al., 1990). Further 
experiments showed that with high calcium intake, hyperplasia and hyperproliferation in 
mice and hyperproliferation in rats was reduced to the level of control amounts despite 
the levels of fat, phosphate and vitamin D remaining unchanged from the first 
experiments (Newmark eta l, 1991). These experiments provide promising evidence that 
perhaps food supplements such as calcium and vitamin D can be used to lower the risk of 
colon cancer without reducing fat and phosphate intake which is an intrinsic part of the 
meat and processed foods rich Westem-style diet. The gene for the vitamin D receptor is 
down-regulated in colorectal cancers and may explain the need for increased intake in 
these patients (Kitahara eta l, 2001).
15
Non-steroidal anti-inflammatory drugs, (NSAIDs), reduce the risk of colorectal cancer as 
proved by epidemiological studies and data from murine models. There is a decreased 
death rate for colorectal cancer associated with aspirin use; the size and number of 
tumours are reduced by the NSAID sulindac in patients with the hereditary disease 
familial adenomatous polyposis (FAP). These drugs inhibit cyclo-oxgenase (COX) genes, 
which results in a decrease in prostaglandin production (reviewed in Prescott and White, 
1996). NSAID derivatives that lack ability to inhibit COX also inhibit tumour growth, 
which demonstrates that there are other additional cellular targets of NSAIDs (He et al., 
1999).
Chemical carcinogens such as those in the diet often cause transversion mutations and 
have signature mutations, but these have not been found in colorectal cancers implying 
that the mutations arise spontaneously and that diet affects tumour development by 
another mechanism. It is though more likely that the signature mutations are not seen as 
there are many different chemicals acting and a distinct pattern cannot be traced to any 
specific mutagen (Ilyas etal, 1999; Greenblatt, 1994).
Another lifestyle factor that affects the relative risk of developing colorectal cancer is the 
level of physical activity. People with sedentary occupations are more at risk of 
developing colorectal cancer than those whose jobs are more physically demanding 
(Mehigan and Monson, 2000).
Colonic flora have also been associated with colorectal cancer. The colon is host to a 
large variety of anaerobic bacteria which live within the colon, many of which are 
essential for fermentation of carbohydrates and also help to lower colorectal cancer risk 
by increasing stool mass by the increase in microbial biomass (Bingham, 1996). 
Conversely, Escherichia coli and a virulent variant of Helicobacter pylori have both been 
linked with an increase in colorectal cancer risk (Swidsinski e ta l, 1998; Shmuely e ta l, 
2001). All the factors discussed here that influence colorectal cancer risk are summarised 
in Figure 1.7.
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Figure 1.7
This diagram summaries the factors which increase (in the red arrow) and decrease (in 
the green arrow) the risk of colorectal cancer.
1.2.3 Genetic pathways of colorectal carcinogenesis
The study of colorectal cancer has been facilitated as all the stages of colorectal cancer 
from normal mucosa to metastatic disease can often be studied from a single patient and 
as a result many of the details of the genetic pathways o f colorectal cancer have become 
established. Vogelstein and Fearon published the first proposed pathway of colorectal 
carcinogenesis in 1990 outlining the genetic changes which occurred as tissue changed 
from normal colonic epithelium through the adenoma stage through to carcinoma, see 
Figure 1.8. Since this paper there have been many additions and alterations to this 
pathway proposed with, for example, colorectal carcinomas arising from mismatch repair 
deficient cells following an alternative pathway than the majority of colorectal cancers.
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The mismatch repair pathway is further discussed in Chapter 4, section 4.1.5. These 
pathway diagrams are often termed Vogelgrams after the author of the first proposed 
pathway.
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Figure 1.8
This diagram is a copy of the first proposed pathway of colorectal carcinogenesis 
published in 1990 by Vogelstein and Fearon. At the time of publication chromosome 
18q21 was identified as key in the progression from intermediate adenoma to late 
adenoma but it was not known which of the genes on this chromosome region, deleted in 
colorectal cancer (DCC), deleted in pancreatic cancer (DPC) or JV18-1 were involved.
As more research is carried out these pathways can become more detailed and alternative 
pathways become substantiated by evidence. Detailed clinical studies have also enabled 
the classification of tumours into these different pathways by various features. For 
example, colorectal cancers can be divided into two different groups, mucinous and non-
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mucinous, according to the presence or absence of secretory mucins in the carcinoma 
tissue. These different phenotypic groups of colorectal carcinoma are thought to arise via 
different genetic pathways as mucinous tumours have a higher frequency of K-ras 
mutations and a low level of p53 mutations as well as other differences such as 
overexpression of the tumour suppressor p21 and the intestinal mucin coding gene 
MUC2 (Hanski, 1995; Backertetal., 1999).
The study of hereditary colorectal cancer has also provided information not only of these 
diseases but also of the sporadic cases which account for the majority of colorectal cancer 
cases.
1.3 Hereditary Colorectal Cancer Diseases
1.3.1 Hereditary non-polyposis colorectal cancer (HNPCC)
Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominant disease 
responsible for approximately 5% of colorectal carcinomas in Western society. HNPCC 
is the most common form of heritable cancer. Patients have a germline mutation in one of 
several mismatch repair genes. 98% of the mutations are in the hMSH2 or hMLHl genes 
with hPMS2 mutated in most of the remaining cases (Liu et al, 1996). The germline 
mutation gives a heterozygous phenotype, a later somatic mutation in the other copy of 
the gene results in a loss of heterozygosity. The result is a defective mismatch repair 
system that gives rise to microsatellite instability. Tumours formed due to this are termed 
replication error positive as they show major microsatellite instability that reflects the 
deficiency of mismatch repair. These tumours are predominantly found on the right side 
of the colon. The patient may also develop cancers in the small intestine, stomach, ovary, 
bladder and endometrium.
Around 60% of HNPCC adenomas have high levels of MSI (MSI-H) (Hamilton and 
Aaltonen, 2000). In adenomas with microsatellite instability, 50% were found to have 
mutated copies of the APC gene. This is a similar spectrum to that found in FAP and
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sporadic colorectal cancers. The p-catenin gene was mutated in 14% of the adenomas and 
has been shown to be associated with microsatellite instability (Akiyama et al, 2000). 
TGF-p RE also has a crucial role in HNPCC tumourogenesis.
The majority of cases are diagnosed when the patients are in their 40’s. Unlike FAP and 
sporadic colorectal cancers which affects males and females equally, in HNPCC the sex 
ratio of patients is 1.5:1 males: females. Despite the name of the disease, HNPCC 
patients do have polyps, up to 10-20, but these are present at far lower levels than patients 
with the heritable condition FAP who have hundreds to thousands of polyps.
The Amsterdam criteria were established for the clinical identification of HNPCC. The 
revised diagnostic criteria known as Amsterdam criteria II state that there should be at 
least three relatives with an HNPCC-associated cancer: colorectal cancer, or cancer of the 
endometrium, small bowel, ureter or renal pelvis. One patient should be a first degree 
relative of the other two, at least two successive generations should be affected, at least 
one tumour should be diagnosed before age 50, FAP should be excluded in the colorectal 
cancer cases and tumours should be verified by histopathological examination (Hamilton 
and Aaltonen, 2000).
13.2 Familial adenomatous polyposis (FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominant genetic disease with an 
incidence of 1/7000. It accounts for less than 1% of colorectal cancers in the United 
States (Navaratnam et al, 1999). Patients with FAP have a germline mutation in the APC 
gene that leads, after further mutations of other genes, to profuse polyposis of the colon 
with, by definition, >100 polyps. The polyps themselves are benign but as they often 
number into their 1000s it is an almost certainty that some will progress into carcinomas. 
Mutations at the 3 ’ region of the APC gene gives attenuated phenotype with fewer polyps 
and a later onset of cancer (Brensinger etal, 1998; Spiro et al, 1993). For FAP patients 
there is an almost 100% chance of developing colorectal cancer by the age of 40yrs 
although the onset of cancer occurs in most patients between 10-30yrs (Mehigan and
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Monson, 2000). The rate limiting step in the initiation of tumours in FAP patients is the 
somatic mutation of the wild type APC allele inherited from the non-infected parent 
(Levy et al, 1994). Unlike HNPCC where tumour progression is accelerated, in FAP it is 
the initiation of tumours that is increased (Lynch et al, 1996). The treatment for the 
disease is often a total colectomy. Other manifestations of the disease include retinal 
lesions, desmoids of the skin, brain tumours and benign bone tissue tumours called 
osteomas.
1.3.3 Ulcerative colitis associated neoplasm (UCAN)
Ulcerative colitis associated neoplasm is another route to colorectal cancer. Ulcerative 
colitis is a condition in which the lining of the colon becomes inflamed and develops 
ulcers. Patients with ulcerative colitis are offered regular screening colonoscopies as they 
have a higher risk of developing colorectal cancer which increases according to the 
length of time the disease has been present up to a 18% increased risk after 30 years 
(Eaden et al, 2001). UCAN is much less common and follows a different pathway than 
the previously mentioned diseases. K-ras mutations in UCAN tumours are half as 
frequent as they are in sporadic cases (Redston et al, 1995; Benhattar and Saraga, 1995). 
Also, p53 allele loss occurs in most dysplasias preceding the appearance of cancer 
(Brentnall et al., 1994). Crohn’s disease is another condition in which the lining of the 
colon becomes inflamed and again carries an increased risk of colorectal cancer (Gillen et 
al, 1994).
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1.4 General aims of this thesis
The mortality associated with colorectal cancer is extremely high, however if the disease 
is caught earlier at Dukes’ stage A then there is a 95% 5 year survival. As well as 
increased awareness of colorectal cancer, it’s symptoms and risk factors, an improved 
screening technique which is less invasive than current methods such as colonoscopy 
may increase uptake by the public. Also, an increase in knowledge of the different 
genetic pathways of colorectal carcinogenesis may help to tailor treatments to individual 
patients.
The experiments described in this thesis address these aims by searching for possible 
biomarkers which may be detectable in stool samples and by looking for early genetic 
alterations at the molecular, gene expression and chromosomal levels.
1.5 Hypothesis
By researching the pathways of colorectal cancer, potential molecular markers for the 
detection of early stage cancers may be identified.
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Chapter 2 
General materials and methods
2.1 General technical information
All research was performed wearing suitable safety clothing including sterile powder- 
free latex gloves (Diamond grip plus, Microflex, Vienna, Austria). All surfaces were 
cleaned using 70% ethanol prior to each experiment. Filter tips and microcentrifuge 
tubes were obtained from Starlab (UK) Ltd (Milton Keynes, UK). All glassware, 
plastics and solutions were sterilized either by autoclave or filter sterilization and all 
water used was deionised, purified water (Milli-Q plus PF, Millipore). This chapter 
contains general materials and methods used, for the specific use of each technique 
there is more detail in the relevant chapter.
2.2 Sample collection
Ethical consent was gained for the samples to be taken for research. Informed consent 
was then obtained from each patient wishing to participate prior to either endoscopy 
or surgery. Samples were taken either from Mr. J. Beynon’s endoscopy clinic or from 
tissue removed from surgery, both at Singleton Hospital, Swansea. Biopsies from 
endoscopy clinic were divided into two parts with a sterile scalpel with one part taken 
to the pathology department for diagnostics and the remaining tissue available for this 
research. For the tissue taken from surgery these samples were taken to the pathology 
department where the consultant pathologist opened up the specimen, washed the 
surface of the colorectum with water, dried the specimen by blotting with disposable 
towels and provided advice from where to sample the tissue. Samples in all cases 
were taken from the colorectal tumour as well as normal mucosa adjacent to the 
tumour and distant to it. If the carcinoma was large enough, samples of the tumour 
from a central location and the periphery of the tumour were collected. Where 
possible, samples were also taken of polyps and of lymph nodes where these were 
suspected to be metastatic. At a later date the pathology reports on the samples were
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received after Dr. Varsha Shah of the histopathology department, Singleton Hospital, 
Swansea, had carried out the histology on the remaining tissue.
The samples were taken differently depending on the further experiments to be carried 
out. For DNA extractions the samples were placed inside sterile bijoux tubes; for 
RNA extractions the samples were thinly sliced and placed immediately into 
RNALater completely immersing the tissue and gently agitated to ensure the slices 
were broken up to allow penetration of the RNA preservative. For FISH, brushings 
were taken using cytology brushes which then had the brush end cut off and immersed 
in 10ml ETN buffer (0.1M EDTA, 0.01M Tris-HCl, 0.02M NaCl2). All samples were 
placed on ice immediately. On return to the laboratory the tissues were kept at -20°C 
and samples in RNA later kept at 4°C until use. The brushings were processed 
immediately as described below.
2.2.1 Brushings
The cytology brushes were immersed in 10 ml ETN buffer and the cells then 
suspended into the buffer by vortexing. The brush was then removed and the cells 
spun down at 9000 x g for 10 minutes. The supernatant was discarded and cells re­
suspended in a further 10ml ETN prior to centrifugation at 9000 x g for 10 minutes. 
To ensure the cells were properly washed, this step was repeated once more. The cells 
were then re-suspended in between 0.5ml and 1ml ETN depending on pellet size and 
lOOpl applied to a cytospin and spun onto coded slides at 9000 x g for 8 minutes. 
After air-drying the cells were fixed in 90% methanol at -20°C for 10 minutes. The 
slides were then air dried and stored at -20°C until use.
2.3 DNA extraction
2.3.1 Fresh tissue sample disruption for isolation of genomic DNA by 
phenol/chloroform extraction
Between approximately 6mg and 200mg of colonic tissue was used for each DNA 
extraction depending on sample size available. The tissue was suspended in 10pl of
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STE buffer (0.1M NaCl, 0.05M trizma base, O.OIM EDTA) and dissected into small 
pieces using a scalpel on a glass slide prior to homogenisation. This aided the break 
down of the cells and was especially important for the mucosa samples, which were 
more difficult to homogenise given the elastic property of this tissue type. The sample 
was then transferred to a glass (Dounce) homogeniser with 300pl STE and was 
thoroughly homogenised. The homogenate was then added to 200pl STE, lOOpl SDS 
(lOg/lOOml lauryl sulfate) and 40pl proteinase K (lOOpg/ml) prior to incubation at 
55°C for lh under continuous agitation. Total genomic DNA was isolated from the 
tissue samples by either phenol-chloroform extraction or using a high salt DNA 
extraction kit (Stratagene).
2.3.2 DNA extraction - Phenol/chloroform
For each sample, 600pl phenol was added and shaken to form an emulsion. The 
organic and aqueous fractions were separated by centrifugation for 5 minutes at 
10,000 x g and the latter phase transferred to a fresh tube taking precaution not to 
draw any cellular debris with the fluid. To this was added 300pl phenol and 300pl 
chloroform and the process repeated. Following this the procedure was repeated using 
600jil of chloroform. The nucleic acid was recovered by precipitating with 600pl iso­
propanol. The nucleic acid was centrifuged and supernatant discarded prior to 
washing with ice cold 70% (v/v) ethanol. The washed nucleic acid was then 
centrifuged and air-dried in an incubator at 37°C for lh. The DNA was resuspended 
in lOOpl sterile H2O and stored until use at 4°C.
2.3.3 DNA extraction from tissue samples - high salt extraction
DNA was extracted using the Stratagene DNA extraction kit. Between approximately 
6mg and 200mg of colonic tissue was used for each DNA extraction. The tissue was 
dissected into small pieces using a scalpel on a glass slide prior to homogenisation. 
The sample was then transferred to a 15ml glass homogeniser (Wheaton, USA) and 
was homogenised in 7ml lysis buffer (lOmM Tris-HCl, pH 8.2, 400mM NaCl, 2mM 
EDTA). The resulting cell suspension was transferred to a 15ml centrifuge tube and 
100|ig/ml pronase (Stratagene) added before incubation, with shaking, at 37°C
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overnight to fully lyse the cells. The samples were then chilled on ice for 10 minutes. 
2.5ml of 6M NaCl was added and incubated on ice for a further 5 min to precipitate 
the proteins. This precipitate was pelleted by centrifugation for 15min at 8000 x g 
after which the supernatant containing the nucleic acids was transferred to a sterile 
0.5ml centrifuge tube and incubated with 20jig/ml RNase (Stratagene) for 15 min at 
37°C. DNA was precipitated an equal volume of iso-propanol, DNA was centrifuged 
and supernatant discarded prior to washing twice with ice cold 70% (v/v) ethanol. The 
washed nucleic acid was then centrifuged and air-dried in an incubator at 37°C for lh. 
The DNA was resuspended in lOOpl sterile H2O and stored until use at 4°C.
2.3.4 DNA quantification
DNA concentration was determined using a Beckman DU-65 spectrophotometer. 
DNA was diluted with H20  before adding to a lOOpl 1cm quartz cuvette. Readings of 
optical density were taken at 260nm to calculate DNA concentration (pg/ml) using 
the equation:
DNA concentration (pg/ml) = optical density260nm x spectrophotometric conversion x 
dilution factor x pathlength
DNA concentration (pg/ml) = A260 x 50pg/ml x dilution factor x 1
DNA solutions were diluted to a working concentration of 0.1 pg/pl and stored at 4°C.
The remaining stock DNA solutions were stored at -20°C.
2.4 Polymerase Chain Reaction
The polymerase chain reaction (PCR) reaction mixtures were set up in thoroughly 
cleaned laminar flow hoods (MDH) in a dedicated PCR laboratory. Pipettes (Finn 
pipette, Thermo Life Sciences) solely for PCR were used with filter tips to prevent 
contamination. 200pl thin walled tubes were used for all reactions to ensure a rapid 
temperature change within the vessel. All tips and tubes used were autoclaved and 
opened only within the flow hoods. Racks and pipettes were cleaned with 70% 
ethanol prior to use.
The PCR reaction mixture consisted of 5pl reaction Buffer A (50mM KC1, lOmM
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Tris-HCl pH 9, 0.1% (v/v) Triton®X-100, Promega), 3pl MgCl2 (25mM, Promega), 
1 jlxI of each dNTP (200pM, Promega), 20pmol of each primer, lpl DNA, 1 unit Taq 
DNA polymerase (Promega) and filtered sterilized deionised H20  to a final volume of 
50pl. Reaction mixtures were briefly vortexed to ensure uniform distribution within 
each tube and centrifuged for 30 seconds prior to thermal cycling (PTC-225 Peltier 
thermal cycler, MJ Research).
The PCR parameters used were denaturation at 94°C for 2 min to ensure complete 
denaturation of the template DNA followed by cycles of denaturation at 94°C for 2 
min, primer annealing at 59°C for 30 seconds and primer extension at 72°C for 1 min. 
For the last cycle, a further 5 min stage at 72°C occurred to ensure full double­
stranded molecules had been produced. Cycle numbers were optimised for each set of 
primers to prevent the production of ambiguous PCR products that suggests the 
plateau phase of PCR has been reached. Optimisation of this PCR protocol in terms of 
MgCl2 volume, primer annealing temperature, annealing and extension time and cycle 
numbers for each primer set, as well as primer sequence can be found in the relevant 
chapters.
2.5 Electrophoresis
2.5.1 Polyacrylamide gel electrophoresis
The PCR products were primarily checked by running on a 6% polyacrylamide gel. 
Each gel was prepared using 3.75ml 10 x TBE buffer (0.09M trizma base, 0.09M 
boric acid, 0.002M EDTA), 7.5ml liquid polyacrylamide (acrylamide: bisacrylamide 
[29:1], NBL Gene Sciences) diluted in 27.25ml deionised H20 . The solution was 
vacuum degassed for 5min prior to polymerisation with llOpl APS (lOg/lOOml 
ammonium persulfate) and 22.5pi TEMED (Life Technologies). The solution was 
poured into a glass gel cast (Protean III gel system BIO-RAD), a 15 tooth gel comb 
inserted and allowed to set at room temperature for a minimum of 30 minutes. The 
gels were loaded in designated wells with 7pl PCR products mixed with 2pl loading 
buffer (1% v/v bromophenol blue, 0.1M EDTA, 1% v/v SDS, 50% v/v glycerol). The 
samples were run alongside a marker consisting of lpl lOObp DNA ladder (Promega), 
2pl loading buffer and 5pi water. Gels were placed in vertical electrophoresis tanks
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(BIO-RAD) filled with 1 x TBE buffer. Each gel was run at a consistent MOV 
supplied by a power pack (BIO-RAD, Power Pac 300) and electrophoresis was 
stopped after 35min when the loading dye was close to the end of the gel.
2.5.2 Agarose gel electrophoresis
3% agarose gels were made by melting 3g of agarose into 100ml TBE in a microwave 
set at medium power until the agarose had just melted and was mixed by gentle 
swirling taking care not to incorporate air bubbles. This solution was then poured into 
gel moulds, a ten tooth well comb inserted, covered to prevent contamination and left 
to set for 40 min. These gels were run on horizontal gel electrophoresis tanks at 100V 
for 2 hr or until the loading dye had run a sufficient length.
2.5.3 Silver staining
For non-quantative staining the gels were silver stained. Each gel was placed in 0.1% 
silver nitrate (Sigma) for 5 min, washed twice with H2O and then incubated for 5 min 
in 1.5% sodium hydroxide (Fisher) and 0.15% formaldehyde (Sigma) to develop the 
gel and visualise the PCR products and marker lane.
2.5.4 SYBR gold staining
The fluorescent stain SYBR gold (Molecular Probes) was used to visualise the DNA 
bands. The polyacrylamide gels were incubated in the stain (1 Ojj.1  SYBR gold, 100ml 
1 x TBE buffer) in the dark at room temperature for lhr.
2.5.5 Image capture of gels
Images of gels once stained were obtained using the GelDoc 2000 (BIO-RAD) 
system. Silver stained gels were illuminated using white light and focused manually 
for clarity. Images of SYBR gold stain gels were captured under UV light to excite 
the stain bound to the DNA. Images were saved to computer and hard copies 
produced using heat sensitive printer paper by a thermal printer (P91, Mitsubishi, 
Japan).
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2.6 PCR purification
PCR products were purified using a QIAgen PCR purification kit (QIAgen) to remove 
excess primer, free nucleotides and short DNA fragments less than 40bp from the 
PCR products. The kit was used as instructed by the manufacturer using a 
microcentrifuge. 200pl buffer PB was added to 40pl of PCR product, the sample 
mixed and applied to the QIAquick column to bind the DNA to the silica-gel 
membrane. The column was centrifuged for 1 min at 11,000 x g and the flow through 
discarded. The membrane was washed with 0.75ml buffer PE and centrifuged for 1 
min at 11,000 x g, the flow through was discarded and the column centrifuged again 
for a further 1 min at 11,000 x g to remove any traces of the wash buffer. The column 
was transferred to a new 1.5ml microcentrifuge tube and the DNA eluted by adding 
30pi H2O directly to the membrane, incubated at room temperature for 1 min prior to 
centrifugation for 1 min at 11,000 x g. The resulting purified PCR product was stored 
at 4°C until use.
2.7 Single Stranded Conformational Polymorphism (SSCP)
2ml of deionised formamide (Sigma) and 2ml of loading buffer was added to 2ml of 
each purified PCR product, these were well mixed and heated to 95°C on a 
thermocycler for 10 minutes. After this they were immediately taken from the 
thermocycler and pushed into ice and put into a freezer at -20°C for 10 minutes. The 
samples were then loaded into wells of a 10% polyacrylamide gel; loaded gels were 
then placed in vertical electrophoresis tanks (Hoeffer SE 660) filled with 1 X TBE. 
Each gel was run at MOV supplied by a power pack (Pharmacia, EPS 3500XL) for 16 
hours at 4°C. The gels were then stained with silver staining and the image captured 
on the gel doc system as described in sections 2.5.3 and 2.5.5 respectively.
2.8 DNA Precipitation
Purified PCR products were precipitated using 3pi 3M sodium acetate and 75pi ice- 
cold ethanol per 30pl sample. After incubation for 30 min at -20°C the DNA was 
pelleted by centrifugation for 15min at 10000 x g at 4°C using a desktop centrifuge
(Micromax, International Equipment Company, USA). The supernatant was carefully 
discarded and the remaining DNA pellet washed for 15 min in 70% ethanol on a cell 
washer (CM4400, Voss). The washed DNA was centrifuged for 15min at 10000 x g at 
room temperature, the supernatant discarded and the pellet dried in an incubator 
(Forma Scientific) at 37°C for 1 hour. The DNA was then resuspended in lOpl H2O.
2.9 Sequencing
DNA concentration of the purified precipitated PCR products was determined as 
described in section 2.3.5. The sequencing reaction was prepared on ice with all 
reagents stored in a cold block until use. Each sequencing reaction contained 
deionised H2O to a total volume of 20pl, 0.5pl-10pl DNA template, 2pl of 
oligonucleotide primer at 1.5pmol/pl and 8pl quick start master mix (Beckman 
Coulter). The sequencing reactions in each 200pi thin-walled tube (ABgene) were 
mixed thoroughly by pipetting and briefly centrifuged prior to thermal cycling (PTC- 
225 Peltier thermal cycler, MJ Research). 30 cycles of thermal cycling occurred each 
consisting of 20 seconds at 96°C, 20 seconds at 50°C and 4 min at 60°C. The resulting 
product was ethanol precipitated, purified and sequenced on a Beckman CEQ 8000 
sequencer. Several samples were sequenced in the Beckman CEQ 8000 sequencer in 
the laboratory; however, due to technical problems the majority were sequenced by 
Oswel Research Products Ltd (UK) using ABI 377 96 lane fluorescent DNA 
sequencing technology.
2.10 Fragment analysis
Labelled fragments were generated by carrying out PCR with primers labelled with 
WellRed dye (Invitrogen). During preparation all PCR reagents were kept on ice. The 
resulting labelled fragments were diluted 1:10 with SLS (sample loading solution) 
and, depending on the efficiency of the PCR reaction, 1 pi -  5 pi of this was added to 
40pl SLS and 0.125pi of WellRed dyelPA (red) labelled CEQ DNA size standard - 
400 (Beckman). These were well mixed and applied to a 96 well plate and a drop of 
sterile mineral oil (Beckman) added to prevent evaporation. The prepared samples 
were loaded into and run on the CEQ 8000 using separation method “frag 3” for 
fragments of size range 60-400bp. As the primers for the different MSI markers had
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been labelled with different coloured WellRed dyes it was possible to multiplex these 
samples in a single well. For these samples an equal volume of each labeled PCR 
product was added to the SLS and size standard with the exception of the products 
labelled with the blue dye as this has a stronger signal. For these products around a 
third less PCR product was added to the mix to give a balanced signal intensity.
2.11 RNA extraction and quantification
2.11.1 RNA extraction
The fume hood, used solely for the extraction of RNA, and all equipment to be used 
was thoroughly cleaned using RNaway to remove RNase. RNA extraction was carried 
out using a QIAgen RNeasy extraction kit with the supplied protocol slightly 
modified for optimal RNA yields from fresh tissue samples. The samples were 
dissected into small pieces using a sterile scalpel on a clean slide. These tissue pieces 
were then transferred into 2ml microcentrifuge tubes and 1.5 ml Trizol added prior to 
homogenisation with rotor-stator homogeniser to disrupt and homogenise the tissue. 
The resulting cell suspension was then incubated at room temperature for 5 minutes. 
300ml chloroform was added and shaken vigorously for 15 seconds prior to 
incubation at room temperature for 3 minutes. This was then centrifuged at 9000 x g 
for 15 min at 4°C. The aqueous phase was transferred to a clean 2 ml microcentrifuge 
tube. 1 volume 70% etOH was added and mixed immediately. The sample was then 
applied to RNeasy midi column and centrifuged for 5 minutes at 9000 x g. The flow 
through was discarded, 700gl RW1 reagent was applied and left to incubate at room 
temperature to stand for 5 minutes prior to centrifugation for 15 seconds at 9000 x g. 
The column was then placed in a new tube and the column washed twice with 500gl 
RPE reagent followed by centrifugation for 2 minutes at 9000 x g. The column was 
transferred to a new 1.5ml lockable tube and the RNA was eluted by applying 30pl 
H2O to the column and leaving to stand for 10 minutes prior to 1 min centrifugation at 
9000 x g.
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2.11.2 Quantification of RNA
RNA concentration was determined using a Beckman DU-65 spectrophotometer. 
RNA was diluted with H2O before adding to a lOOpl 1cm quartz cuvette. Readings of 
optical density were taken at 260nm and the concentration calculated using the 
equation:
RNA concentration (pg/ml) = optical density260nm x spectrophotometric conversion x 
dilution factor x pathlength
Concentration of RNA sample (pg/ml) = A260 x 40 x dilution factor x 1
To establish the purity of the RNA the samples were diluted in lOmM Tris-Cl, pH7.5 
buffer, which is more sensitive than water in detecting protein contamination. 
Readings of optical density were taken at 260nm and 240nm and a A260/A240 ratio 
calculated to determine the quality of the extracted RNA in terms of purity with 
respect to contaminants such as protein, which absorb UV.
2.12 Arrays
2.12.1 Array hybridization
GEArray Original Series Human Cancer/Tumour Suppressors Gene Array nylon 
membrane arrays were obtained from SuperArray and were used as directed by the 
manufacturer’s instructions. The arrays were composed of 23 tumour-suppressors, 
two housekeeping genes P-actin and GADPH as well as bacterial plasmid pUC18 as a 
negative control. The gene list can be found in table 5.1. The images were captured 
using the ChemiDoc system from Bio-rad and the array spot intensities measured 
using the GEArray software package.
2.12 Array analysis
The first stage of the analysis is a consolidation stage. As each gene had at least 2 
spots per array, a mean value for these intensities was produced using GEArray
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software. Analysis was then undertaken to allow meaningful comparisons between 
array experiments to be made. The first stage of this analysis is the removal of 
background noise levels. pUC18 is a bacterial plasmid included on the array as a 
negative control as there should be none of this RNA present in human tissue 
samples. The areas on the array for pUC18 confirm there has been no contamination 
of the array or sample and the intensity level at these spots are used in the array 
analysis to subtract background noise from the intensities of the cDNA spots. 
Following the subtraction of background noise, the arrays are normalised so that 
arrays can be compared. This is carried out by dividing the spot intensities by the 
average intensity of the constitutively expressed housekeeping gene p-actin. This 
allows analysis to be undertaken between arrays of, for example, normal mucosa and 
polyp samples. Ratios were calculated of the expression level of, for example, polyp 
tissue, divided by the expression level of the normal mucosa. The data were then log2 
transformed to correct for gene expression ratios which give down-regulated genes 
lower ratios than up-regulated genes which have altered by the same fold difference 
(Quackenbush, 2002). This treatment of the data gives genes which are up-regulated 
by a factor of 2 a log2 ratio of 1 and genes down-regulated by a factor of 2 have a log2 
ratio of -1. Genes which do not alter in expression have a log2 ratio of 0. Fold changes 
in gene expression are calculated by taking the anti-log2 of the absolute value of the 
log2 ratio. This is either an increase or decrease in expression change according to the 
positive or negative value of the log2 ratio respectively.
2.14 FISH
2.14.1 Pepsin treatment of slides
Slides were treated with pepsin to digest the cellular proteins in the cells to allow the 
FISH probes and DAPIII to penetrate the nuclei of each cell. The pepsin (300pl/ml 
0.01M HC1 pH 2.8) (Sigma) and slides were preheated to 37°C prior to application of 
pepsin for between 0.5 and 7 minutes at 37°C depending upon the cell density on each 
slide. The pepsin was deactivated by washing the slides for 5 min in phosphate 
buffered solution (PBS) followed by 5 min in PBS/50mM MgCh at room 
temperature. A wash for 2 minutes in 2 x SSC followed. The slides were then
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dehydrated by washing in an ethanol series consisting of 70%, 80% and 95% etOH 
for 2 minutes in each. The slides were air dried prior to storage until use at -20°C.
2.14.2 FISH with Abbott probes
Commercially available spectrum green labelled centromeric probes for chromosome 
6 were purchased from Abbott. Slides were prepared as described above and warmed 
to 37°C on a slide warmer (Cytocell EC3-133, JLS Ovens Ltd, Birmingham, UK). A 
probe mixture was made in a black microcentrifuge tube with 3.5pi hybridisation 
buffer, lp l H2O and 0.5pi probe per slide. 5pi of this mixture was then added to the 
cytodot on each slide and covered with a 1.5cm x 1.5cm plastic coverslip (Oncor). To 
hybridise the probe with the DNA of the cells, the slides were placed on a covered 
hotplate at 73°C for 2 minutes and then hybridized in a lightproof humidity chamber 
in an incubator at 37°C for 30 minutes. The slides were then washed in 0.1% SSC at 
73°C for 2 minutes followed by a wash in 2xSSC with 0.3% Nonident P40 for 30 
seconds. Slides were air dried and counterstained with lOpl DAPI II (125ng/ml) and 
the anti-fade p-phenylenediamine in PBS and glycerol (Vysis, UK) for lOmin prior to 
viewing.
2.14.3 Scoring
FISH slides were viewed using an Olympus BX 50 epifluorescence microscope and 
images captured using a charge-coupled device (CCD) camera operated using Mac- 
Probe 4.1 software (Applied Imaging, UK). Slides were numerically coded without 
reference to the histology of the sample to eliminate any bias on scoring. For each 
sample, 400 complete nuclei were scored, depending upon slide quality this was 
between 1 and 5 slides per sample. This was then repeated to give a minimum total of 
800 nuclei scored per sample. Only clearly defined complete, evenly stained nuclei 
were scored to avoid including any partial or overlapping nuclei. Nuclei with no clear 
probe signal were not scored to ensure only sufficiently hybridized nuclei were 
scored.
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2.14.4 The selection and amplification of clones
Clones were obtained from Children’s Hospital Oakland Research Institute (CHORI). 
The clones acquired were RP1-108K11, RP3-431A14 and RP11-52A1. The clones 
were shipped as bacterial LB agar stab cultures. The plasmids were harboured in 
DH10 E.coli. These host cells were grown in the presence of 20pg/ml 
chloramphenicol for bacterial artificial chromosome (BAC) clones and 25pg/ml 
kanamycin for PI artificial chromosome (PAC) clones to select for E.coli that had 
taken up the plasmids. Upon receipt, the bacteria were inoculated into universal tubes 
containing 15 ml of LB medium containing the relevant antibiotic at the above 
concentrations and grown overnight in a shaking incubator at 37°C. Stocks of the 
transformed bacteria were frozen at -85°C after the addition of 25% glycerol. 
Remaining cultures were then used to harvest plasmids containing the clones.
2.14.5 Plasmid extraction
To isolate the plasmids, two overnight 15ml cultures for each clone were spun down 
at 9000 x g for 15 minutes and the pellets pooled prior to plasmid extraction using the 
QIAgen spin miniprep kit. The kit was used as per the manufacturer’s instructions 
using the recommended amendments for larger plasmids. The pellets were 
resuspended in 500pl Buffer PI containing RNase and transferred to a 2ml 
microcentrifuge tube. 500gl Buffer P2 was added and the solution gently mixed by 
inverting the tube until the solution became viscous and slightly clear. In all cases this 
was within 5 minutes. 700pl Buffer N3 was added and the solution thoroughly mixed 
by inverted the tube repeatedly. The cellular debris was separated from the solution by 
centrifuging for lOmin at 11,000 x g and the supernatant removed and applied to the 
QIAprep column. This was the centrifuged for 1 min at 10,000 x g and the flow 
through discarded. The column was then washed with 750pl Buffer PB and 
centrifuged for 1 min at 10,000 x g. This stage was necessary to remove the nuclease 
activity of the DH10 E.coli. The flow-through was discarded and the column 
centrifuged for a further 1 min at 10,000 x g to remove any remaining traces of wash 
buffer. The column was placed in a fresh sterile microcentrifuge tube. To elute the 
vector 30pl H2O at 70°C was added to the column and left to stand at room 
temperature for 1 min before centrifuging at 10,000 x g for 1 min. A further 30pl of
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H20  at 70°C was added and left to incubate at room temperature for 5 min prior to 
further centrifugation at 10,000 x g for 1 min. The extracted vector was then 
quantified by spectrophotometry as described in section 2.3.5.
2.14.6 Nick translation
To create the FISH probe for the region around p21, nick translation was carried out 
to incorporate fluorescent labelled nucleotides into the DNA from the extracted 
vector. This was done using the nick translation kit from Invitrogen. For each reaction 
5(^ 1 dNTP (-dTTP), 0.5(il ChromaTide™ (red) labelled dUTP (ImM, Molecular 
Probes), lpg DNA from plasmid, H20  to a volume of 50pl, 5pl DNase/ DNA 
polymerase mix were added in that order to thin walled tubes on ice. The reagents 
were mixed by pipetting and briefly centrifuged. The reactions were then incubated at 
15°C for 1-3 hours after which 5 pi stop buffer was added to halt the reaction. Products 
were then run on 3% agarose gels, as described in section 2.5.2, to assess the size of 
nick translation products which, for optimal results, should be a range of fragments 
200-800bp in length. The fragments were then purified using a QIAgen PCR 
purification kit as described in section 2.6 and quantified as described in section 2.3.5.
2.14.7 Hybridisation Mix
Hybridisation mix was made in a batch for 100 reactions to reduce any pipetting error 
from the viscous reagents used. This master mix contained 500pl formamide, lOOpl 
20 x SSC, 200pl dextran sulphate, lOOpl 1% salmon sperm DNA and lOOpl H20. The 
hybridisation mix was well mixed and divided out into 5 reaction (50pl) aliquots; this 
was stored at -20°C until use.
2.14.8 Making of the p21 probe
200ng of each of the three nick translation products were added to a 500pl 
microcentrifuge tube. 15pi human Cot-1 DNA (1 mg/ml, Invitrogen), which is 
placental DNA, enriched for repetitive DNA sequences, was added to the clone DNA 
to suppress cross-hybridization. To precipitate the DNA, 1/10th of the volume of 3M 
sodium acetate and 2 volumes 100% ethanol were added, the mixture vortexed and
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incubated for 3 min at room temperature. To pellet the DNA the mixture was 
centrifuged at 11,000 x g for 10 min and the supernatant discarded. The remaining 
pellet was washed with 70% ethanol and centrifuged at 11,000 x g for 5 min and the 
supernatant discarded; this washing step was then repeated using 150pl ethanol. The 
remaining pellet was left to air dry in the dark. The pellet of probe was then 
resuspended in lOpl hybridisation mix.
2.14.9 FISH with probe made from clones
Slides were prepared as described in section 2.2.1 and treated with pepsin as in 
section 2.14.1. The p21 probe mixture denatured by heating to 72°C for 10 min in an 
agitated waterbath and incubated for 20 min at 37°C for the repetitive DNA sequences 
to pre-anneal. Slides were denatured in 70% formamide / 2 x SSC at 75°C for 5 min in 
an agitated waterbath. The slides were then quenched in an ice-cold ethanol series of 
70%, 80%, 95% and 100% for 2 min in each. The slides were then left to air dry and 
warm in an incubator at 37°C. The denatured probe was added to the cytodot of nuclei 
on each slide and covered with a 1.5cm x 1.5cm plastic coverslip (Oncor). The slides 
were incubated in a lightproof humidity chamber in an incubator at 37°C overnight. 
The coverslip was then removed and the slides were then washed in 0.1% SSC with at 
73°C for 2 minutes followed by a wash in 2xSSC with 0.3% Nonident P40 at room 
temperature for 30 seconds. Slides were air dried in the dark and counterstained with 
12pi DAPI for 10 min prior to viewing.
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Chapter 3 
Detection of mutations in the mitochondrial genome control region 
using the single stranded conformational polymorphism technique
3.1 Introduction
3.1.1 Mitochondrion
The mitochondrion is a cytoplasmic organelle and the cellular site of energy 
production in all eukaryotes. With the exception of erythrocytes, they are present in 
all human cells. Mitochondria can occupy up to a quarter of the volume of the 
cytoplasm, where they produce 80% of all the energy required by the cell in the form 
of adenosine 5’-triphosphate (ATP) by the biochemical process of oxidative 
phosphorylation (OXPHOS) (Lodish et a l , 1995). This process also generates 
reactive oxygen species, which cause oxidative damage to lipids, proteins and nucleic 
acid molecules. The role of the mitochondria is not limited to energy production, 
mitochondria are also responsible for executing the process of programmed cell death, 
known as apoptosis (Singh 1998; Zamzami et al, 1996).
Mitochondria are generally oval in shape, with their size ranging from l-2pm in 
length and 0.5-l|im in width. The organelle is encased by a double membrane 
structure, the outer of which encloses the mitochondria and the inner membrane 
consists of many cristae, or folds, which greatly increase the internal surface area. 
Oxidative phosphorylation occurs on the inner mitochondrial membranes where the 
enzymes required for this process are located and the number of cristae and therefore 
the surface area is proportional to the energy production of the cell (Modica- 
Napolitano et a l , 2002). Mitochondria have been observed to be dynamic and have 
been seen in living cells travelling along a molecular ‘highway’ created by a network 
of microtubules and intermediate filaments (Aufderheide, 1980; Summerhayes et al, 
1983).
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Several features o f the mitochondria such as a double membrane structure and circular 
DNA molecule with mitochondrial specific genetic code indicate the origin o f the 
organelle as a separate oxidative bacterium which formed a symbiotic relationship 
with a proto-eukaryotic cell around 1.5 billion years ago (.Anderson et al., 1981; Gray, 
1992; Wallace, 1999).
The mitochondria in all the cells o f  the human body are derived from those present in 
the oocyte at fertilization and are therefore inherited only from the maternal lineage. 
There are two main theories to explain maternal inheritance, either this is simply a 
result o f dosage as the oocyte has a 103-fold greater number o f  mitochondria 
compared to the sperm (Hiraoka and Hirao, 1988) or a degradation o f the paternally 
inherited mitochondrial genome (Birky 1994). The reality maybe a combination o f 
both o f these factors.
M i tochondr ion
Intermembrane space
Outer
membrane
Inner
membrane 
'Cristae <
Matrix
100 nm
Figure 3.1
This diagram illustrates the position o f the mitochondrion within the cytoplasm o f the 
cell as well as the structure o f the mitochondrion itself. The electron micrograph 
shows the scale o f the organelle with this particular example having a length o f 
approximately 1pm. Illustration derived from Campbell, 1996.
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3.1.1.2 The mitochondrial genome
As well as nuclear DNA, human cells also contain DNA in their mitochondria; this is 
termed mitochondrial DNA (mtDNA) and was first reported by Schatz et a l (1963). 
Within each cell there are between 1 and 2,000 mitochondria depending upon the 
energy requirements of the cell type (Campbell, 1996). Within the matrix of each 
mitochondrion there is an average of 4.5 mtDNA molecules; this figure varies 
between 2 and 60 copies (Kowald and Kirkwood, 1993), resulting in approximately 
1000 to 13,000 copies of the circular DNA molecule per cell (Miller et a l , 2003).
The mtDNA genome was sequenced in 1981 (Anderson et a l , 1981) and is a 
16,569bp double stranded circular molecule consisting of a guanine-rich H-strand (H, 
to denote heavy) and a cytosine-rich L-strand (L, to indicate the lighter). The mtDNA 
genome encodes for 13 polypeptides required for oxidative phosphorylation, 22 
transfer RNAs and 2 ribosomal RNAs involved in mitochondrial protein synthesis, 
see Figure 3.2. Of these, the H-strand encodes 12s and 16s rRNAs, 14 tRNAs and 12 
proteins involved in oxidative phosphorylation (6 subunits of complex I NADH 
ubiquinose oxidoreductase, 3 subunits of complex III ubiquinol cytochrome c 
oxidoreductase, 1 subunit of complex IV cytochrome c oxidase and 2 subunits of 
complex V ATP synthase), whereas the L-strand encodes only 8 tRNAs and NADH 
dehydrogenase 6 (ND6) a subunit of complex I NADH ubiquinose oxidoreductase. 
The remaining metabolic enzymes, polymerases, ribosomal proteins, mtDNA 
regulatory factors and proteins required for OXPHOS found in the mitochondria are 
encoded by nuclear genes.
The mitochondrial genome is highly compact with 93% of the mtDNA having a 
coding function; the only non-coding region is the (D) displacement-loop. This is 
marked in green on the mitochondrial genome map in Figure 3.2. The D-loop contains 
a promoter region with origins of replication for both the H and L strand and contains 
elements for the initiation of leading strand replication. The regulation of replication 
and transcription is mediated by the interaction of mtDNA with nuclear and ribosomal 
proteins.
Mitochondria contain around 1000 proteins and, other than the 13 coded for by the 
mtDNA, they are all synthesised in the cytoplasm of the cell and imported into the
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mitochondria. As the mtDNA does not encode all the proteins required for the 
organelle to function it follows that defective nuclear genes which code for the 
remaining proteins can affect the function o f the mitochondria.
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Figure 3.2
The circular human mitochondrial genome with gene locations and the D-loop or 
control region illustrated. Within the highlighted D-loop the H-strand origin o f 
replication and the H- and L-strand promoters are marked Ph and Pl respectively. 
Also marked is the portion o f  the molecule removed in the common 5 kb deletion. 
This illustration is adapted from Mitomap, 2004.
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All the enzymes required for the replication and growth of mitochondria are imported 
from the cytosol. MtDNA is replicated by the enzyme DNA polymerase y. DNA 
polymerase y  subunit 1, the catalytic subunit, is located on chromosome 15q25 of the 
nuclear genome. Despite an early study of polymerase y  in HeLa cells that 
demonstrated the enzyme was inaccurate for base substitution errors, DNA 
polymerase y  has now been shown to have a high fidelity, more accurate than both 
polymerase a, responsible for nuclear DNA synthesis, and polymerase p, which is 
responsible for DNA repair synthesis (Kunkel and Loeb, 1981; Kunkel, 1985). DNA 
polymerase y  has 3’—>5’ exonucleolytic proofreading activity (Kunkel, 1985; Kunkel 
and Soni, 1988; Pinz etal., 1995).
The replication of the mtDNA genome is much slower than that of the nuclear 
genome and is also highly asymmetric. During replication, the daughter H strand 
displaces the parental H strand and remains single stranded until the daughter L strand 
is synthesised. As the spontaneous mutation rate of single stranded DNA is much 
greater than that of double stranded DNA this is another explanation for the overall 
higher mutation rate seen in mtDNA (Tanaka and Ozawa, 1994). This higher rate of 
mutation can also be explained as mtDNA undergoes many more rounds of 
replication than chromosomal DNA with replication occurring throughout the cell 
cycle. The lack of protective histones also leaves mtDNA more vulnerable to 
mutation from causes such as oxidative damage.
Tissues, cells or even single mitochondria may contain a mixture of wild type mtDNA 
molecules and mutated copies of the mitochondrial genome; this is known as 
heteroplasmy (Shay and Ishii, 1990). Homoplasmy describes a state in which all the 
copies of mtDNA have the same sequence. This can occur from a state of 
heteroplasmy via a process called replicative segregation in which different copies of 
the mtDNA genome are randomly segregated into daughter cells, which, over many 
generations, can drift to one version of the DNA molecule (Wallace, 1999).
3.1.1.3 The mitochondria and energy production
Energy, in the form of adenosine triosphosphate (ATP), is produced in the 
mitochondrion primarily by the process of oxidative phosphorylation. Electrons are
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passed along a series o f respiratory enzyme complexes situated in the inner 
mitochondria! membrane. This transfer o f electrons releases energy, which is utilised 
to pump protons across the membrane. This causes an electrochemical gradient that 
enables ATP synthase to synthesise ATP from ADP and phosphate (Saraste, 1999). 
The electron transport chain also produces DNA damaging reactive oxygen species 
(ROS) such as hydroxyl radicals (OH’). These processes are illustrated in Figure 3.3.
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Figure 3.3
Diagram showing the energetics occurring in the mitochondria, illustrating oxidative 
phosphorylation, ATP synthesis and reactive oxygen species generation. Pyruvate 
enters the mitochondria via pyruvate dehydrogenase (PDH), generating acetyl-CoA 
which enters the tricarboxylic acid (TCA) cycle by combining with oxaloacetate 
(OAA) to form citrate. Aconitase converts citrate to isocitrate, this is converted to 
succinate and succinate ubiquinone oxidoreductase converts this to fumerate which is
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then converted into OAA. This cycle produces 10 high energy phosphate bonds for 
every acetyl-CoA molecule that is oxidized (Stryer, 1995). Lactate dehydrogenase 
(LDH) converts excess pyruvate along with NADH to lactate (Wallace, 1999). 
Oxidative phosphorylation occurs as free electrons pass through the electron transfer 
chain consisting of the complexes I to IV. The resulting proton gradient is used by 
complex V to make ATP which is passed out of the mitochondria via adenine 
nucleotide translocator (ANT) and voltage-dependent anion channel (VDAC) 
(Saraste, 1999). Adapted from Mitomap, 2004.
3.1.1.4 Oxidative damage to mitochondrial DNA
Nuclear and mitochondrial DNA are constantly being exposed to damaging agents, 
from endogenous and exogenous sources. In particular, reactive oxygen species 
(ROS) are formed at high levels as by-products of normal metabolism. Upon 
oxidative attack of DNA many DNA lesions are formed and oxidized bases are 
generated with high frequency. Radiation from y-rays also causes oxidative damage to 
mtDNA whilst nuclear DNA is thought to be protected to a limited extent from this 
damage by shielding proteins (Richter et a l , 1988). MtDNA is not complexed to 
histones that protect the integrity of the nuclear genome, leaving mtDNA more 
susceptible to oxidative damage (Richer, 1992). These factors and the lack of efficient 
nucleotide excision repair system of the nuclear genome lead to the mtDNA having a 
mutation rate approximately 17-fold higher than that for nuclear DNA (Richter, 
1988).
Mitochondrial DNA has been shown to accumulate high levels of the highly 
mutagenic lesion 8-hydroxy-2'-deoxyguanosine (8-oxo-dG), the product of 
hydroxylation of guanine at carbon 8 (Figure 3.4a). This form of oxidative damage in 
syn configuration can mispair with deoxyadenosine and if, left unrepaired, can cause 
G:C —► A:T transversion mutations (Figure 3.4b,c) (Grollman and Moriya, 1993).
The 8-oxo-dG lesion in mtDNA has been reported to occur at a frequency of over 16 
times greater than in nuclear DNA at around 1 in 8000 bases (Richter et a l , 1988). 
However, a more recent study using a protocol to isolate mitochondria which is less 
likely to cause physical mtDNA damage, suggests that the level of this lesion is
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actually far lower at 1 in 80,000bp (Higuchi and Linn, 1995) and under physiological 
conditions the level around 1 in 50,000 bp (Hegler et a l , 1993). Another reason for 
the vast range in oxidative damage levels detected in various studies is that the 
process of isolating mitochondria itself produces oxidative damage. A comparative 
study showed that detecting oxidative damage after the isolation of mitochondria gave 
levels 3 times higher than in studies that did not isolate the mitochondria and thus the 
higher levels reported are due to an artefact rather than a true representation of the 
damage levels found within the cellular system (Anson et a l, 2000). It has also been 
found that pure mtDNA is more resistant to hydrogen peroxide (H2O2) damage than 
mtDNA within whole cells implying that intracellular, extra-mitochondrial factors are 
required to induce mtDNA damage (Higuchi and Linn, 1995).
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Figure 3.4 Modes of base pairing for 8oxoG. a, Oxidation of guanine at C8 by 
reactive oxygen species (ROS). b, 8oxoG in base pair with dC. Dashed lines indicate 
hydrogen bonds, c, 8oxoG (syn) in a base pair with dA (anti). From Hsu et al., 2004.
The ROS superoxide anions (O2' ), hydrogen peroxide (H2O2) and hydroxyl radicals 
(OH*) are mainly generated in the mitochondria. Although a variety of enzymes in the 
cytosol, such as oxygenases, peroxidases and oxidases, generate small amounts of
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ROS, it is estimated that more than 95% of O2 ‘ produced during normal metabolism 
are generated at the electron transport chain in the inner mitochondrial membrane 
during oxidative phosphorylation. MtDNA is the main cellular target for ROS induced 
oxidative damage due to the close proximity of the molecule to the inner 
mitochondrial membrane. Oxidized bases in mtDNA are found at levels 2-3 times 
greater than in nuclear DNA (Hudson et a l , 1998).
3.1.1.5 The Repair of damage in mtDNA
Less is known about the various repair pathways of mtDNA than that of nuclear 
DNA. It is recognized that mitochondria do have proficient short patch base excision 
repair (BER) and also direct reversal DNA repair. There is also evidence that the 
organelles lack nucleotide excision repair (NER); but there is greater uncertainty over 
recombination post replication repair and mismatch repair (MMR) (Bohr, 2002).
Mitochondrial DNA polymerase y misincorporates dA opposite 8-oxo-dG at a high 
level and this is not removed by the 3’—>5’ exonuclease activity of the enzyme (Pinz 
et a l , 1995), but most of these small base modifications are repaired by the BER 
pathway. Despite the initial belief that mitochondria lack DNA repair, experimental 
evidence, derived from yeast models, now show that mitochondria are very proficient 
in BER of oxidative DNA damage (O’Rourke et a l , 2002). The proteins necessary for 
this repair pathway, such as apurinic/apyrimidinic (AP) endonucleases and a specific 
DNA glycosylase, have also been isolated from mammalian mitochondria (Bohr et 
a l , 2002).
Experiments using rats and mice have demonstrated that mammalian mitochondria 
efficiently remove 8-oxo-dG from their genome and this process becomes more 
efficient with age (Stevnsner et a l , 2002). This removal of 8-oxo-dG has also been 
shown to occur in human cells, occurring at an equal rate between the light and heavy 
strands and also between regions of the mitochondrial genome that differ significantly 
in terms of transcriptional activity (Anson et a l , 1998).
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3.1.1.6 Mitochondrial damage and aging
Mitochondrial function deteriorates with age and skeletal muscle, liver and brain have 
all been reported to have reduced OXPHOS enzyme activity with age (Wallace, 1999; 
Trounce et a l, 1989). The reduced respiratory function causes an increase in ROS 
production through increased electron leak of the electron transport chain. Levels of 
intracellular antioxidants and free radical scavenging enzymes also decrease with age, 
which, in turn exacerbates the damage to the enzymes involved in OXPHOS (Wei et 
al, 1998). These factors give rise to an age associated increase in mutation frequency 
in the mitochondrial genome.
The mtDNA copy number per cell in humans has been shown to remain constant from 
neonates to adults over the age of 80 indicating that a cause other than number must 
be a reason for reduced mitochondrial function in the elderly (Miller et al, 2003). 
Experiments have shown that mtDNA in skeletal muscle from humans over the age of 
50 has a large number and type of rearrangements whereas in skeletal muscle from 
people aged 40 or under there are virtually no mtDNA mutations present (Melov et 
al, 1995). The control region for replication of human fibroblast mtDNA from 
normal elderly subjects contains a high number of point mutations that only appear in 
a given individual in advanced age (Michikawa et a l, 1999). The common 5kb 
deletion has also been found to accumulate in brain tissue of humans over the age of 
75 (Corral-Debrinski et al, 1992). The 5kb deletion region is marked on Figure 3.2. 
Mutations within the control region of the mitochondrial genome have also been 
found to accumulate with age in muscle but not in brain tissue (Murdock et a l, 2000). 
The reason for this has not, as yet, been identified.
Inefficient repair of oxidative damage to mtDNA has the potential to lead to the 
accumulation of mutations and ultimately mitochondrial dysfunction, which is 
associated with pathological processes such as degenerative diseases and aging. The 
mitochondrial hypothesis for aging proposes that symptoms of aging and senescence 
are a result of a reduced bioenergetic capacity of mitochondria due to the 
accumulation of mtDNA mutations caused by increased levels of ROS associated 
with age (Harman, 1972). The extent of this effect varies from tissue to tissue
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depending upon energy requirements and can explain the damage seen to the brain 
and heart tissue of the elderly (Wei et a l , 1998).
3.1.1.7 The role of mitochondria in apoptosis
The discovery that anucleated cells could be induced to undergo apoptosis sparked 
research into the role of cytoplasmic structures, including mitochondria, in apoptosis. 
Early observations noted that, at the start of the apoptosis process, the mitochondrial 
transmembrane potential drops (Zamzami et a l , 1995). To investigate this further, 
experimental cell free systems were established, these showed that mitochondria with 
open mitochondrial transition pores were able to induce apoptosis and so had a central 
role in this process (Zamzami et a l, 1996).
Further research has found that the inner mitochondrial membrane space contains 
several proteins that induce programmed cell death. The mitochondrion initiates 
apoptosis after increased ROS exposure, reduced ability for energy production or 
excess uptake of calcium ions. At this point the mitochondrial permeability transition 
pore (mtPTP) through the inner and outer mitochondrial membranes opens. The 
mtPTP is created by the interaction of the voltage dependent anion channel, adenine 
nucleotide translocator, Bax and cyclophilin D at contact sites between the inner and 
outer mitochondrial membranes. It is through this pore that apoptosis inducing factors 
are released, including cytochrome c (CytC), caspases and apoptosis-inducing factor 
(AIF). CytC activates the cytoplasmic protein Apaf-1 which then activates the latent 
pro-caspase-9 which in turn, degrades the cellular proteins of the cytoplasm. AIF 
translocates to the nucleus where it induces apoptosis by chromatin condensation and 
endonuclease-mediated DNA fragmentation (Zamzami et al, 1996; Wallace 1999).
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Figure 3.5
This diagram shows a section o f a mitochondrion and illustrates the cascade o f events 
leading to apoptosis. The mitochondrial permeability transition pore (mtPTP) is 
created at points o f contact between the inner and outer mitochondrial membranes 
where the Voltage-dependent anion channel (VDAC), Adenine nucleotide 
translocator (ANT) cyclophilin D (CD) and Bax come together to form a channel into 
the cytoplasm. The relative concentrations o f the pro-apoptotic protein Bax and anti- 
apoptotic protein Bcl-2 are thought to mediate apoptosis and interact with the 
benzodiazepine receptor (BD) (Wallace 1999). When the channel is open the 
apoptosis inducing factor (AIF) and cytochrome C (CytC) are released out o f the 
mitochondrion into the cell cytoplasm where it activates Apaf-1 which in turn 
activates caspases and leads to apoptosis o f the cell. Adapted from Mitomap, 2004.
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3.1.1.8 MtDNA and associated disease
In 1988 there were reports of mtDNA missense mutations present in the 
mitochondrial ATP synthase gene ATP6 in patients suffering from the maternally 
inherited disease Leber’s hereditary optic neuropathy, a degeneration of the optic 
nerve, (Wallace et a l , 1988) and large-scale mtDNA deletion mutations present in 
patients with Kearns-Sayre syndrome, a degenerative disease of the central nervous 
system associated with defects of the eye (Zeviani et a l , 1988). This prompted 
mtDNA research into many other diseases and mutations were found in patients 
suffering from a wide range of symptoms including blindness, deafness, diabetes and 
heart disease. Tissues most commonly affected by mitochondrial disease are those 
with high energy requirements such as skeletal and cardiac muscle, nerves and 
endocrine system. MtDNA mutations are also associated with aging and 
neurodegenerative diseases such as Alzheimer’s disease and Mitochondrial 
Encephalopathy, Lactic Acidosis and Strokelike episodes (MELAS) (Wallace, 1992; 
Yoneda et a l, 1992). An estimated 0.1% of births in the US are affected by 
mitochondrial diseases (Singh, 1998).
Patients sharing the same mtDNA mutation may differ greatly in the severity of their 
symptoms; this can be explained by the degree of heteroplasmy present in the cells. 
Patients with a high ratio of wild type to mutated mtDNA are likely to have less 
severe symptoms than those with a low ratio whose mitochondria are less likely to 
function correctly.
As well as mutations in the mitochondrial genome, mitochondrial associated diseases 
can arise from mutations in nuclear genes which encode proteins required for 
mitochondrial function. An example of this is autosomal dominant spastic paraplegia 
which is associated with the mutation of the gene encoding a mitochondrial protease­
like ATPase (Casari eta l, 1998).
A delayed onset is a common trait in mitochondrial diseases. This and the progressive 
nature of these diseases suggests that, in addition to the predisposing mutation, the 
phenotype of the disease is exacerbated by an age factor that decreases the functional 
ability of the mitochondrion (Wallace, 1999).
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Figure 3.6
Schematic diagram o f the mitochondrial genome showing the positions o f known 
mitochondrial disease causing mutations. The acronyms for the diseases marked are 
Leber’s hereditary optic neuropathy (LHON), neurogenic muscle weakness, ataxia 
and retinitis pigmentosa (NARP) also known as Leigh disease, myoclonic epilepsy 
and ragged-red fiber disease (MERRF), late on-set Alzheimer’s disease (ADPD), 
mitochondrial encephalopathy, lactic acidosis and strokelike episodes (MELAS) 
which also causes diabetes mellitus, chronic progressive external ophthalmoplegia 
(CPEO). Deletion o f the 4.9kb fragment also causes Kearns-Sayre Syndrome (KSS) 
(Singh, 1998). Image adapted ffom Wallace, 1999.
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3.1.1.9 Mitochondrial DNA as a biomarker for cancer
It has been known for nearly 50 years that the role of the mitochondrion is different in 
some tumour cells as studies have shown mitochondrially-mediated oxidative 
phosphorylation is diminished in cancer cells with some tumours relying on the 
energy obtained by glycolysis (Warburg, 1956). In addition to this, more recently 
links with mtDNA mutations and cancer have been established. Mutations in the 
mtDNA of human solid tumours were first reported in 1989 where mutations within 
the cytochrome oxidase subunit 1 gene were found in the benign solid tumours known 
as oncocytomas (Welter et a l, 1989). Deletions have been reported in the mtDNA of 
cirrhotic liver tissue surrounding hepatocellular carcinoma; these were suggested to be 
an endogenous factor in the induction of nuclear genome somatic mutations and to 
contribute to carcinogenesis (Yamamoto etal., 1992).
In a gene expression study, 15 nuclear encoded mitochondrial proteins were found to 
be down-regulated in colorectal cancer. Of these genes, 3 were found to be down- 
regulated at all Dukes’ stages of cancer progression. These were rhodanase 
(thiosulfate sulfurtransferase), 3-hydroxy-3-methylglutaryl Co A synthase and SCAD 
(acyl-CoA-dehydrogenase). SCAD was found to have expression decreased by 7-fold 
in Dukes’ A tumours. A deficiency of this protein results in an increase in butyric 
acid, which at low concentrations stimulates growth, and in higher concentrations 
stimulates apoptosis. This again provides evidence to indicate a central role for 
mitochondria in colorectal carcinogenesis (Birkenkamp-Demtroder eta l, 2002).
MtDNA may act as transposable elements to modify the nuclear genome. 
Mitochondrial DNA sequences have been identified within the nuclear genome, 
depending upon where these sequences are incorporated it is possible for these to 
disrupt genes which are involved in the maintenance of cell growth and repair and as 
a result initiate carcinogenesis (Mishmar et al, 2004). Increased oxidative stress is 
thought to increase the transfer of mtDNA fragments into the nuclear genome 
(Richter, 1988). These types of mutations have been found in low-grade tumours and 
in the HeLa cell line (Singh, 1998).
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Cell fusion experiments have also shown that extra-nuclear factors also play a role in 
tumorigenesis. For example, when tumourigenic HeLa cells are fused with other 
tumourigenic cells the mitochondria are randomly segregated and the tumorigenicity 
of the cells correlates with the type of mtDNA retained (Shay and Ishii, 1990). In the 
same series of experiments, the fusion of HeLa cells with non-tumourigenic cells 
frequently resulted in the loss of the mtDNA originally from the HeLa cells after 
several weeks of cell culture. The factors which determine this process are still 
unclear as further cell hybrid experiments have shown this segregation of 
mitochondrial genome types maybe merely the result of stochastic events (Shay and 
Ishii, 1990).
Differences between mitochondria in normal and tumour cells provides scope for an 
alternative cancer treatment to traditional chemotherapy which targets actively 
replicating cells but with a low specificity for tumourigenic cells (Weissig and 
Torchilin, 2001). The dosage of mtDNA may also be important in the sensitivity of 
cells to cancer therapeutic agents. Cells lacking mtDNA have been found to be 
extremely resistant to cell death induced by the anticancer agents adriamycin and 
photodynamic therapy (Singh et al, 1999). Pharmacological agents can impede or 
induce the opening of the mitochondrial permeability transition pores either inhibiting 
or inducing apoptosis respectively, providing a target for cytoprotective and cytotoxic 
therapy (Zamzami et al, 1996). Indeed, in a patient trial prostate cancer cells have 
been selectively killed by adenoviral-mediated delivery of the novel cytokine gene 
mda-lRL-24 which promotes apoptosis in cancer cells but not in normal cells. The 
gene is able to do this by promoting mitochondrial dysfunction and ROS production 
(Lebedeva et a l, 2003).
The mitochondrial membrane potential falls in cells undergoing apoptosis (Zamzami 
et a l, 1995), but in cancer cells the membrane potential is increased thus giving the 
cell a greater resistance to apoptosis (Modica-Napolitano and Singh, 2002). Anti­
cancer drugs which contain delocalised lipophilic cations (DLCs) accumulate 
preferentially in the mitochondria and the membrane potential difference between 
normal and cancerous cells provides a possible target for these types of drugs. Several 
of these DLCs have effectively exploited this transmembrane potential difference in
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carcinoma cells and providing selective cytotoxicity to these cell types (Modica- 
Napolitano e ta l, 1996; Modica-Napolitano and Singh, 2002).
Mutations in the mitochondrial genome have been detected in a wide range of 
different cancer types including leukaemia, ovarian, thyroid, salivary, renal, liver, 
lung, colonic, gastric, brain, and breast cancer as well as the benign condition goitre 
(Modica-Napolitano and Singh, 2002). One study has shown that tumours from the 
human lung, bladder and head and neck contained a high frequency of mtDNA 
mutations. These mutations were also detectable in the paired bodily fluids, lung 
lavage fluid, urine and saliva and were more common than mutated copies of the 
tumour suppressor gene p53 (Fliss et al, 2000). Mutant mtDNA has been reported to 
be 220 times more abundant than mutated nuclear molecular markers (Singh, 1999). 
This may provide a non-invasive method of screening for many types of cancer, 
which is more sensitive than nuclear DNA molecular markers. A study sequencing the 
complete mitochondrial genome of 10 colorectal cell lines and primary tumour cells 
found mitochondrial mutations in 70% of the cell lines (Polyak e ta l, 1998).
There are several ways in which mtDNA mutations may contribute to the progression 
of cells through to carcinogenesis such as alterations in cellular energy capacities, 
increases in mitochondrial oxidative stress and by the decreased initiation of apoptosis 
(Modica-Napolitano and Singh, 2002). However, tumours with no mitochondrial 
DNA have also been observed, this may either indicate that mtDNA mutations can 
have no role in the process of carcinogenesis or that the very absence of this mtDNA 
was a contributory factor in the tumour’s development (Morais et al., 1994).
Although the role of mtDNA in cancer is still under debate, the study of mtDNA 
mutations is still of value as these may act as a molecular marker to aid the early 
detection of cancers. The mutational spectra may also be of use in tracking down the 
mutagens responsible for any damage observed.
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3.1.2 Mutation Detection
3.1.2.1 Mutation detection techniques
When examining DNA for mutations there are several different techniques which can 
be employed, such as, restriction fragment length polymorphism (RFLP), restriction 
site mutation assay (RSM), single stranded conformational polymorphism (SSCP) and 
direct sequencing (Cotton, 1993). Both RFLP and RSM require the mutations to occur 
within restriction sites in order to be detected making these techniques more 
appropriate for sequences of DNA where there are known mutational hotspots within 
restriction enzyme sites. As this is not true of the region of the mitochondrial genome 
to be studied these were not deemed to be suitable techniques for this study. 
Sequencing obviously provides not just information about the presence or absence of 
mutations but also the exact nature of the change. This information is expensive and 
time-consuming to obtain because of high equipment costs, both for initial purchase 
and maintenance. This makes the technique impractical for preliminary experiments 
or for tightly budgeted projects as the equipment is costly and expensive to maintain 
often requiring a dedicated technician. SSCP is a very simple technique for detecting 
unknown mutations within DNA; as discussed later, it requires only standard 
laboratory equipment and is both rapid and cost effective with very little loss of 
sensitivity for mutation detection in comparison to direct sequencing. For these 
reasons SSCP was chosen for the experiments described within this Chapter.
3.1.2.2 Single Stranded Conformational Polymorphism
Single-strand conformation polymorphism (SSCP) analysis allows detection of 
unknown point mutations in DNA up to 800bp in length. The technique, first 
described in 1989 (Orita et al., 1989), is arguably one of the simplest, cost efficient 
and possibly amongst the most sensitive PCR-based methods for detecting mutations 
(Hayashi, 1992). The technique, originally developed using radioisotopes, has now 
been optimised for use with standard mini gel electrophoresis apparatus and 
conventional silver staining methods without the need for radioactivity making the 
technique safer, simpler and less expensive (Oto eta l, 1993).
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The assay is based on the principle that single-stranded DNA molecules form 
sequence specific conformers under non-denaturing conditions and therefore have 
different electrophoretic mobilities. The technique is able to detect differences 
between molecules that differ by even a single base substitution, which alters the 
secondary and tertiary structure of the DNA molecule and causes a difference in 
migration through a non-denaturing polyacrylamide gel. It is reported that SSCP 
detects 99% of mutations in 100 -  300bp fragments and 89% in fragments of 300 -  
400bp and has an equal ability to detect transition and transversion mutations 
(Hayashi 1991; Sheffield et a l 1993).
The sensitivity of PCR-SSCP has been assessed in several studies to establish the 
ability of the technique to detect mutations in mixed cell populations. This is 
particularly important for studies of mtDNA as not only are there different cells but 
each cell contains several mitochondria, which in turn contain several copies of the 
mitochondrial genome. These studies have shown that PCR-SSCP is able to detect 
mutations found in between 1 in 4 and 1 in 33 copies of the mutated DNA amongst 
wild type sequences. (Smith et a l , 1992; Wu et al 1993) A study of mtDNA 
demonstrated the ability to detect a defined mutation within the mitochondrial 
genome was 93% for SSCP alongside 98% for direct sequencing. This study clearly 
confirms the usefulness and accuracy of this technique used for the study of mtDNA 
(Jaksch e/a/., 1995).
It is important to understand that this technique does not always discriminate between 
mutant and wild-type alleles, even at mutation concentrations of 50%. Furthermore, it 
is dependant upon the sequence of the DNA to be screened and the position of the 
mutation within the DNA fragment. This is because in certain locations within a 
sequence of DNA the base mutated does not effect the folding of the single strand of 
DNA into it’s secondary and tertiary structures making the mutation undetectable by 
this technique (Hayashi 1992; Hayashi and Yandell 1993; Glavac and Dean 1993). 
The region of DNA to be amplified by PCR prior to SSCP must therefore be tested 
after selection to ensure that the technique produces clear banding patterns. The PCR 
must be carried out using high fidelity enzymes to eliminate any possible artefacts 
from the amplification stage of the assay.
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Occasionally the SSCP bands may appear very diffuse or there may be a heavily 
smeared background despite the demonstration of a single strongly stained DNA band 
after PCR purification. The addition of formamide to the PCR product prior to heating 
and rapid cooling can sharpen the ssDNA bands and ease the detection process. By 
adding a denaturing agent, the multiple highly similar conformations of ssDNA for a 
single sequence, which are thought to be the reason for background smearing, migrate 
in a more uniform manner. Increasing the concentration of acrylamide in the gel and 
lowering the temperature at which the gel is run can also sharpen the bands. There is 
though a limit for both of these factors at which the bands do not separate enough to 
distinguish between them (Yip et al., 1999).
The DNA fragment length is another factor which alters the sensitivity of SSCP, with 
the optimal DNA fragment length for mutation detection being approximately 150bp 
(Sheffield, et a l , 1993). It is also possible to screen larger fragments by digesting with 
restriction enzymes before running on a two-dimensional gel, the first dimension of 
electrophoresis to separate the fragment by size and the second dimension to detect 
for mutations as in a standard SSCP assay. This technique has been used to 
successfully analyse fragments of 2.7kb (Kovar e ta l , 1991).
Electrophoretic conditions such as running time and current intensity also influence 
the ability of this technique to detect sequence differences. Polyethylene glycol has 
also been shown to enhance the technique by increasing gel viscosity when added to 
polyacrylamide gel, especially for fragments of 400-500bp (Markoff et a l, 1997).
The technique can also be used for RNA SSCP, which is reported to be more sensitive 
than standard SSCP due to the larger number of secondary forms RNA can assume. 
This adaptation of SSCP does lack the simplicity of standard SSCP due to the extra 
transcription stages involved and the increase in sensitivity of RNA SSCP may not 
warrant the much more time consuming process (Cotton, 1993).
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3.1.3 Rationale of the study
The purpose of the experiments described in section 3.2 was to analyse the control 
region of the mtDNA genome of colorectal adenocarcinomas, normal colonic 
tissue and where possible, intermediate stages such as metaplastic polyps and 
adenomas, as well as lymph node tissue and liver biopsies. The aim of this was to 
gauge the level of mutation of the mitochondrial genome and search for possible 
molecular markers for colon cancer. Also, if mutations could be localised to a 
small fragment of the mitochondrial genome, screening for mutations in the paired 
bodily fluid samples for patients would become a viable clinical application of this 
non-invasive, sensitive method. These experiments also aimed to see if mtDNA 
mutations were an important contributor to the process of carcinogenesis.
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3.2 Materials and Methods
3.2.1 Sample collection
65 fresh tissue samples were obtained as described in Chapter 2, section 2.2 from 24 
sporadic colorectal cancer patients. The mean age of these patients was 69 years of 
age at the time of sample collection; the patients consisted of 13 females and 11 males 
(1.2F : 1M). 12 of these patients had adenocarcinomas of the rectum, 2 of the sigmoid 
colon, 4 of the transverse colon and 2 of the caecum. 1 patient had a rectal polyp, 3 
had sigmoid polyps. 6 of these samples had metastatic tissue samples from liver or 
lymph node.
3.2.2 DNA extraction
Fresh tissue samples were disrupted as described in Chapter 2, section 2.3.1 prior to 
DNA extraction using the high salt method described in Chapter 2, section 2.3.3.
3.2.3 DNA quantification
DNA concentration was established as described in Chapter 2, section 2.3.5.
3.2.4 Polymerase Chain Reaction (PCR)
A section of D-loop or control region of the mitochondrial genome from position L29 
to H408 was amplified for each sample. This section contained the hypervariable 
segment 2, the H-strand origin, conserved sequence block 1, mtTFl binding site, 
conserved sequence block 2, replication primer, conserved sequence block 3, the mt4 
H-strand control element, the mt3 H-strand control element and part of the L-strand 
promoter. The entire amplified fragment of the mtDNA genome is within the 
membrane attachment site, which spans from position 15925 -  499 (Albring et al, 
1977).
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L_L
□ a
15,000 1 6 ,569 /0  100
□  PCR product (29-408)
□  D-loop (16024-576)
□  Membrane attachment site (15925-499)
■  Hypervariable segment 2 (57-372)
□  H-strand origin (110-441)
■  Conserved sequence blocks 1, 2, and 3 
(213-235, 299-315, 346-363)
200 300 400 500
□  mtTFl binding site (233-260, 276-303)
□  Replication primer (317-321)
□  mt4 H-strand control element (371-379)
□  mt3 H-strand control element (384-391)
□  7S DNA (16106-191)
□  L-strand promoter (392-445)
Figure 3.7
This figure illustrates the locations o f various functional sequences o f the 
mitochondrial genome for the section o f interest in this Chapter on a linear schematic 
o f human mtDNA. The PCR primers described in section 3.2.4 amplify the region 
highlighted in pale yellow on this diagram, the resulting PCR product contains all or 
part o f  the functional regions listed. The numbers alongside the diagram and 
following the functional sequence descriptions are the relevant nucleotide positions o f 
the mitochondrial genome according to the Cambridge mtDNA sequence (Mitomap, 
2004).
This was carried out as described in Chapter 2, section 2.4 using the following 
oligonucleotide primers (Vigilant et a l., 1989) and under the conditions listed in table
3.1 for 35 cycles in the presence o f  1.5pi MgCh.
Forward primer: GGTCTATCACCCTATTAACCAC 
Reverse primer: CTGTTAAAAGTGCATACCGCCA
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PCR Stage Temperature (°C) Length of stage (seconds)
Denaturation 95 30
Annealing 58 30
Elongation 72 30
Table 3.1
Table of the conditions required for the PCR of the D-loop section
3.2.4 Electrophoresis
PCR products were evaluated by polyacrylamide gel electrophoresis described in 
Chapter 2, section 2.5.1, the gels stained with silver stain, Chapter 2, section 2.5.3 and 
images captured as in Chapter 2, section 2.5.5.
3.2.5 PCR purification
Successfully amplified control region PCR products were purified to remove excess 
primer, free nucleotides and short DNA fragments less than 40bp using the PCR 
purification protocol described in Chapter 2, section 2.6.
3.2.6 Single Stranded Conformational Polymorphism (SSCP)
SSCP was carried out on the purified PCR products to detect any mutations present in 
these samples. This was carried out as described in Chapter 2, section 2.7. Each 
sample was amplified and analysed by this technique a minimum of 4 times.
3.2.7 Sequencing
To establish the nature of the mutations detected by SSCP and to evaluate the 
sensitivity of the technique in detecting mutations the PCR products were sequenced 
as described in Chapter 2, section 2.9.
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3.3 Results
3.3.1 Results of SSCP analysis
There was an abundance of variation of band migration patterns between individuals 
in the control region of both the normal and carcinoma samples indicating the 
presence of many germline variations for this region. A total of 10 different 
polymorphisms were seen from the 24 patients, these are listed in Table 3.3.
9 out of the 24 (37.5%) patients exhibited tumour specific mutations, that were not 
present in the paired normal mucosa from the same patient, in the control region of 
the mitochondrial genome amplified in these experiments, see Table 3.2. These 
patients did not significantly differ in age (67.6 years of age) or sex ratio (1.24F: 1M) 
from the overall cohort of patients (68.9 years of age; 1.2F: 1M).
Mutations were only present in the later stages of carcinogenesis, none of the normal 
mucosa, neither adjacent nor distant, contained mutations in this region. The polyps 
were also found to be free of mutations within this region.
The samples with SSCP detectable mutations were in the distal sections of the colon, 
either rectal adenocarcinomas or sigmoid colonic adenocarcinomas, of which 6/9 
(67%) were rectal tumour samples. The remaining samples with mutations were either 
sigmoid colonic tumours or metastatic tumours from liver or lymph node. No 
mutations were found in the 6 adenocarcinomas of the transverse colon or the caecum. 
One of the patients (patient 3) had SSCP detectable mutations in both the rectal 
tumour and the metastatic lymph node, although the bands for these mutations 
appeared to have migrated to different locations within the gel and therefore maybe 
different mutations. Another patient, (patient 14) had a detectable mutation in the 
metastatic liver tissue but not in the rectal adenocarcinoma or metastatic lymph node.
3 of the mutations were present in the heteroplasmic form, this could be seen on the 
SSCP gel pictures as a further band in addition to the two bands for the original allele 
(Figure 3.8).
All PCR products were then sequenced to confirm these results and to provide greater 
detail of the nature of the mutations and polymorphisms detected with SSCP.
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Patient
no
Sample
no
Age Sex Sample type SSCP
change
Heteroplasmic
1 4 64 F Rectal polyp
5 Adjacent mucosa
2 9 80 M Rectal tumour
10 Distant mucosa
3 11 79 F Lymph node Y
13 Rectal tumour Y Y
14 Distant mucosa
4 16 64 M Rectal tumour Y
17 Adjacent mucosa
5 19 64 F Distant mucosa
20 Sigmoid polyp
6 24 71 F Distant mucosa
25 Rectal tumour Y
7 28 78 M Distant mucosa
29 Rectal tumour
8 30 64 M Rectal polyp
31 Liver biopsy
33 Distant mucosa
34 Rectal tumour Y Y
35 Adjacent mucosa
9 36 70 F Sigmoid tumour Y Y
37 Distant mucosa
38 Sigmoid polyp
39 Adjacent mucosa
10 40 59 F Adjacent mucosa
42 Transverse polyp
43 Transverse tumour
11 44 67 M Distant mucosa
45 Rectal tumour
12 46 63 F Rectal tumour
47 Distant mucosa
13 50 73 M Sigmoid polyp
51 Adjacent mucosa
14 53 68 M Distant mucosa
54 Lymph node
55 Rectal tumour
56 Liver biopsy Y
15 57 85 M Transverse tumour
58 Distant mucosa
60 Caecal polyp
Table 3.2 continued overleaf
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Patient
no
Sample
no
Age Sex Sample type SSCP
change
Heteroplasmic
16 68 68 F Lymph node
69 Distant mucosa
70 Rectal tumour
71 Adjacent mucosa
17 72 65 F Distant mucosa
73 Sigmoid polyp
74 Adjacent mucosa
18 76 65 F Distant mucosa
77 Caecal tumour
78 Caecal polyp
19 81 73 M Distant mucosa
82 Lymph node
83 Transverse tumour
20 87 64 F Rectal tumour Y
88 Adjacent mucosa
21 99 83 F T ransverse tumour
100 Adjacent mucosa
22 102 58 M Sigmoid tumour Y
104 Distant mucosa
105 Lymph node
23 122 70 F Rectal tumour Y
124 Distant mucosa
24 96 58 M Caecal tumour
97 Adjacent mucosa
98 Distant mucosa
Table 3.1
This shows an overview of the SSCP analysis results. Where a shift in band height, was 
detected between the samples of the same patient the sample is marked with a Y in the 
SSCP change column, if the SSCP bands indicated were heteroplasmic this column is 
marked Y.
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Figure 3.8
(i) Gel image showing SSCP products for the normal (N) and rectal adenocarcinoma 
tissue (T) for three patients (patient numbers 2, 7 and 11). The alleles A, D and C 
present in the normal and adenocarcinoma samples can be seen in homoplasmic form, 
this highlights the variation between individuals for this region o f the mtDNA.
(ii) Photograph o f a SSCP gel for control region o f the normal (N) and sigmoid 
adenocarcinoma (T) tissue samples from patient number 9, sample 36. The gel image 
shows the normal tissue from one patient to be homoplasmic for allele A whereas the 
adenocarcinoma from the same patient is heteroplasmic for both the A and B alleles.
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3.3.2 Results of sequencing
The 10 different polymorphisms detected in the 24 patients by SSCP analysis were 
also detected by sequencing, see Table 3.3. All o f the polymorphisms had been 
previously recorded on Mitomap with the exception o f the A-G change at position 
178 seen in patient number 9 (Mitomap, 2004). Several samples contained more than 
one polymorphism. 4 o f the polymorphisms were due to deletions or insertions within 
repeat sequences o f G (G6. position 66-71) or C (C7 , position 303-309; C5, position 
311-315), these altered from the Cambridge sequence in 15/24 (63%) patients with 
three patients having polymorphisms in more than one o f  these sequences (figure 3.9).
Nucleotide
position
Cambridge
sequence
Variation Frequency
66-71 g 6 G 5 3
114 c T 1
152 c T 1
178 A G 1
222 C T 1
303-309 c7 c6 5
303-309 c7 c8 7
310 T TT 1
311-315 c5 c6 3
Table 3.3
The polymorphisms detected across the cohort o f 24 patients. Nine polymorphisms 
are listed, 3 samples had no variation to the Cambridge sequence.
The sequencing also confirmed all o f the mutations detected by SSCP, see Table 3 .4. 
One lymph node sample (patient 14, sample 54) contained a homoplasmic G—>C 
transversion mutation which was not detected by SSCP. This gave an overall mutation 
rate o f 9 patients with mutations out o f the sample size o f 24 (37.5%).
Two o f the rectal tumour samples contained more than one mutation (patient number 
3, sample 13; patient number 8, sample 34) and two patients had mutations in more 
than one o f  the tissues sampled. In total there were 15 mutations from 9 patients out 
o f the cohort o f 24 colorectal cancer patients.
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Patient
Num ber
Sample
Num ber
Sample type Sequence
alteration
Function of affected mtDNA
3 11 Lymph node C del from C tract 
pos 303
Conserved sequence block 2, 
mtTFl binding site,
13 Rectal tumour Heteroplasmic 
G78A/G, 
ATG>GCC, pos 
83,84,85
Hypervariable region 2
14 Distant mucosa
4 16 Rectal tumour 50bp del 
pos 298-347
Hypervariable region 2 
MtTFl binding site 
H-strand origin 
Conserved sequence block 2 
Replication primer 
Conserved sequence block 3
17 Adjacent mucosa
6 24 Distant mucosa
25 Rectal tumour C del in C-tract pos 
303
Hypervanable region 2 
Conserved sequence block 2, 
mtTF 1 binding site,
8 30 Rectal polyp
31 Liver biopsy
33 Distant mucosa
34 Rectal tumour Heteroplasmic
A83G/A,
C del in C tract pos 
303
A83G - Hypervariable region 2 
C del - Conserved sequence block 2, 
C del - mtTFl binding site,
9 36 Sigmoid tumour Heteroplasmic (*) 
G178A/G
Hypervariable region 2 
H-strand origin
37 Distant mucosa
38 Sigmoid polyp
39 Adjacent mucosa
14 53 Distant mucosa
54 Lymph node G69C Hypervariable region 2
55 Rectal tumour
56 Liver biopsy C152T Hypervariable region 2 
H-strand origin
20 87 Rectal tumour CT ins in C tract 
pos 310
Hypervariable region 2 
Conserved sequence block 2
88 Adjacent mucosa
22 102 Sigmoid tumour C ins pos 78 Hypervariable region 2
104 Distant mucosa
105 Lymph node
23 122 Rectal tumour C320G Hypervariable region 2 
Replication primer
124 Distant mucosa
Table 3.4
This table includes all the patients from Table 3.1 which had a sequencing alteration. 
The nucleotide positions given for each mutation are in reference to the Cambridge 
sequence. The affected regions for each o f the sequence alterations are as listed in 
Mitomap; C tract refers to the C7 sequence from position 303-309 (Mitomap, 2004). 
(*) This sample was heteroplasmic for 1/4 repeats for the change at position 78.
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4 of the mutations were C deletions (3) or insertions (1) within the C-tract, Cambridge 
sequence position 303-309, (figure 3.9). This hotspot was mutated in 4/9 (44%) of the 
patients with mutations.
AC C C CCC CC TCCC CC C Q AC C CCC CCTCCC CCC Q 
3 003 10 32
Figure 3.9
These traces show the C-tract region, Cambridge position 303-317 for the normal 
mucosa and rectal tumour of patient number 6. It can be seen that the normal tissue 
has CgTC6 whereas the rectal adenocarcinoma tissue from the same patient has C7TC6 
in the same region. This patient had a polymorphism in this sequence in both of the C 
repeats as the Cambridge sequence is C7TC5. The numbers present on the sequencing 
traces are the number of bases into the sequencing run which vary slightly between 
runs and do not correlate to the standard Cambridge sequence numbering.
The sequencing also confirmed the heteroplasmy of 2 of the samples (patient 3, 
sample 13 and patient 8, sample 34). All of the heteroplasmic samples were G—»A or 
A—>G transition mutations. The traces showed peaks for both A and G bases and in 
both cases the heights of these peaks were approximately equal to each other for all 
repeats. One sigmoid tumour sample (patient 9, sample 36) which was heteroplasmic 
in all repeats of the SSCP analysis but was less consistent in the sequencing analysis 
(figure 3.10). The sample was PCR amplified and resequenced four times. One of the 
sequencing traces showed heteroplasmy with equal peak heights for both the G and A 
bases, confirming the SSCP analysis. However, three of these repeats showed the 
mutation to be homoplasmic for G—>A although this may be as the smaller peaks on 
the sequencing traces could not be differentiated from the background levels.
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GTGTGC GTNTGC GTATGC
i)k
ATGTTAC.
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ATNTTAC
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ATATTAC
170
iv)
Figure 3.10
These two sets o f sequencing traces show the heteroplasmy present in the samples. 
The top row o f traces show the (i) normal mucosa, (ii) rectal adenocarcinoma and (iii) 
lymph node sample traces from patient 3. It can been seen in these traces that the 
normal tissue has A at position 78 whereas the rectal adenocarcinoma is 
heteroplasmic for A/G and the lymph node is homoplasmic for A in this position. The 
second row show traces from patient 9 for (iv) normal mucosa and (v and repeated in 
vi) sigmoid adenocarcinoma. The normal tissue has G at position 168, whereas one 
trace for the adenocarcinoma is heteroplasmic for A/G and a repeat PCR and 
sequence is homoplasmic for A.
Mutations were present in the rectal adenocarcinoma tissue and also in the metastatic 
lymph node of one patient (patient number 3). The mutations found in each tissue 
were different.
From another patient (patient number 14) we were able to obtain sample tissue from 
normal mucosa, rectal adenocarcinoma and metastatic adenocarcinomas from lymph
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node and liver biopsy. Mutations were detected in the metastatic adenocarcinoma 
samples from liver and also, although not identified by SSCP, mutation in the 
metastatic lymph node was also detected. The mutations in these metastatic tissues 
were different from each other.
One patient (patient number 4) had a tumour specific 50bp deletion present in the 
rectal adenocarcinoma; the fragment deleted included the C tract.
The mutations were predominantly transition mutations (40%), deletion and insertion 
mutations accounted for a third of the total mutations, transversion mutations made up 
a fifth and the remaining mutation was a 50bp deletion, see Table 3.5.
Mutations Types of mutation Heteroplasmy
15 mutations from 9/24 patients 
(37.5%)
6/15 (40%) transition 
3/15 (20%) transversion 
3/15 (20%) deletion 
2/15 (14%) insertion 
1/15 (6 %) large scale deletion
3/9 (33%)
Table 3.5
A summary of the types of mtDNA mutations found in the 24 colorectal cancer 
patients
None of the normal mucosa samples from either adjacent to the adenocarcinoma or 
distant to it contained mtDNA mutations. Likewise, none of the polyps from any of 
the sampled locations within the colorectum had mutations in the mitochondrial 
genome. Mutations were found in the adenocarcinoma samples although not from 
those located within the caecum or transverse colon. Half of the 12 rectal tumours and 
both of the sigmoid adenocarcinomas contained mtDNA mutations. The metastatic 
samples were also found to contain mutations, 2/5 lymph nodes and 1/2 of the 
metastatic liver samples were mutated in their mitochondrial genomes, see Table 3.6.
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Tissue Type Number of 
samples
Number 
Mutated (%)
Adjacent mucosa 9 0
Distant mucosa 17 0
Rectal polyp 2 0
Sigmoid polyp 4 0
Transverse polyp 2 0
Caecal polyp 2 0
Rectal tumour 1 2 6  (50%)
Sigmoid tumour 2 2  ( 1 0 0 %)
Transverse tumour 3 0
Caecal tumour 2 0
Metastatic lymph node 5 2 (40%)
Metastatic Liver 2 1 (50%)
Table 3.6
The number of various sample types analysed and the number of these found to 
contain mtDNA mutations.
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3.4 Discussion
3.4.1 Evaluation of techniques
These experiments have proven SSCP to be a valuable quick screening method for 
identifying previously unknown mutations within the D-loop, especially for the 
detection of heteroplasmy, as further explained in section 3.4.2. Polyethylene glycol, 
found in other studies to aid band clarity (Markoff et al. 1997), made no discemable 
alteration to the differentiation of banding patterns in these experiments.
SSCP produced no false positive results for the region amplified. One mutation 
(sample number 36, A178G) was not detected despite repeated SSCP; this mutation 
was detected only by sequencing. This false negative result represents 6.7% (1/15) of 
the mutations detected by sequencing but only 1.7% (1/60) of all the samples 
analysed. This level of sensitivity is slightly higher than previous studies gauging the 
sensitivity of SSCP at 89% using PCR products 400bp in length (Hayashi, 1991).
3.4.2 The detection of heteroplasmy
SSCP was more sensitive than sequencing at detecting heteroplasmy, 3 
adenocarcinoma samples were found to be heteroplasmic. The 2 rectal tumour 
samples (patients 3 and 8 ) were found to have 2 alleles present in their mtDNA in all 
repeats of SSCP and sequencing. The third sample was a sigmoid tumour (patient 9), 
this sample showed heteroplasmy in all repeats of SSCP, see Figure 3.8ii, yet was 
only detected in 1 of 4 sequencing repeats, see Figure 3.10iv-vi. In the other 3 repeats 
the sequencing trace appeared homoplasmic for the mutant allele. This discrepancy 
may be due to the inability of sequencing to distinguish between minor allele peaks 
and background noise.
The intensities of the bands on the SSCP gels varied within each sample, see Figure 
3.8, with one band often more intensely stained than the others. This may be an 
indication of the ratio of alleles present with heteroplasmic samples, with the darker 
band representing the predominant mtDNA type within a cell with mixed mtDNA. 
For example, referring to the sigmoid adenocarcinoma tissue of patient 9 seen in
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Figure 3.8ii, the darker bands correlates to the wild type mtDNA whereas the lighter 
band in this heteroplasmic sample is formed from the mutated sequence and as this 
band is lighter this may indicate this type of mtDNA to be less frequent in the tissue 
than the wild type. Although these gels have been silver stained which is a non- 
quantative staining method, this difference in intensities was also observed when the 
gels were stained with the quantative stain SYBR gold. It may however be an artefact 
as a result of different efficiencies of various sequences to form a specific 
conformation. From comparison of the SSCP bands of the homoplasmic samples 
where one band is frequently more intense than the other for the same allele there is 
no correlation between band intensity and allele frequency within a sample and this 
observation is merely an artefact of the technique. The respective peak heights on 
sequencing traces also do not correlate to the differences seen in SSCP band 
intensities although this may be due to the sequencing traces themselves not being 
accurate to measure allele frequencies (Sigurdardottir et a l , 2000).
3.4.3 Polymorphisms detected
A review of several studies indicates that the mutation rate for this region has been 
estimated at 0.0115 per generation (Sigurdardottir et al., 2000). The variety of 
polymorphisms in this study was notable with 1 0  different germline sequences present 
in the sample group of 24 patients, see Table 3.3. Several samples had more than one 
polymorphism in the fragment analysed and only 4/24 (17%) patients exactly matched 
the Cambridge sequence. The large amount of variation between individuals within 
the control region is well documented and all of the polymorphisms detected in this 
study have been previously recorded with the exception of A178G seen in patient 
number 9 (Mitomap, 2004). This highlights that it is essential to use matched control 
tissue from the same patient for any mitochondrial genome study.
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3.4.4 Mutations detected
3.4.4.1 Age and sex of patients with mutations
As there was no significant difference between the ages of the patients with mtDNA 
mutations (67.6 years) and that of the overall cohort of patients (68.9 years) this 
indicates that the somatic mtDNA mutations observed are not purely due to aging. 
Sex is also not a factor in susceptibility for mutation of the mitochondrial genome as 
there was no significant difference in the sex ratio of patients with mutations (1.24 F: 1 
M) compared to the overall cohort of patients (1.18 F: 1 M).
3.4.4.2 Mutation rate
The mutation rate of 37.5% was higher than previously published for this region in 
colorectal samples. These findings differ from those of previous studies of colorectal 
tumour cells in which no mutations were found within the control region (Heerdt et 
al, 1994; Polyak et a l, 1998). This difference may have arisen because Heerdt’s 
group only analysed 200bp of the control region from nucleotide position 371-570 
(Heerdt et al, 1994), which does not include the hypervariable segment 2 within 
which all o f the mutations detected in this present study were found. Since the control 
region contains hypervariable regions, mutations occur in the control region at a 
greater rate than the rest of the mitochondrial genome as the remainder coding DNA 
is well conserved. Despite this relative stability, mutations are well described within 
the coding region and it is therefore unlikely that the more unstable control region 
would not contain mutations. It therefore seems unlikely that despite mutations being 
found in the coding regions of the mtDNA of colorectal tumour cell lines used in 
Polyak’s group that these genomes did not also contain control region mutations 
(Polyak e ta l, 1998).
3.4.4.3 Comparison to similar studies
The results from this study do correlate very well with studies of oesophageal, 
bladder, lung and head and neck tumours which had D-loop mutation frequencies of 
between 31-36%, see Table 3.5 (Kumimoto e ta l, 2004; Fliss et a l, 2000). The level 
of heteroplasmy found in this study is at a very similar level to that found in 
oesophageal tumours at 33% and 31% respectively. The types of mutations found in
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the four studies outlined in Table 3.7 followed a similar pattern to each other and, 
with the exception of the oesophageal study, transition mutations were the most 
prominent type of mutation. These types of mutation are consistent with ROS related 
mutation (Cadet et al, 1997).
Study Tissue Technique Mutations Types of mutation Hetero­
plasmy
D-
Loop
Current
study
Colorectal
tumour
surgical
resections
PCR-SSCP and 
sequencing of 
400bp region of 
D-loop
15 mutations 
from 9/24 
patients (37.5%)
40% transition 
20% transversion 
21% deletion 
13% insertion 
6% large scale 
deletion
3/9
(33%)
9/24
(37.5%)
Polyak et 
al., 1998
Colon cancer 
cell lines
PCR and 
sequencing of 
whole
mitochondrial
genome
12 mutation 
from 7/10 
patients (70%)
84% transition 
8% transversion 
8% insertion
2/7
(29%)
0/10
(0%)
Kumimoto 
et al., 2004
Oesophageal
tumour
biopsies
PCR and 
sequencing of 
hypervariable 
regions of D- 
loop
14 mutations 
from 13/38 
patients (34%)
21% transition 
50% deletions 
29% insertions
4/13
(31%)
13/38
(34%)
Fliss et al., 
2000
Bladder
tumour
surgical
resections
PCR of 80% of 
the genome 
including the 
D-loop
20 mutations 
from 9/14 
patients (64%)
75% transition 
10% transversion 
10% deletion 
5% insertion
2/14
(14%)
5/14
(36%)
Head and 
neck tumour 
surgical 
resections
PCR of 80% of 
the genome 
including the 
D-loop
9 mutations 
from 6/13 
patients (46%)
78% transition 
11% deletion 
11% insertion
0/13
(0%)
4/13
(31%)
Lung tumour
surgical
resections
PCR of 80% of 
the genome 
including the 
D-loop
10 mutations 
from 6/14 
patients (43%)
80% transition 
10% transversion 
10% deletion
0/14
(0%)
5/14
(36%)
Total of all above studies 80 mutations 
from 50/112 
(45%)
61% transition 
9% transversion 
18% deletion 
11% insertion 
1% large scale 
deletion
11/109
(10%)
36/112
(32%)
Table 3.7
A comparison of mutation frequencies across four studies of mitochondrial mutations 
in tumourigenic tissues. The table also indicates the proportion of samples with 
mutations present in the D-loop region.
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The level of C tract mutations in this study was 4/9 (44%) patients, this was similar to 
that of the oesophageal tumour study at 11/38 (29%) patients this reiterates the highly 
mutable status of this sequence of the control region.
4 of the 9 patients (44%) had mutations within the C tract. Within the nuclear genome 
insertions or deletions within repeat sequences known as microsatellites indicate a 
form of genomic instability known as nuclear microsatellite instability (nMSI). These 
C tract mutations can be described as the mitochondrial equivalent and is termed 
mitochondrial microsatellite instability (mtMSI). Nuclear MSI occurs as a result of a 
deficiency in mismatch repair (MMR), little however is known about the role of 
MMR in the mitochondrial genome. Work using yeast models have identified proteins 
involved in nuclear MMR within the mitochondria; this had led to the belief that some 
form of MMR of mtDNA does exist (Reenan and Kolodner, 1992). Studies of mtMSI 
in oesophageal, breast and colorectal cancer have found no correlation between 
mitochondrial and nuclear MSI (Kumimoto et a l , 2004; Richard et a l, 2000; Polyak 
et a l , 1998). A study of gastric cancers has though found a positive correlation for 
these forms of genomic instability (Habano et al, 2000).
3.4.4.4 Detection of 50bp deletion
One patient (patient number 4, sample 16) had a rectal tumour containing a 
homoplasmic mtDNA 50bp deletion, flanked by a 9bp direct repeat, see Figure 3.11.
CCA CCAAACCCCCCCTCCCCCGCTTCTGGCCACAGCACTTAAACACATCTCTG CC AAACCCC AA
Figure 3.11
The light strand of the Cambridge sequence for nucleotides 295-358. The sequence 
highlighted in the green box is the 50bp portion of the mtDNA deleted in the rectal 
adenocarcinoma of patient 4. The 2 sequences in red are 9bp direct repeat sequences.
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The mtDNA molecule had the 4bp replication primer region as well as 50bp o f the H- 
strand origin o f replication deleted. The missing fragment also contained 5bp o f the 
mtTFl binding site, all o f the 16bp conserved sequence block 2, 2bp o f the conserved 
sequence block 3 and 50bp o f the hypervariable segment 2. It is unlikely that such a 
large scale deletion would not affect the replication o f the mtDNA molecule and in 
turn the function o f the mitochondria and at the higher level o f the cell and tissue.
29 408
15,000 16 ,569 /0  100 200 300 400 500
□  PCR product (29-408)
□  D-loop (16024-576)
□  Membrane attachment site (15925-499)
■  Hypervariable segment 2 (57-372)
13 H-strand origin (110-441)
■  Conserved sequence blocks 1, 2, and 3 
(213-235,299-315, 346-363)
□  mtTFl binding site (233-260, 276-303)
□  Replication primer (317-321)
□  mt4 H-strand control element (371-379)
□  mt3 H-strand control element (384-391)
□  7S DNA (16106-191)
□  L-strand promoter (392-445)
sample 16 (298-347)3  50bp deletion seen in the rectal tumour o f patient 4,
Figure 3.12
This figure illustrates the position o f the 50bp deletion within the PCR product o f the 
mtDNA control region. It can be clearly seen that the deleted fragment includes 50bp 
o f the D-loop, membrane attachment site, hypervariable segment 2 and H-strand 
origin as well as the entire replication primer and conserved sequence block 2 and 
portions o f the mtTFl binding site and conserved sequence block 3. The numbers 
alongside the diagram and following the functional sequence descriptions are the 
relevant nucleotide positions o f the mitochondrial genome according to the 
Cambridge mtDNA sequence (Mitomap, 2004).
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Although it has been shown that specific alleles can dominate mitochondrion and 
become homoplasmic with no selective advantage (Coller et al, 2001) it seems that 
despite the deletion of the H-strand origin of replication, the 50bp deletion seen in this 
sample may have an advantage over full length mitochondrial genomes in terms of a 
shorter replication time. As a result, this smaller molecule came to dominate the 
mitochondria and cell and through the clonal mechanism of tumorigenesis this has 
then become homoplasmic for the rectal adenocarcinoma.
This large scale deletion has also been found as a somatic mutation in gastric cancers 
(Burgart et al, 1995). In this study the mutation was found in 4/77 (5.2%) gastric 
adenocarcinomas, a similar level to this current study 1/24 (4.2%). Half of these 
affected tumours were homoplasmic for this deletion whilst the other two cases had 
the mutation present in the heteroplasmic form accounting for <5% of the mtDNA. 
This study suggests that the 50bp deletion may have no effect on the function of the 
mitochondria as the mitochondrial DNA was able to replicate without the H-strand 
origin of replication and suggested the deletion may have created a new heavy strand 
promoter (Burgart e ta l, 1995).
3.4.4.5 Level of heteroplasmy
All of the normal and precancerous tissues in all patients were homoplasmic. The 
level of heteroplasmy found in this study was 3/9 (33%) patients with mtDNA 
mutations. This level is very similar to that found within oesophageal tumours 4/13 
(31%) and colorectal cell lines 2/7 (29%) (Kumimoto et al, 2004; Polyak et al, 
1998). However, a far lower level of heteroplasmy was detected in another study of 
lung 0/14 (0 %), bladder 2/14 (14%) and head and neck 0/13 (0 %) tumours (Fiiss et al,
2000).
The study of oesophageal tissue found 4/38 normal tissues to be heteroplasmic within 
the C tract region from Cambridge sequence position 303-309. This was not observed 
in this research of colorectal cancer patients or in the other studies reviewed in Table 
3.4.
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Cell fusion experiments have shown that mitochondrial DNA from tumours can have 
a significant replicative advantage over other types of mtDNA and even give 
significant selective advantage on a cellular level (Shay and Werbin, 1978; Shay and 
Ishii, 1990). When two tumour cell lines are fused the mitochondria of one rapidly 
replace those of the other, it has been suggested that this is due to the mutated mtDNA 
molecules replicating at a higher rate to compensate for the affect on OXPHOS that 
deleterious mtDNA mutations may cause (Polyak et a l , 1998). These theories can 
explain the homoplasmy seen in other studies and the homoplasmic mutations seen in 
this study, such as the 50bp deletion seen in the tumour tissue of patient 4 which 
would be likely to have a negative effect upon the OXPHOS of the cell. The selective 
growth advantage may be a result of mutations in either the mitochondrial or nuclear 
genome (Augenlicht and Heerdt, 2001). This may though also be a result purely of 
random segregation from the high number of cell generations, around 600, seen in 
tumour tissue (Coller et a l, 2001). This homoplasmy however was not seen in all the 
samples of this present study, it is possible that the heteroplasmy was not detected in 
previous studies of lung, bladder and head and neck tumours which relied entirely on 
sequencing (Fliss et a l, 2000), as in this study sequencing also did not always detect 
the less prominent allele. It has previously been estimated that the minor allele needs 
to be present at a frequency of >30% in order to be detectable by sequencing 
(Nickerson et al, 1997). Other studies have shown respective sequencing trace peak 
heights to vary according to sequencing direction and concluded that sequencing is 
not a reliable technique for determining degree or presence of heteroplasmy for the 
control region of mtDNA (Sigurbardottir et a l, 2000). In the experiments described in 
this chapter all cases of heteroplasmy were detected on the SSCP gels, which 
exhibited extra bands for the heteroplasmic tissues whereas only two clear bands 
could be seen for other homoplasmic tissues. If previous groups have relied on 
sequencing alone and the sequencing traces not analysed for minor alleles this may 
explain why little heteroplasmy has been reported in some of the previous studies.
3.4.5 Effect of the mtDNA mutations
There has been much debate as to the role of mtDNA mutations in carcinogenesis. 
Whereas mutations in the mitochondrial genome have long since been known to cause 
diseases such as Leber’s hereditary optic neuropathy, their role in cancer development
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is still uncertain. It is unclear whether these mutations are simply the result of cellular 
instability due to mutations in nuclear oncogenes which affect the stability of both the 
nuclear and mitochondrial genomes or whether the damaged mtDNA is directly 
involved in causing the cancer. One way in which this is possible is if  mtDNA 
mutations cause an increase in the amount of ROS which mutates the mtDNA further 
and also causes mutations within the nuclear genome. Another possible mechanism 
for the mtDNA to play a role in carcinogenesis is through apoptosis. Mutations within 
the mtDNA may affect the membrane potential of the mitochondria making it less 
able to release the pro-caspases required in the initiation of apoptosis. This makes the 
cell more resistant to apoptosis and so may replicate with high levels of genetic 
damage and assist the pathway of carcinogenesis.
Decreased mitochondrial gene expression has been reported in colonic tumours 
(Heerdt et al., 1990). The majority of the mutations detected in this study would 
though be unlikely to affect the function of the mitochondria as 73% (11/15) of the 
mutations lay within the hypervariable region II. 27% (4/15) of the mutations were in 
the C-tract, which is a variable region across individuals (Mitomap, 2004). This is in 
accordance with the results for this region previously published (Heerdt et a l , 1994). 
However, there were some mutations lying within sequences of the mitochondrial 
genome which have a critical role in the function of the mtDNA such as the promoter 
regions for the L- and H-strand. Despite this it is still difficult to establish the effect of 
mutations in the mtDNA as it is as yet unknown how the mitochondrial genomes 
within the individual mitochondria and within the cell interact with respect to genetic 
dominant and recessive effects (Augenlicht and Heerdt, 2001). Even when the cell is 
homoplasmic the function of the mitochondria is dependant also upon the nuclear 
genome as the mtDNA does not code for all of the proteins the organelle requires (Fos 
et al., 1990; Dunbar et a l , 1995). It has also been estimated that up to 80% of the 
cells mitochondrial genomes can be mutated with no phenotypic effect (Shoffner and 
Wallace, 1992).
As the mutations detected in this study are unlikely to have an effect on the function 
of the mitochondria and as these mutations were only found in the later stages of 
cancer development this suggests that the mutations are an epiphenomenon resulting
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from changes in the nuclear genome and are not actually causative of carcinogenesis 
in their own right.
3.4.6 Location of mutated samples within the colon
All of the mtDNA mutations were found in the sigmoid colon and rectum, with no 
mutations present in either the ascending or transverse colon samples. The location 
within the colon of the tumours found with mitochondrial mutations may be a result 
of the differing functions along the length of the colon. The ascending and transverse 
sections of colon contain more dilute faecal matter, which is continuously being 
moved by smooth muscle contractions along the colon known as peristalsis. The 
sigmoid colon and rectum contain more concentrated faeces where they are stored 
until expulsion. This results in a prolonged exposure to higher levels of potential 
carcinogens from endogenous and exogenous agents in the faeces in comparison to 
other regions of the colon. One such mutagenic agent is bile acid, which is found to be 
excreted more in those with a higher consumption of fat (Reddy, 1981), another 
colorectal cancer risk factor. A study has shown an increase in excreted faecal 
unconjugated bile acids in patients with colorectal cancer and polyps (Imray et a l, 
1992). After the consumption of a fatty meal, the level of bile in the faeces increases 
to a concentration which causes DNA damage by the production of ROS. The 
damaged cells then undergo apoptosis (Glinghammar et a l, 2002). After cells in an 
area of mucosa have been killed, surviving cells from nearby areas migrate to produce 
a new epithelium. Cells are more likely to survive exposure to cytotoxic agents if they 
have a higher resistance to apoptosis. Therefore, over time, the colonic mucosa of 
those eating many high fat meals may become populated by an increased number of 
cells resistant to apoptosis and so the burden of irreparable DNA damage increases 
giving a higher colorectal cancer risk (Bernstein et a l, 1999). This can also explain 
why 50% of colorectal tumours are found in this region despite this region being less 
than a third of the total colon and that different mechanisms for tumorigenesis are 
responsible for the majority of cancers found in the different regions of the colon 
(Spence and Johnston, 2001). Tumours which exhibit nuclear microsatellite instability 
are predominantly located on the right side of the colon; yet none of the tumours 
exhibiting mitochondrial microsatellite instability (mtMSI) were in this location.
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It is possible that other exogenous factors are responsible for an increased risk of 
causing mtDNA mutations; for example, mtDNA has been shown to be mutated by 
carcinogens such as benzo(a)pyrene, polycyclic aromatic compounds and aflatoxin at 
a higher rate than nuclear DNA (Backer and Weinstein, 1980; Allen and Coombs, 
1980; Niranjan et a l , 1982). Studies on the parotid gland found mtDNA mutations in 
the histologically normal tissue samples from 22% of the smokers analysed (Lewis et 
a l , 2002). However, an evaluation of smoking status and alcohol consumption levels 
of patients with oesophageal cancers found no significant relationship between these 
lifestyle factors and presence of mtDNA mutation (Kumimoto et a l, 2004). 
Unfortunately data on diet, smoking status and alcohol consumption levels were not 
obtained for the colorectal cancer patients in this study.
3.4.7 Assessment of mutation level within coding regions of the mtDNA
In a scan using SSCP of a 473bp fragment of the conserved gene NADH 
dehydrogenase subunit 2 (ND2) of 34 of the patient samples used in the above 
described experiments I found no detectable mutations. In a previous study of this 
ND2 region of the mtDNA in the histologically normal parotid tissue of smokers, 
21.7% (5/23) of the samples were found to contain point mutations compared with 
none of the 16 non-smokers (Lewis et al, 2002). Although the parotid tissue mtDNA 
mutations could be detected before any histological changes could be seen, in 
colorectal adenocarcinoma tissue, which is clearly different from normal mucosa, no 
such mutations in the ND2 gene were detected by SSCP.
3.4.8 Samples and sample numbers
This is one of the largest studies of its kind with 65 samples from 24 patients; it is also 
the only study to look at mtDNA mutations within pre-cancerous polyp samples and 
metastatic secondary cancers in the liver and lymph node. The sex ratio and the age 
range of the cohort also typical for colorectal cancer in the general population. There 
was a bias in the locations of the tumours within the colon with the majority of 
cancers from the rectal region of the colorectum with 1 2 / 2 0  (60%) of the 
adenocarcinoma samples from the rectum. The samples were collected over 12 
months simply as they became available through surgery and as such they are
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representative of the occurrence of these cancers within South Wales. Patients with 
left-sided tumours generally present earlier as these affect bowel function sooner and 
may result in fresh bleeding par rectum. Right-sided tumours are less likely to affect 
bowel function but patients present with more vague symptoms such as chronic 
tiredness due to anaemia. These latter tumour types are therefore more likely to be left 
until much later stages of carcinogenesis where the cancer becomes inoperable and 
are therefore not seen as often in surgery although the rate of incidence may be higher 
than the number of these sample types in this study suggest.
Another point that must be clarified is that all of the mtDNA mutations seen in 
primary tumours were found in either rectal or sigmoid adenocarcinoma tissue 
samples. This is 50% of all the rectal adenocarcinomas sampled and all of the sigmoid 
tumours. However, whilst there were 12 rectal tumours sampled there were only 2 
sigmoid tumours in the sample group. The small number of sigmoid adenocarcinomas 
in this study means that whilst the two samples may be representative of tumours 
from this region this is unlikely due to the possibility of sampling error and it is 
therefore impossible to extend the claim that all sigmoid adenocarcinomas contain 
mtDNA control region mutations
3.4.9 Diagnostic potential of mitochondrial DNA mutations
This study found tumour specific mitochondrial DNA mutations in 37.5% (9/24) of 
patients and of these 44% (4/9) were in a short sequence of the control region, the ex­
tract spanning from nucleotide position 303-309. One purpose of these experiments 
was to discover if there were any mutational hotspots within the mitochondrial 
genome which could be used to screen for colorectal cancer as screening the entire 
genome is not a cost effective method, at least not with currently available techniques. 
Mutations in the tumour suppressor gene p53 have been detected in the faeces of 
patients whose tumours contained these mutations (Dong et a l, 2001). These 
mutations occur late in the progression of carcinogenesis and so an earlier marker 
would be a significant advance in the field of colorectal cancer diagnostics. The 
results from these experiments show that 17% (4/24) of patients have a tumour 
specific mutation within a 7 base sequence of their mitochondrial genomes. As this is 
such a small region, it is a realistic target for screening. Since these C-tract mutations
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were not detected in all of the patients, this would have to be used as part of a bank of 
screening methods to detect all colorectal cancers. This bank of markers could include 
APC which is mutated early on in cancer progression and, to detect other cancers 
developed from other pathways, a marker for nMSI such as transforming growth 
factor (3-type receptor type II (TGF(3RII) which again occurs early in the development 
of carcinomas which have deficiencies in mismatch repair (Atkin and Martin, 2001; 
Grady e ta l , 1998; Samowitz e ta l, 2001b).
The other notable point about these results in terms of the potential for this region to 
be used for screening is the stages at which these mtDNA alterations were detectable. 
The perfect screening method for colorectal cancer would be non-invasive, cost- 
effective, accurate and sensitive to the earliest detectable changes as cancers form 
where treatment less radical, often requiring surgery alone and if detected at Dukes’ 
stage A or B the overall survival rate is 80-95%. Whilst the results in this study 
provide scope for a non-invasive screening technique that is cost effective the 
mutations were only detected in the adenocarcinoma and metastatic carcinoma stages 
of progression. At these stages the cancers are rarely asymptomatic and, for example, 
if detected in Dukes stage C or D, where 63% of colorectal cancers are detected, there 
is a 5 year survival rate of between 5-20% and as such this proposed screening 
method has little clinical value. Whether the cancers with these mutations respond 
differently to various forms of treatment such as chemotherapy or are particularly 
aggressive or indeed have a higher rate of survival than the cancers without 
mitochondrial genome aberrations is an area worthy of further investigation.
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3.4.10 Discussion summary
This is the first study of its kind to analyse precancerous lesions such as polyps as 
well as colorectal carcinomas and normal mucosa from distant and adjacent positions 
to the adenocarcinomas. This is also the largest mtDNA study of colorectal cancer 
patients and used surgical samples rather than cell cultures which tend to obtain 
mutations as they undergo the many generations typical of cell culture. This has 
provided valuable information as to when the mtDNA mutations occur against the 
progression of carcinogenesis within the colorectum.
As no mutations were present in any of the normal, adenoma and hyperplastic polyp 
samples and in one patient found in metastatic adenocarcinomas tissue but not in 
matched adenocarcinoma tissue this suggests that these mitochondrial mutations 
occur at a late stage of progression. These results suggest that mtDNA mutations are 
an epiphenomenon rather than a driving factor of colorectal carcinogenesis. These late 
occurring mutations would therefore be of little clinical significance in terms of an 
early molecular biomarker for the detection of colorectal cancer. Despite this, these 
mutations, which were found in 9/24 (37.5%) patients, could still be valuable as a late 
biomarker. These could be valuable in detecting fully formed carcinomas in, for 
example, the faeces of patients post operational to detect recurrence of the disease. 
These results are also of importance in the context of elucidating more about the 
different mechanisms in the carcinogenesis of colorectal tumours in different 
locations within the colon. It may also be possible to identify environmental agents 
responsible for causing colorectal cancer by comparing the mutational spectra of the 
tumours against those recorded for various carcinogens. Due to the nature of the 
mutations, predominantly in microsatellites within the mtDNA, these results also may 
add insight into the mismatch repair mechanisms of the mitochondrial genome. To try 
to establish any connection between mtMSI and nMSI I have assessed all the samples 
analysed in this chapter for nMSI. This research is the content of Chapter 4.
85
Chapter 4
The evaluation of nuclear microsatellite stability 
status using fragment analysis
4.1 Introduction
Colorectal cancer arises when epithelial cells within the colorectum become mutated 
so that the normal controls regulating cell growth and cell death are no longer able to 
balance these processes leading to tumour development. There are several proposed 
pathways by which carcinogenesis can occur (Narayan and Roy, 2003). The majority 
of colorectal cancers arise from the chromosome instability (CIN) pathway which is 
discussed further in Chapter 6 . However, a significant proportion of sporadic 
colorectal cancers and also those cancers which develop in patients with the familial 
disease hereditary nonpolyposis colorectal cancer arise from a different route known 
as the microsatellite instability (MSI) pathway (Minamoto and Ronai, 2001). The 
proposed pathways of colorectal carcinogenesis are illustrated in Figure 4.1 with the 
MSI pathway highlighted in blue. In Chapter 3, mutations were found in a polyC 
microsatellite present within the control region of the mitochondrial DNA of tumour 
tissue in 17% of patients studied. The purpose of this current chapter is to analyse 
these same patients to establish whether there is a link between microsatellite 
instability (MSI) in the mitochondrial and nuclear genomes.
4.1.1 Microsatellites
The term microsatellite is derived from the term for satellite DNA from the 
observation that fragments of DNA with tandemly-repeated sequences form 3 
‘satellite’ bands when genomic DNA is fractionated by density gradient centrifugation 
as these fragments of DNA have atypical buoyant densities in comparison to the 
average density of human DNA (Brown, 1999; Gall et a l, 1973). Microsatellites are 
repetitive sequences of nucleotide repeats usually less than 1 0 0  bases in length 
(Lodish etal., 1995). These tandem repeated sequences are usually between lbp, such 
as mononucleotide repeats of cytosine (poly(C) tracts) and pentanucleotide motifs of
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5bp repeats. These types of sequences are frequent throughout the genome and are 
randomly distributed (Sutherland et al., 1995). The function of microsatellites is as 
yet unknown (Brown, 1999).
4.1.2 Microsatellite instability
Microsatellite instability (MSI) is characterised by alterations to these simple repeat 
sequences, including insertions and deletions both of which result in frameshift 
mutations and in turn, where these lie in coding regions, in truncated proteins. 
Microsatellites are prone to these mutations which occur as a result of slipped strand 
mispairing. This mispairing predominantly occurs during DNA replication when the 
normal pairing between complementary DNA strands is altered by staggering of the 
repeats on the 2 strands. Deletions or insertions are a result of the newly synthesised 
strand slipping forward or backwards respectively (Strachan and Read, 1998).
MSI arises due to defects in the system responsible for maintaining genomic stability 
known as mismatch repair (MMR) (Wheeler et a l , 2000). MMR increases the fidelity 
of DNA replication by identifying and removing single-base mismatches and 
insertion-deletion loops that may arise from strand slippage. MMR involves 
replication, repair and recombination stages (Narayan and Roy, 2003). This repair 
system is the reason why, despite their more vulnerable sequences, the mutation rate 
at these microsatellite sites is only slightly higher than at other genomic sites at 
around 5 x 10-4 to 5 x 10'5. However, in cells that are MMR deficient the overall 
mutation rate is 100-1000 fold higher than in normal cells (Hearne et al., 1992; 
Narayan and Roy, 2003). A germline or somatic mutation in any of the genes 
encoding for the proteins involved in any part of this complex process, such as hMSH2, 
hMSH6 , MLH3 and hMLHl, can give rise to MSI (Wu et a l , 2001; Wu et a l , 1999; 
Wheeler et a l , 2000). MMR is discussed further in Chapter 1, section 1.1.1.3. MSI 
tumours are also termed mismatch repair deficient (MMR') or replication error positive 
(RER^ as they are unable to repair errors occurring during DNA replication.
Throughout their development, MSI tumours accumulate over 1 0  ^ clonal somatic 
deletions and insertions in the microsatellite repeats with at least 1 0  occurring in 
functional sequences (Ionov et al, 1993; Ionov et a l, 2000; Duval et al, 1999). MSI
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tumours often have frameshift mutations within the repeat sequences in the MMR 
genes hMSH3 and hMSH6  (Malkhosyan et al., 1996; Wu et a l, 1999). Transforming 
growth factor-P receptor II (TGF-pRII), Bax, insulin-like growth factor II receptor 
gene (IGFIIR), phosphatase and tension homologue deleted on chromosome 10 gene 
(PTEN) and caspase 5 are all known gene targets of MMR gene inactivation as these 
have microsatellite regions prone to mutation and are also all involved in cell growth 
regulation (Souza et al, 1996; Narayan and Roy, 2003). Associations have been 
established between MMR deficiency and loss of normal cell cycle control, 
particularly G2 arrest as a result of the disruption of these targeted genes (Fallik et al., 
2003).
As well as the length of the microsatellite and the preceding nucleotide sequence, the 
nature of the base repeat sequence (such as mono- or dinucleotide repeats) and the 
chromatin structures surrounding the repeat sequence are also important factors for 
determining the rate of mutation within the microsatellite (Zhang et al, 2001; Boyer 
et al, 2002). For example, mononucleotide repeat sequences of G have been shown to 
be significantly more prone to mutation than A tracts (Zhang et a l, 2001; Boyer et al., 
2002). The mutation of coding microsatellites in MMR' tumours also appear to be 
affected by the gene function as these mutations are non-random and several genes 
are targeted (Duval and Hamelin, 2003). This is explained in further detail later in this 
chapter.
4.1.3 Microsatellite instability and colorectal cancer
4.1.3.1 Hereditary non-polyposis colorectal carcinoma (HNPCC)
The hereditary disease HNPCC is caused by inherited dominant germline mutations 
of mismatch repair genes and is responsible for between 5-13% of colorectal 
carcinomas (Wheeler et al., 2000; Minamoto and Ronai, 2001). The resulting 
carcinomas have a mutator phenotype due to replication errors that are not repaired 
with these mutations mainly occurring in microsatellites. hMLHl or hMSH2 
mutations account for the majority of germline mutations in HNPCC families (Ward 
et a l, 2001). As HNPCC polyps develop to malignancy at a faster rate than familial 
adenomatous polyposis (FAP) polyps it is thought that the MSI mutator phenotype
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may be responsible for this acceleration of tumour development (Chung, 2000). This 
disease has also provided invaluable insight into this MSI pathway of carcinogenesis 
which also occurs in around 6-18% of sporadic colorectal cancer cases (Young et al, 
1993; Thibodeau e ta l , 1993; Ionov etal., 1993; Chao etal., 2000).
4.1.3.2 Microsatellite instability and sporadic colorectal cancer
Sporadic colorectal cancers with MSI occur as a result of hypermethylation of the 
promoter region or new somatic mutation of mismatch repair genes (Herman et al., 
1998). Mutations within poly(A) tracts were first used to define MSI in human 
tumours. This study of sporadic colorectal cancers suggested that 12% of colorectal 
carcinomas contained these mutations and the instability of simple repeat sequences 
was greater in one subset of colon tumours than others, suggesting a different 
mechanism of tumourigenesis (Ionov et al, 1993). This research promoted further 
studies and higher order microsatellites (such as di-, tri- and tetra-nucleotide repeats) 
were analysed in sporadic and familial colorectal cancers and again alterations were 
found (Young eta l, 1993).
Studies have shown that 93% of MSI sporadic tumours are located in the proximal 
colon; but proximal colonic tumours are not predominantly micro satellite unstable 
(Thibodeau et al, 1998; Ward et al, 2001, Chung, 2000). Sporadic MSI tumours have 
a mucinous phenotype, are generally at Dukes’ stage B (stages of colorectal cancer 
are described in Chapter 1, section 1.2.1) and more frequently occur in women (Ward 
et al., 2001; Thibodeau et al, 1998; Samowitz et a l, 2001b; Chung, 2000). Tumours 
with MSI also have distinctive clinical features such as poor differentiation, reduced 
invasiveness, prominent infiltration of lymphocytes and a Crohn’s-like reaction in 
surrounding tissue where there is an aggregation of lymphoid cells (Chung, 2 0 0 0 ). 
Although originally no correlation with MSI tumours and age was found this may 
have been because the mean age is the same for MSI and microsatellite stable (MSS) 
patients. The distribution of ages is though very different for MSI tumours which have 
a bimodal distribution with most of these tumours developing in younger patients as 
well as in patients over 75 years (Thibodeau et al., 1993; Chao et al, 2000).
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MSI tumours have been linked to cigarette smoking, with a linear relationship 
between risk of MSI tumours and amount smoked in terms of cigarettes per day and 
number of years of smoking (Slattery et a l , 2000; Samowitz et a l , 2001b). From a 
study of over 1500 patients, it has been estimated that smoking > 2 0  cigarettes a day 
doubles your risk of MSI colon cancer, a risk that is only removed after having 
stopped smoking for over 15 years. A recent study has suggested that 21% of MSI 
colon cancers can be attributed to cigarette smoking (Slattery et a l , 2000).
4.1.3.2.1 MSI and prognosis in sporadic colorectal cancer
MSI tumours were also shown to be linked to a better prognosis, especially in patients 
under 50 years old, with a reduction of approximately 60% in the risk of death due to 
colorectal cancer (Gryfe et al, 2000; Samowitz etal., 2001a). This increase in patient 
survival is possibly due to an induction of an antitumour response, as lymphocytic 
infiltrates have been detected in these tumour types (Chung, 2000; Ward et al., 2001). 
Another possible explanation for the enhanced survival of patients with these cancer 
types could be the tendency of MSI-H tumours to fail to progress from localised to 
metastatic tumours as the mutational load of these tumours becomes detrimental to the 
growth of the tumour and limits the metastatic potential (Shibata et al, 1994). This 
reduction in the ability to progress through the carcinogenesis pathway could be a 
result of the correlation of MSI-H tumours with wild type p53. The lack of p53 
mutation may also explain why many MSI-H tumours in stages II and III are larger in 
size than MSS tumours and therefore may have an increase in severity of symptoms 
prompting the patient to present earlier than those with MSS tumours (Ward et al,
2001). MSI tumours have been thought to have a reduced risk of liver metastasis 
(Ionov et a l, 1993; Gryfe et al., 2000). A more recent study has challenged this, 
finding their series of liver metastatic tumours to have a similar proportion of MSI as 
colorectal carcinomas which did not metastasise (Fallik e ta l, 2003).
4.1.4 Microsatellite instability and choice of chemotherapeutic treatments
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As well as mutation, RER+ has been shown to be caused by biallelic hypermethylation 
of the promoter regions of MMR genes especially in sporadic cases (Herman et al., 
1998; Cunningham et a l, 1998). This hypermethylation of MMR gene promoter 
regions may explain why MMR' cells have been found to be highly tolerant to 
methylating chemotherapeutic drugs and therefore less effective at treating these types 
of tumour (Claij and Riele, 1999). Methylating chemotherapy agents also work by 
producing 0 6-methylG which then mispairs with thymine. This is then excised by 
MMR but is then replaced by the same mutation, MMR occurs again and so long­
standing DNA breaks occur which trigger apoptosis (Ma et al, 2002). In cells that lack 
MMR, these methylating agents can simply cause further mutation. Studies have also 
shown that metastatic colorectal tumours with MSI have a better response to the 
chemotherapeutic agent irinotecan than those that are not MSI (Fallik et a l, 2003). 
Therefore, MMR status plays a crucial role in the toxicity of DNA-damaging drugs 
used in cancer chemotherapy and is important in the choice of treatments for 
colorectal cancer, especially where first-line treatments such as 5-fluorouracil have 
failed (Carethers et al, 2003). 5-fluorouracil has been found to be less effective in 
MMR' cell lines and more importantly has been shown to actually reduce the survival 
of patients with MSI-H stage II and III colorectal tumours. This is because patients 
lose their improved survival if treated with 5-fluorouracil with the 5 year survival 
dropping from >85% if untreated to only 70% following treatment (Carethers et al., 
2003; Ribic et al, 2003). Other drugs such as the topoisomerase-I inhibitor 
chemotherapeutic agent camptothecin have been shown to successfully kill MMR' 
cancer cells exhibiting MSI-H (Bras-Goncalves et al., 2000). These studies have 
highlighted the importance of establishing the MSI status of a tumour before deciding 
the most appropriate chemotherapeutic treatment.
4.1.5 Pathway of tumourigenesis for MMR' tumours
Studies analysing patients with the familial disease hereditary nonpolyposis colorectal 
cancer (HNPCC) have provided insights into not only this disease but also into the 
subset of MSI sporadic colorectal cancers. One of the earliest studies to suggest a 
different pathway for these cancers was published by Konishi in 1996. It found that 
replication error positive status occurs at an early stage of carcinogenesis in HNPCC
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but at a later stage in non-HNPCC and suggested that this may indicate that HNPCC 
tumours develop through a different adenoma-carcinoma sequence (Konishi et a /., 
1996).
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Figure 4.1
This diagram illustrates the proposed pathways to colorectal cancer that currently 
exist. The original pathway based on Vogelstein’s model is shown as the chromosome 
instability (CIN) pathway and has red arrows with the key changes required for cancer 
progression labelled. The microsatellite instability (MSI) pathway is at the top o f the 
diagram and is highlighted in blue listing the main genes involved in mismatch repair 
(MMR) which, once mutated, cause the hypermutable phenotype. The main target 
genes mutated in MSI colorectal cancers are then listed, frameshifts within these 
causing the MSI tumour to develop into a carcinoma. The remaining three pathways 
have several question marks to indicate the ambiguity surrounding these pathways 
and it is possible these pathways may overlap in several respects. UCACRC is the 
initialisation used for ulcerative colitis-associated colorectal cancer. Diagram from 
Narayan and Roy, 2003.
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The pathway for sporadic cancers with MSI-H differs from the adenoma-carcinoma 
pathway seen in the majority of colorectal cancers, see Figure 4.1 (Jass et a l , 2000). 
There are many studies, with many different findings to back up this hypothesis. 
Experiments have shown that MMR' tumours and carcinomas with TGF-PRII 
mutations are less likely to have mutations in the tumour suppressor gene K-ras 
(Slattery et al., 2000). Another study has shown MSI to be three times more prevalent 
in tumours with wild type p53, APC and K-ras, all of which are key genes in the 
standard Vogelstein model of carcinogenesis (Iacopetta et al, 1998; Fearon and 
Vogelstein, 1990). To add support to the theory that MSI tumours develop through a 
different mechanism to other carcinomas, an inverse relationship was found between 
MSI tumours and those with APC and p53 mutations and tumours exhibiting LOH for 
chromosomes 5q (APC), 17p (p53) and 18q (DCC) (Ionov et al., 1993; Thibodeau et 
al., 1993; Aaltonen etal., 1993; Konishi etal., 1996).
Although the genes involved in HNPCC and sporadic MSI colorectal cancer may be 
the same, the mode in which these MMR genes become inactivated is different, with 
hMSH2 and hMLHl being mutated in hereditary cases but are, in contrast, inactivated 
through hypermethylation in the majority of sporadic cases (Jass, 2000; Herman et al., 
1998; Cunningham et a l, 1998). Another difference between the heritable and 
sporadic disease is the lack of sporadic adenomas with high levels of MSI (MSI-H) 
despite 80% of HNPCC adenomas having a MSI-H phenotype (lino et al., 2000). 
There is also an increased frequency of MSI-H carcinomas in sporadic rather than 
inherited cancers. This may be due to a rapid evolution of adenoma to carcinoma, the 
sporadic MSI-H adenomas being flat and therefore missed at endoscopy, an 
alternative pathway or a combination of these ideas (Pawlik et a l, 2004). The 
possibility of small adenomas being missed is very dependent upon the experience of 
the surgeon and is critical with adenomas of less than 5mm which have been found 
with MSI-H (lino et al, 2000). A new technique known as chromoendoscopy has now 
been adopted by many endoscopy units to facilitate the detection of small or flat 
lesions which may otherwise be missed. This technique involves applying a dye to the 
colonic mucosa which stains these growths so that far fewer are missed at 
colonoscopy even by less experienced surgeons (Kiesslich e ta l, 2001).
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Even within the classification of sporadic MSI-H colorectal cancers, differences 
between reports of sporadic MSI from groups based in Western countries and those 
from Asia have been highlighted, and it is suggested that MSI-H tumours may arise 
from two pathways, one via serrated polyps and one via flat adenomas (Shitoh et al, 
2000; Jass, 2001a)
4.1.6 Detecting microsatellite instability
MSI assays have focused on the effects of the mutations of MMR genes in terms of 
microsatellite alterations as these has been found to be a more efficient method of 
measuring instability than looking directly at the MMR genes as there are so many 
involved in the process (Minamoto and Ronai, 2001). As opposed to HNPCC, 
mutations in the MMR genes of sporadic cancers are relatively infrequent, with the 
wild type genes becoming inactivated by the process of biallelic hypermethylation of 
the promoter regions (Jass, 2001b). This is especially true of the MMR gene hMLHl, 
the altered expression of which is thought to be responsible for the RER+ phenotype 
in the majority of MSI-H tumours (Herman et a l, 1998; Veigl et al, 1998; 
Cunningham et a l , 1998).
Immunohistochemistry has been used to assess for altered protein levels and the 
method has demonstrated hMLHl protein expression is absent in 90% of MSI 
colorectal cancers (Thibodeau et a l, 1998). Whilst PCR-based analysis of 
microsatellites is recognised as the most sensitive method of MSI identification, 
immunohistochemical staining for MLH1 and hMSH2 is a technically simpler, 
inexpensive, rapid and accurate method of MSI-H detection with a predictive value 
for MSI-H tumours of over 96% (Ward et al, 2001).
Hundreds of MSI assays studying microsatellite alterations have now been undertaken 
and the occurrence of MSI in colorectal tumours is well documented, with rates of 
MSI ranging from 85-90% in HNPCC tumours (Aaltonen et al, 1993) to between 6 - 
30% in sporadic cases (Ionov et a l, 1993; Thibodeau et a l, 1993; Watatani et al, 
1996). The majority of sporadic cancers occurring in young people below the age of 
36 are MSI with a rate of around 64%, much higher than in patients over 36 for which 
the rate of MSI is around 12%. In the younger cohort of patients 42% had germline
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mutations of a MMR gene. By contrast, in MSI cases in older patients, MMR 
germline gene mutations are only very rarely found (Liu et al., 1995a; Liu et al., 
1995b). In a study of familial adenomatous polyposis (FAP) tumours MSI was found 
in only 5% of tumours (Konishi et al., 1996). Overall, taking into account heritable 
diseases such as HNPCC and sporadic cases, 25% of colon cancers are microsatellite 
unstable (Coleman and Tsongalis, 2002).
The frameshift mutations that arise from unrepaired slipped strand mispairing, 
generate nonsense mutations, the RNA transcripts for which are usually targeted for 
degradation through the process of nonsense mediated decay (NMD). NMD is a very 
rapid process which recognises and breaks down mRNA molecules which contain 
premature termination codons (Holbrook et al, 2004). This process can also be 
utilised to identify genes with tumour suppressor functions. For this technique NMD 
is blocked and stress response genes are suppressed so that the increased levels of 
mutant mRNA molecules containing premature termination codons can be detected. 
Using this technique, the gene p300 has been shown to be inactivated in MSI 
tumours; the function of this gene is as yet unknown (Ionov et al, 2004).
4.1.6.1 The Bethesda panel of MSI markers
The National Cancer Institute recently devised a system to classify tumours by their 
degree of MSI. Three categories were made, microsatellite stable (MSS), low level of 
MSI (MSI-L) and high level of MSI (MSI-H) and tumours categorised according to 
how many PCR marker sets were unstable (Liu et al, 1995a; Boland et al, 1998; 
Thibodeau et al., 1998). A panel of five microsatellite markers for MSI analysis were 
proposed by the International Workshop on MSI and RER phenotypes in Cancer 
Detection and Familial Predisposition in 1997 in an attempt to standardise the MSI 
markers used. These markers consisted of two mononucleotide repeats (BAT25 and 
BAT26) and three dinucleotide repeats (D2S123, D5S346 and D17S250) and are 
collectively known as the Bethesda markers (Boland e ta l, 1998). Potential genes for 
the screening of MSI in colorectal cancers should have a high mutational frequency, 
biallelic inactivation, a role in a growth suppressor pathway, alterations also in MSI 
negative tumours and there should be functional evidence (Boland et a l, 1998). Two 
of these criteria, a high mutational frequency and functional evidence are generally
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agreed to be the most important of these factors, especially in the search for novel 
MSI target genes (Vilkki et al, 2002).
The BAT26 locus contains a A26 tract within the hMSH2 gene and is the most 
sensitive of these markers (Ward et a l, 2001, Loukola et al., 2001) and has been used 
alone in several studies (Samowitz et al, 1999; Zhou et al, 1998; Hoang et al, 1997) 
and been shown to detect MSI in 97-99.5% of MSI-H tumours (Loukola et al, 2001; 
Zhou et al, 1998). Although polymorphisms in Caucasian populations are rare 
(0.08%), in African-American populations germline variation for BAT26 has been 
found to be between 7.7 - 12.6% and therefore this marker should be used along side a 
matched normal control tissue (Pyatt et al, 1999; Samowitz et al, 1999). This also 
applies to the T25 tract within the c-kit gene known as MSI marker BAT25 which 
exhibits allelic variation in over 18% of African-Americans (Pyatt et al., 1999). 
Matched normal tissues are also required for the dinucleotide markers D2S123, 
D5S346 andD17S250 (Loukola etal., 2001).
The Bethesda markers, especially the dinucleotide repeats, have also been criticised 
for frequently requiring reamplifications to obtain successful amplifications and 
reproducible unambiguous results. The ambiguity of scoring these markers has also 
been commented on, with these markers deemed only suitable for those with 
experience in interpretation (Loukola et al., 2001) and may be a reason for the wide 
range of prevalence of MSI tumours reported in different studies despite the attempt 
to standardise MSI analysis.
4.1.6.2 Mononucleotide coding region MSI markers
Further discussion of potential target genes for the screening of MSI in colorectal 
cancers has occurred and it has been suggested that markers for MSI should meet 
several criteria such as a high mutational frequency, biallelic inactivation or 
imprinting of one allele and a role in cell growth suppression, apoptosis, cell 
differentiation, cell senescence or the escape from immune surveillance (Boland et al., 
1998; Perucho, 1999). Transforming growth factor-P receptor II (TGF-PRII), BAX, 
human Saccharomyces cerevisiae MutS homolog 3 (hMSH3) and insulin-like growth 
factor II receptor gene (IGFIIR) all meet these criteria and have previously been used
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in MSI studies and the approximate timing o f these mutations within the MSI tumour 
progression pathway are shown in Figure 4.2 (Souza et al., 1996; Rampino et al., 
1997; Ikeda et al., 1998; Molenaar et al., 1998).
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Figure 4.2
Diagram showing the evolution o f the microsatellite instability during MSI-H tumour 
progression from normal epithelium to advanced carcinoma. The inactivation of 
MMR genes hM LHl or hMSH2 triggers the mutator phenotype causing the total 
number o f mutations to increase at short coding repeat sequences such as TGF-pRII 
and Bax. Meanwhile, long non-coding mononucleotide repeats such as Bat-25 or Bat- 
26 are more and more deleted by a multistep cumulative unstable process. Adapted 
from Duval and Hamelin, 2002.
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4.1.6.2.1 Transforming growth factor-p receptor II (TGF-pRII)
A microsatellite in the gene sequence of the tumour suppressor gene transforming 
growth factor-P receptor II (TGF-PRII) is frequently mutated in colorectal tumours. 
Transforming growth factor p (TGF-p) inhibits the growth of endothelial and most 
epithelial cell types and induces cells to enter a post-mitotic state (Massague, 1990). 
TGF-p induces Gi-phase cell cycle arrest and induces apoptosis through the 
expression of the COX2 gene (Hannon and Beach, 1994; Wang et a l, 1995a). There 
are three polypeptide variant forms. Mutations in TGF-pRII form are found in 
HNPCC carcinomas and sporadic MMR* colorectal carcinomas. TGF-PRII is 
inactivated by mutation within Aio tract in the coding region of the gene from 
nucleotide position 709-718. This mutation, which occurs at the beginning of the 
coding sequence, inactivates the gene which in turn disables the receptor and makes 
the cell resistant to the growth inhibitory effects of transforming growth factor-P 
(Markowitz et al, 1995). The gene is often considered a tumour suppressor as 
restoring the mutated gene to the cell’s wild type state cancels the tumourigenicity of 
colon cancer cell lines containing mutated TGF-pRII (Wang et al, 1995b).
These mutations of TGF-pRII have been proven to be excellent markers for MSI as 
they are found mutated in around 90% - 100% of MMR deficient sporadic colorectal 
tumours, 57% of HNPCC adenomas and 85% of HNPCC carcinomas (Parsons et al, 
1995; Souza et al, 1996; Iacopetta et al., 1998; Zhang et a l, 2001; Akiyama et al, 
1997a). TGF-pRII mutations are thought to be the earliest mutational event in MSI 
tumours since they are so widespread and have also been found in metaplastic polyps, 
adding to the evidence that these growths are in fact a form of neoplasm and not 
simply benign polyps (Duval et al., 2001; Markowitz et a l, 1995; Young et al, 1995; 
Konishi et al, 1996). The level of MSI in sporadic adenomas has been very varied 
between studies, with some stating it is very rare (Young et al, 1995) whilst others 
detecting a level of 27% of colorectal adenomas to be MSI, using markers which are 
relatively specific for MSI-H (Grady et al, 1998). This discrepancy may be due to 
different proportions of early and late adenomas, as TGF-pRII mutations, which occur 
in nearly all MSI tumours, occur in advanced adenomas and have not been found in 
early adenomas, linking this mutation with the progression of these adenomas to
98
cancer (Young et a l , 1995; Abdel-Rahman et a l , 1999; Grady et a l, 1998; Duval et 
al, 2001).
The presence of TGF-pRII mutations has no discernible effect upon survival for 
patients with the earlier stages of colorectal cancer. However, mutations in this gene 
are associated with a significantly better prognosis in patients who have tumours with 
distant metastasis (Iacopetta et al, 1998; Ionov e ta l, 2000; Samowitz et al, 2001a).
4.1.6.2.2 BAX
BAX is a tumour suppressor gene which, when transactivated by p53, promotes 
apoptosis. A lower level of functional BAX protein alters the balance of this protein 
with the anti-apoptotic protein Bcl2 which in turn prevents cells from undergoing 
apoptosis (Korsmeyer, 1995). A diagram of the role of BAX in apoptosis by creating 
channels within the mitochondrial membranes through which cytochrome C is 
released, beginning the cascade of apoptosis is in Chapter 3, figure 3.5. Around 50% - 
58% of MSI colorectal tumours are found to have mutations in the Gs microsatellite 
between codons 38-41 of the 3rd exon of BAX (Abdel-Rahman et al, 1999; Rampino 
et a l , 1997, Ionov et al., 2000; Zhang et al, 2001). BAX mutations occur at a later 
stage in cancer progression, apparent due to a lack of clonality in tumours with these 
mutations (Abdel-Rahman et al, 1999; Rampino et al., 1997). BAX inactivation 
confers a selective advantage during clonal evolution by enhancing survival and may 
be involved in metastatic progression (Abdel-Rahman et a l, 1999; Fallik et al., 2003; 
Ionov et al., 2000). For these reasons BAX inactivation, which rarely occurs in MSS 
tumours, is an indicator of poor prognosis for patients with MSI tumours (Rampino et 
al, 1997; Ionov et al., 2000). Along with MSI, loss of BAX expression is a marker 
for patients that respond well to the chemotherapeutic agent irinotecan (Fallik et al, 
2003).
4.1.6.2.3 Human Saccharomyces cerevisiae MutS homolog 3 (hMSH3)
hMSH3 (also known as DUG, DUT or DUC-1) is a gene involved in the hMSH2- 
dependent mismatch repair process repairing di- and tetranucleotide repeats by 
forming a heterodimer with hMSH2 and binding to insertion-deletion loops (Risinger
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et al, 1996; Palombo et al, 1996; Acharya et a l, 1996). hMSH3 also itself contains 
an Ag microsatellite within exon 7 of the gene’s open reading frame that is frequently 
mutated in MSI tumours. Mutations in hMSH3 have been found in 50% - 58% of 
HNPCC cancers (Yin et al, 1997; Akiyama et a l, 1997b) and around 30% - 53% of 
sporadic MSI colorectal cancers of which virtually all the mutations reported were 
lbp deletions (Yin et a l, 1997; Malkhosyan et a l, 1996; Jeong et al, 2003; Abe and 
Masuda, 2000; Yamamoto et a l, 1997). Another study reported a level of 37.5% of 
MSI tumours containing hMSH3 mutations. Yet when these MSI tumours were 
categorised into MSI-H and MSI-L the levels of mutation were 67% and 0% 
respectively (Ikeda et a l, 1998). This again provides support that MSI-H and MSI-L 
colorectal tumours arise from different pathways and grouping these subsets together 
only confuses the observable genetics patterns and phenotypes of these groups. 
Mutations in hMSH3 have not been found in MSS colorectal tumours (Abe and 
Masuda, 2000).
4.1.6.2.4 Insulin-like growth factor II receptor gene (IGFIIR)
IGFIIR is essential for the degradation of the potent growth stimulant IGFII and also 
activates TGF-PRI which then acts as a growth suppressant (Wang et al, 1997; 
Dennis and Rifkin, 1991). IGFIIR is not only therefore important in epithelial cell 
growth regulation, but is also prone to mutation within its coding sequence as it 
contains several microsatellites. Historically, IGFIIR was the second gene after TGF- 
pRII discovered to have mutations in the microsatellites within its coding region 
(Souza et a l, 1996). The Gg microsatellite from nucleotide position 4089-4096 is the 
site which is most frequently mutated within IGFIIR in MSI colorectal cancers. 
Tumour samples which contained mutations within the Gg microsatellite were also 
examined at another Gg locus but no mutations were found at this site, supporting the 
theory that these mutations are non-random, but are in fact targeted mutations within 
the mutator phenotype (Souza et al, 1996). IGFIIR has been reported to be mutated in 
around 13% of HNPCC colorectal cancers and approximately 10% - 36% of MSI 
sporadic colorectal cancers. No mutations have been reported in the tissues of MSS 
colorectal cancer patients (Souza et a l, 1996; Jeong et a l, 2003; Woemer et a l, 
2001).
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4.1.7 Degree of MSI in colorectal tumours
There has been argument to merge the classifications MSS and MSI-L because it is 
thought that with enough markers all colorectal cancers may exhibit some level of 
MSI and the clinical features of these groups are so similar that it is not a useful 
differentiation to make (Thibodeau et al, 1998; Jass et a l, 1998; Loukola et a l, 2001; 
Ward et al., 2001). For example, there is an increased expression of specific mucins 
with MSI-H cancers as opposed to MSI-L or MSS cancers (Thibodeau et a l, 1993; 
Jass, 2000).
It has been proposed that MSI-L tumours may develop from metaplastic polyps by a 
distinctive pathway and clinically may behave differently from both MSS and MSI-H 
tumours (lino et a l, 1999; Ward et a l, 2001). It is also a possibility that serrated 
polyps and MSI-L colon cancers are related histogenetically as there is a similarity in 
early morphogenesis for MSS and MSI-H, but differences for MSI-L cancers (Jass, 
2001a). With these differences of opinion and with very little known about 
hyperplastic and serrated polyps and the possible pathways of carcinogenesis involved 
with these aberrations, it is still of value to differentiate between MSI-L and MSI-H in 
studies, especially while there is such uncertainty (Shitoh et al, 2000; Jass, 2001a, 
Jass 2001b).
4.1.8 Rationale of the study
As the experiments from Chapter 3 showed, the tumour specific mutations in the 
mitochondrial genome were predominantly in poly-C microsatellites. This chapter 
describes studies which aimed to analyse the same samples as the previous chapter in 
order to establish whether there is a link between MSI in the mitochondrial and 
nuclear genomes. Each sample will be examined at four nuclear microsatellites which 
have been proved in research from other groups to be frequently mutated in MSI 
tumours, in order to assess the level of nuclear microsatellite instability. The results of 
these experiments will provide more information regarding the repair mechanisms of 
the mitochondrial genome and whether there is a correlation between nMSI and 
mtMSI. If such a correlation can be shown, this would provide evidence of a mtDNA 
mismatch repair system which utilises some of the same repair proteins as nDNA or 
even a shared pathway of mismatch repair.
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4.2 Materials and Methods
4.2.1 Sample collection
The 65 tissue samples from 24 patients used in these experiments were the same as 
those used in Chapter 3. These are detailed in appendix I. The mean age of these 
patients was 69 years of age at the time of sample collection; the patients consisted of 
13 females and 11 males (1.2F : 1M). 12 of these patients had adenocarcinomas of the 
rectum, 2 of the sigmoid colon, 4 of the transverse colon and 2 of the caecum. 1 
patient had a rectal polyp, 3 had sigmoid polyps. 6 of these samples had metastatic 
tissue samples from liver or lymph node. DNA extraction and quantification was 
previously carried out as described in section 3.2.2 and 3.2.3
4.2.2 Polymerase Chain Reaction (PCR)
4.2.2.1 Choice of microsatellites to analyse
Four microsatellites were chosen for this study on the basis that they had been widely 
used in previously published studies of MSI and are all mononucleotide repeats which 
are generally more sensitive to MSI than more complex repeat sequences. These 
microsatellites lie within TGF-PRII, BAX, IGF and hMSH3; details of these 
microsatellite markers can be seen in Table 4.1. TGF-PRII has also been shown to be 
at least as sensitive to MSI as a panel of markers and mutations within this gene occur 
in the vast majority of MMR deficient tumours (Zhang et a l , 2001; Iacopetta et al., 
1998; Guanti et al., 2000).
4.2.2.2. PCR conditions and primer labels
PCR was optimised using un-labelled primers and, once optimised, oligonucleotides 
(Invitrogen) labelled with WellRed dye (Beckman) were used for forward primers. 
The primer sequences and dye colour for each primer set are detailed in Table 4.1. 
PCR conditions for these primer sets are listed in Table 4.2. Each PCR reaction began 
with 1 min at 94°C to fully denature the target DNA and ended with a 5 min stage at 
72°C to ensure full length PCR products were produced.
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For each sample the PCR reaction and subsequent fragment analysis was repeated at 
least once to confirm results.
Gene Primers
WellRed
labelling
dye
Product
length
(bp)
Micro-
satellite Reference
IGFIIR Forward -
GCAGGTCTCCTGACTCAGAA 
Reverse -
GAAGAAGATGGCTGTGGAGC
Dye4PA
Blue
109 (G)s Souza et 
al, 1996
BAX Forward -
ATCCAGGATCGAGCAGGGCG 
Reverse -
ACTCGCTCAGCTTCTTGGTG
Dye3PA
Green
92 (G)s Rampino 
et al., 
1997
hMSH3R Forward -
GAGATAATGACTGAT ACTTCT ACC 
Reverse -
CATTTGTTCCTCACCTGCAAAG
Dye2PA
Black
131 (A)s Ikeda et 
al, 1998
TGF-
PRII
Forward -
ATGCTGCTTCTCCAAAGTGC ATT A 
Reverse -
GCACTCATCAGAGCTACAGGAACA
Dye2PA
Black
85 (A) 10 Molenaar 
et al, 
1998
Table 4.1
PCR primer sequence and labels for the micro satellites used for fragment analysis.
Primer set MgCl2amount
(m0
Denaturation Annealing Elongation Number 
of cyclesTemp(°C)
Time
(s)
Temp
(°C)
Time
(s)
Temp
(°C)
Time
(s)
IGFIIR 2.0 94 30 58 30 72 30 35
BAX 2.0 94 30 62 30 72 30 35
hMSH3R 2.5 94 30 64 30 72 40 38
TGF-PRII 1.4 94 30 62 30 72 30 35
Table 4.2
PCR conditions for each microsatellite primer set.
4.2.3 Fragment analysis
This was carried out as described in Chapter 2, section 2.10.
4.2.4 Sequencing
Several samples were sequenced as described in Chapter 2, section 2.9
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4.3 Results
4.3.1 Fragment analysis results
A full table o f the values obtained for fragment length for all 4 o f the analysed 
microsatellites for all the samples from the 24 patients studied can be seen in 
appendix I. Figure 4.3 shows a typical fragment analysis trace and details how these 
results are read.
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Figure 4.3
This figure shows a typical fragment analysis trace. The x axis illustrates the size, in 
bp, o f fragments within the sample and the y axis shows the intensity o f the dye signal 
o f each dye labelled fragment. The red peaks result from the red labelled size standard 
which is added to the sample to give an accurate scale from 60bp to 420bp against 
which the PCR product labelled with a different coloured dye can be measured. The 
black peak corresponds to the labelled PCR product and the size o f this is accurately 
measured and written at the apex o f the peak.
105
17500 - -
Patient 4 - Tumour A
15000 - -
12500 - -
10000  - -
7500 - -
5000 - -
2500 - -
0 —I—I—L L , I |~ K  - 4 — J U  ~h-  j  -  - I— t  — |— j ------1-^1 ----- 1— ^ ----- |----- 1— 4 -  - 4 -  -4— f ----I h I -
50 100 150 200 250
Size (nt)
300 350 400
Patient 4 -  Normal mucosa
12900
10000
7500
5000
2500
100 150 200 2500 50 300 360 400 450
S z e ( r t )
Figure 4.4
Fragment analysis traces showing the length of the PCR products for the hMSH3 microsatellite for 
patient 4 represented by black peaks. A is the resulting trace for amplifications from sample 16, 
rectal tumour and B is the trace from the normal adjacent mucosa sample number 17. Both of 
these samples have fragment lengths corresponding to wild ty pe sequence for this microsatellite.
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F igure 4.5
Fragment analysis traces showing the length of the PCR products for the TGF-R1I microsatellite 
for patient 24 represented by black peaks. C is the resulting trace for amplifications from sample 
96, caecal adenocarcinoma and shows a fragment length of lbp less than the wild type sequence. 
D is the trace from the normal adjacent mucosa sample 97 and has a fragment length 
corresponding to the wild type sequence for this microsatellite.
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Figure 4.6
Fragment analysis traces showing the length of the PCR products for the TGF-RII microsatellite 
for patient 2 represented by black peaks. E is the resulting trace for amplifications from sample 9, 
rectal tumour and shows a fragment length of lbp more than the wild type sequence. F is the trace 
from the normal distant mucosa sample 10 and has a fragment length corresponding to the wild 
type sequence for this microsatellite. Trace F also has a blue peak representing the length of the 
PCR fragment amplified from the IGFIIR microsatellite, again this has the same length as the wild 
type sequence.
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Figure 4.7
Fragment analysis traces showing the length of the PCR products for the TGF-RII microsatellite 
for patient 1 represented by black peaks and the products of IGFIIR by blue peaks. G is the 
resulting trace for amplifications from sample 5, normal adjacent mucosa and H is the trace from 
the rectal polyp sample 4 and both traces show fragment length corresponding to the wild type 
sequence for both microsatellites.
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Figure 4.8
Fragment analysis traces showing the length of the BAX PCR products for patient 7 represented 
by green peaks and, on trace I, the products of hMSH3 by black peaks. I is the resulting trace for 
amplifications from sample 28. normal distant mucosa and J  is the trace from the rectal 
adenocarcinoma sample 29 and both traces show fragment length corresponding to the wild type 
sequence for the BAX microsatellite and trace I shows a wild type sequence length for hMSH3.
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Figure 4.9
Fragment analysis traces showing the length of the BAX PCR products for patient 8 represented 
by green peaks and, on trace K, the products of hMSH3 by black peaks. K is the resulting trace for 
amplifications from sample 33, normal distant mucosa and shows wild type sequence lengths for 
both the BAX and hMSH3 PCR products. L is the trace from the normal adjacent mucosa sample 
35 and shows fragment length corresponding to a sequence length 2bp longer than the wild type 
sequence.
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Fragment analysis traces showing the length of the BAX PCR products for patient 8 represented 
by green peaks. M and N are the resulting traces for repeat amplifications from sample 35, normal 
adjacent mucosa both traces show fragment length corresponding to the wild type sequence for the 
BAX microsatellite.
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PCR fragment length (bp)
Patient
No.
Sample
No.
Sample
Type
TGF-
(3R1I BAX hMSH3 IGF
2 9 Rectaltumour 86 86 92 92 131 131 109 109
10 Distantmucosa 85 85 92 92 131 131
109 109
8 30 Rectalpolyp 85 85 92 92 131 131 109
109
31 Liverbiopsy 85 85 92 92 131 131
109 109
33 Distantmucosa 85 85 92 92 131 131 109
109
34 Rectaltumour 85 85 92 92 131 131 109 109
35 Adjacentmucosa 85 85 94 92 92 131 131 109 109
24 96 Caecaltumour 84 84 92 92 131 131 109 109
97 Adjacentmucosa 85 85 92 92 131 131 109 109
98 Distantmucosa 85 85 92 92 131 131
109 109
Table 4.3
Table o f fragment analysis data for patients which showed an anomaly in fragment 
length. The figures give the length in base pairs (bp) o f each o f the PCR fragments 
containing the microsatellite. Figures in bold represent fragment lengths that were 
different from the wild type (WT) sequence length for that PCR product. The 
remaining patients were all WT for all microsatellites tested, this data is included in 
appendix I.
Microsatellite marker Number o f patients with alteration Frequency
TGF13-RII 2/24 8.3%
BAX 0/24 0%
hMSH3 0/24 0%
IGF 0/24 0%
Table 4.4
Table showing the number o f each microsatellite marker found altered in the patients 
analysed in this study.
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4.3.2 The results of sequencing
All the samples from patients showing an anomaly in any o f the MSI marker PCR 
products by differing from the wild type sequence length were sent for sequencing to 
elucidate more about these changes. Samples from patients 1, 3, 4, 5 and 6 were also 
all sequenced to confirm these sequences were wild type. Table 4.4 details all the 
changes that were detected by sequencing, all other sequences were confirmed as wild 
type. Sequencing confirmed the fragment analysis results.
Patient
No.
Sample
No.
Age Sex Sample Type Dukes’
Stage
Microsatellite change
2 9 80 M Rectal tumour C Ai insertion in TGF-pRII
10 Distant mucosa
24 96 58 M Caecal tumour Cl Ai deletion in TGF-BRII
97 Adiacent mucosa
98 Distant mucosa
Table 4.5
Table detailing the patient information for patients exhibiting microsatellite instability 
and the details o f the microsatellite change as confirmed by sequencing.
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4.4 Discussion
4.4.1 Choice of MSI markers
There have been many studies assessing sporadic colonic cancers for MSI and the 
levels detected have ranged from 6% to 29% (Young et a l, 1993; Thibodeau et a l , 
1993; Ionov et al, 1993; Chao et a l, 2000; Watatani et a l, 1996). This wide range is 
most likely to be a result of the different loci studied, ranging from mononucleotide 
repeats to more complex tetranucleotide microsatellites. The loci also vary in their 
genomic location in various genes and non-coding regions on different chromosomes, 
making it difficult to establish the variation in MSI levels of colorectal tumours. It 
was for this reason the standard markers were established in 1998. However, these are 
not used in this current study as these markers contain polynucleotide repeats which 
were not present in mtDNA and there have also been reported problems using the 
Bethesda markers in terms of amplification difficulties and problems with interpreting 
the results (Boland et a l, 1998; Loukola et a l, 2001). The markers selected for this 
study were chosen as the microsatellite altered in the mitochondrial genome was a 
mononucleotide repeat and so the markers in this study are also mononucleotide 
repeats. These have all been used in studies by other groups to assess for MSI (Souza 
et al., 1996; Rampino et al., 1997; Ikeda et al., 1998; Molenaar et al., 1998). These 
microsatellites also meet the revised Bethesda criteria set for choosing target genes as 
opposed to so-called bystander genes which, although may be mutated, have no 
significant effect upon tumourigenesis (Boland et al., 1998; Perucho, 1999). The 
criteria include: a high mutational frequency, biallelic inactivation or imprinting of 
one allele and, a role in cell growth suppressing, apoptosis, cell differentiation, cell 
senescence or the escape of immune surveillance (Perucho, 1999).
Microsatellites with mononucleotide repeats were chosen as these would be altered 
not only by deficiencies in the hMSH2 and hMLHl genes but also in tumours 
deficient in hMSH6 (Fallik et al 2003; Loukola et al 2001). These microsatellites 
have also been found to be more sensitive than more complex repeat sequences at 
detecting MSI (Loukola et al., 2001; Ward et al., 2001; Chen et al., 1995). In a study 
comparing the effectiveness of all 4 of the microsatellites (hMSH3, BAX, IGFRII and 
TGF-PRII ) analysed in this study with the Bethesda consensus markers, there was
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found to be no significant difference between the two sets of markers (Samowitz et
al, 2001b). Another 2001 study of MSI colorectal tumour tissue found all 24 of these
samples to contain mutations within the TGF-PRII microsatellite, compared with 96% 
of samples having mutations within the non-coding Bethesda BAT25 marker (Zhang 
et al, 2001).
Microsatellite instability for each marker site was defined as an increase or decrease 
in size by one or more bases in comparison to the normal DNA sample. These criteria 
have been used in several studies (Samowitz et al., 2001b).
4.4.2 Levels of mutations found in this study 
4.4.2.1 Transforming growth factor-p receptor II (TGF-pRII)
Mutations within the Aio microsatellite within TGF-pRII have been found to occur 
very early in tumour progression, and mutations within this gene have been found in 
around 90% - 100% of MSI colorectal cancers (Parsons et al., 1995; Zhang et al, 
2001; Guanti et al, 2000). In the study described in this chapter 2/24 (8.3%) of 
patients were found to have mutations within this micro satellite within their tumour 
tissue. No normal tissues were found to contain mutations within the section of TGF- 
PRII analysed, confirming the accuracy of this locus to detect MSI mutations.
There is another microsatellite within TGF-pRII that was not amplified in the PCR 
reactions in these experiments, as this fell outside the primer set used. This 
microsatellite is a dinucleotide repeat of (GT)3 located at nucleotides 1931-1936 and 
has been found to contain an insertion in 1/11 (9%) MSI colorectal tumour cell lines 
examined (Markowitz et al, 1995). This microsatellite was not examined in this study 
as in comparison to the Aio tract it is relatively infrequently mutated in MMR 
deficient tumours and therefore not as suitable as a molecular marker for MSI.
4.4.2.2 BAX
Previous studies have found BAX to be mutated within the Gs microsatellite in 
around 50% of MSI colorectal tumours (Abdel-Rahman et al, 1999; Rampino et al,
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1997, Ionov eta l, 2000). Because of this, alterations in the microsatellite within BAX 
are not enough alone to diagnose a tumour as MSI. However, they are effective as 
part of a panel of markers and may also provide prognostic information about the 
degree of severity of the tumour. In this study, there were no BAX mutations detected 
in any of the patients including those tumours mutated within the reliable MSI marker 
TGF-pRII microsatellite. As there were only 2 such tumours in this study it is not 
possible from these figures to challenge the levels of BAX mutations found in 
previous studies. It has been reported that BAX mutations are very rare in MSS 
tumours (Rampino et a l, 1997; Ionov et a l, 2000) and this was also found in this 
study where no MSS tumours (0/22) were found to have mutations within the BAX 
microsatellite.
Neither of the 2 patients deemed as MSI by the presence of TGF-PRII microsatellite 
mutations had metastatic carcinomas. Previous studies have found BAX mutations 
occurring at a later stage in cancer progression and as being involved in metastasis, it 
would be expected that these patients would be unlikely to have BAX mutations, as 
indeed they did not (Abdel-Rahman et al., 1999; Rampino et al., 1997; Fallik et al., 
2003; Ionov et al., 2000). Together, TGF-pRII and BAX may act as a good marker set 
for colorectal cancers with MSI as these mutations are likely to be detectable in the 
faeces of patients with tumours which contain these mutations. These markers would 
detect adenomas progressing to carcinomas and also give an indication of prognosis 
(Rampino et a l, 1997; Dong et al, 2001).
4.4.2.3 Human Saccharomyces cerevisiae MutS homolog 3 (hMSH3)
There were no mutations found within the Ag microsatellite of hMSH3 of any of the 
samples from any of the patients examined in this study. Levels of hMSH3 mutation 
in previous studies have ranged between 30-53% of sporadic MMR' tumours (Yin et 
al, 1997; Malkhosyan et al., 1996; Jeong et a l, 2003; Abe and Masuda, 2000, 
Yamamoto et al, 1997; Ikeda et al., 1998). As there were very low overall levels of 
MSI in the patient cohort, it is impossible to draw any conclusions from the lack of 
hMSH3 mutations found in this study other than, if it is assumed 22 of these patients 
are MSS then, there have been no false positives from this MSI marker.
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hMSH3 mutations have been linked with MSI-H tumours (Duval et al., 2001; Ikeda et 
al., 1998) and the inactivation of this gene is thought to be, after the alteration of a 
first MMR gene, a second critical event during MSI-H tumour progression by 
increasing the overall instability from MSI-L to MSI-H (lino et al, 2000; Duval et al., 
2001). It may be that the 2 patients with TGF-RII mutations only had low levels of 
MSI and so mutations within hMSH3 would be unlikely. Also as BAX mutations 
have been associated with hMSH3 mutations in MSI tumours (Duval et al., 2001) the 
absence of BAX mutations again suggest that it would be unlikely that these samples 
would have hMSH3 mutations as these mutational events seem to occur late in the 
MSI carcinogenesis pathway.
4A.2.4 Insulin-like growth factor II receptor gene (IGFIIR)
There were no mutations detected within the section of the IGFIIR gene amplified in 
any of the samples analysed in this study. In previous studies, levels of IGFIIR 
mutations in sporadic MSI tumours are between 10% - 24% (Souza e ta l , 1996; Jeong 
et a l, 2003). As there were only 2 patients found to have MSI colorectal tumours in 
this study it would have been approximately 20%-50% chance for either of these to 
have been mutated in this micro satellite based on levels found in previous studies. It 
is however not possible with such a small number to draw conclusions from this data, 
other than there were no samples from the 22 patients with MSS tumours with 
mutations at these loci. Therefore this gene would be effective as a marker in respect 
that there are no MSS colorectal cancers with false positive results for the IGFIIR 
microsatellite.
4.4.2.5 Overall MSI level in the sample group
If the assumption is made that tumours with mutations within the TGF-pRII 
microsatellite are indicative of MSI, as these mutations are found in 90-100% of 
MSI+ tumours, then the level of MSI in the patients of this study is 2/24 (8.3%). This 
is further qualified as there are no reported cases of mutations within the As 
microsatellite of the gene in MSS tumours and therefore these results are unlikely to 
be false positives. There is however the possibility that there may be false negative
118
results within this group since up to 10% of MSI+ tumours may lack mutations within 
the TGF-pRII Ag microsatellite.
The level of 8.3% of sporadic colorectal tumours with MSI falls well within the 
previously reported levels of 6-18% (Young et a l, 1993; Thibodeau et a l, 1993; 
Ionov et al, 1993; Chao et al, 2000).
4.4.3 Types of mutation found in microsatellites analysed
The 2 mutations found in this study were lbp deletion and lbp insertion within the 
TGF-pRII microsatellite. These are entirely consistent with previous studies such as a 
study which analysed the types of mutation within 29 microsatellites containing 
mononucleotide repeats and have found that 41% of mutations are lbp insertions, 
55% bp deletions and 4% involved shifts of 2bp (Zhang et al, 2001).
4.4.4 Profile of patients with MSI tumours
The details of the two patients which had MSI tumours are listed in Table 4.3. The 
details of the overall cohort are tabulated in appendix I.
4.4.4.1 Sex ratio of patients with MSI tumours
Although no statistical significance can be determined from these results as the 
sample size of patients with MSI tumours is very small, there was no apparent sex 
bias with one male and one female patient with MSI tumours. A female bias of MSI 
tumours has been repeatedly reported (Ward et a l, 2001; Samowitz et al, 2001b; 
Thibodeau et a l, 1998)
4.4.4.2 Ages of patients with MSI tumours
The ages of these two patients (80, 58, average age 69) were typical of those with 
MSI tumours as it has been reported that although the average age of patients with 
MSI tumours is not significantly different to those with MSS tumours (66 and 64 
years respectively), the spread across age groups is significantly different following a
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J-shaped distribution with peaks of incidence at the younger and older age groups 
(Samowitz et al, 2001b; Chao et al, 2000). The highest proportion of patients with 
MSI tumours are aged 80 years and older (Chao et al, 2000). This statistic is in 
agreement with this study where one of the two patients with MSI tumours was 80 
years at the time of surgery. There are also a large number of patients diagnosed at a 
younger age although the age of cut-off for this cohort varies between studies from 
under 50 years (Chao et al, 2000) to under 55 years (Samowitz et a l, 2001b). From 
these age groupings the 58 year old male patient displaying MSI in this study is 3 
years older than the cut off point for those patients regarded as young in previous 
studies.
4.4.4.3 Anatomical locations of MSI tumours with the colorectum
MSI tumours are predominantly found in the proximal colon (Thibodeau et a l, 1993; 
Samowitz et al, 2001b; Ward et al., 2001; Chao et al, 2000). There have been few 
studies assessing the level of MSI in rectal as opposed to colorectal tumours; 
however, those that have differentiated between colon and rectum, report lower levels 
of MSI in rectal tumours than studies which group these cancer types together 
(Nilbert etal, 1999; Kapiteijn e ta l, 2001).
The locations of the 2 MSI tumours found in this study were the proximal colonic 
region, the caecum, and the distal colorectal region, the rectum. As there were only 6 
proximal tumours included in this study this gives a level of 1/6 (16.7%) of proximal 
tumours with MSI and 1/2 (50%) of caecal tumours. There were 14 distal colorectal 
adenocarcinomas, of which 1/14 (7.1%) displayed MSI; of these 12 were rectal 
tumours of which 1 was found to have MSI. This level of 1/12 (8.3%) higher than the 
3/165 (1.8%) level found to have MSI in a previous study of rectal tumours and it has 
been suggested by other groups that rectal MSI is a result of a hereditary 
predisposition (Nilbert et al, 1999). The patients included in this study were selected 
as they were sporadic cases with no family history of colorectal cancers. Although it 
is feasible that the patient with a rectal MSI tumour had an undiagnosed inherited 
condition, it is more likely that the patient was a sporadic case. More studies 
examining specifically rectal tumours for MSI need to be undertaken to assess levels 
of MSI in this region of the colorectum. The study of rectal tumours by Nilbert and
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colleagues examined 165 patients, a much larger study of these tumour types than this 
current study of 13 rectal tumours and can therefore be considered a more accurate 
measure of MSI in rectal tumours, with this current study including a non-typical 
population.
The level of MSI found in this study 2/24 (8.3%) is slightly lower than reported in 
some studies and may be a result of the majority of the polyps and tumours in this 
sample group 18/24 (75%) originating from a distal location and only 6/24 (25%) 
from a proximal location. None of the 5 lymph node samples analysed in this study 
showed MSI consistent with the observations that this pathway of carcinogenesis is 
linked with an improved prognosis.
4.4.4.4 Tumour stages of MSI tumours
The tumours of the patients were both at Dukes stage Cl, at which point the tumour 
has spread to lymph nodes but has not at this point metastasised to distant organs such 
as the liver. This stage is more advanced than the Dukes stage B, at which there is no 
lymph node involvement, which, according to some studies is highly associated with 
MSI tumours (Samowitz et al, 2001b; Thibodeau et al., 1998). There are also studies 
where MSI has been linked to a higher grade of tumour (Ward et al, 2001; Chao et 
al., 2000) although there are also many studies which have shown a negative 
correlation with metastatic disease (Shibata et al, 1994; Ionov et a l, 1993; Gryfe et 
al, 2000).
Neither of the patients with MSI tumours had mutations in the microsatellite within 
the BAX gene which is an indicator of poor prognosis with the MSI subset of 
colorectal cancers and is also linked to metastatic progression of colorectal cancer 
(Abdel-Rahman et al, 1999; Fallik et al, 2003; Ionov et a l, 2000). BAX inactivation 
confers a selective advantage during clonal evolution by enhancing survival 
advantage and may be involved in metastatic progression (Abdel-Rahman et al, 
1999; Fallik et a l, 2003; Ionov et al, 2000).
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4.4.5 Is there a link between mtMSI and nMSI?
In Chapter 3 mutations within a microsatellite in the mitochondrial genome were 
found in several patients and one of the goals of the experiments in this chapter was to 
establish whether or not there is a link between microsatellite instability in the nuclear 
genome (nMSI) and mitochondrial genome (mtMSI). Neither of the two patients with 
nMSI tumours had mutations within the control region of the mtDNA; likewise none 
of the patients with mtDNA microsatellite mutations had nMSI mutations.
These findings are in agreement with those of Heerdt et a l (1994) in whose study of 
24 colonic tumours it was reported that none of the tumours exhibiting nuclear MSI 
showed coincident mtMSI at a (CA)n locus. A study by Habano et al., (1998) also 
detected no mtMSI in the colorectal tumours which were unstable in the nuclear 
microsatellite loci analysed. Also, a study of microsatellite instability of the nuclear 
and mitochondrial genomes of gastrointestinal cancer found no association between 
these types of mutations (Schwartz and Perucho, 2000). From these sets of results it 
was reasoned that there were separate mechanisms for genomic instability between 
the nuclear and mitochondrial genomes with different enzymes responsible for the 
mismatch repair of the two genomes (Heerdt et al, 1994; Habano et al, 1998).
The same conclusions have also been drawn from similar studies examining different 
tumour types such as a study of breast tumour tissue which found 17/40 (42.5%) of 
the tumours to have mutations within microsatellites in the mitochondrial genome and 
20/40 (50%) to have nMSI but with no correlation between the mtMSI and nMSI. 
From this study it was thought that this is a result caused by abnormalities at different 
stages of the pathway leading to cell transformation (Richard et al, 2000).
The presence of mtMSI may be a result of higher levels of strand slippage mispairing 
in the mitochondrial genome compared to that of nuclear genome rather than a 
difference in mismatch repair capabilities. Mutation rates in microsatellites within 
mtDNA may be so high that even with MMR the microsatellite mutation level 
observed is still higher than that in the nuclear genome where the rate of mutation in
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microsatellites may have been lower, allowing for repair to be complete. It is thought 
that mtMSI is more dependent upon polymerase-y mismatch repair than the damage 
caused by ROS (Richard et a l , 2000). Therefore the difference between 
mitochondrial and nuclear MSI status may hinge on the efficiency of the MMR 
function of polymerase-y which may be altered through the pathway in which mtMSI 
is observed.
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4.4.6 Discussion Summary
Mutations in microsatellites were found in 2/24 patients, both of which were found 
within the TGF-PRII gene. As this gene has been shown to be an exceptionally 
sensitive marker of MSI in colorectal cancers, it was assumed from this that these 2 
patients were MSI and that, although it cannot be ruled out that there may be other 
patients of this phenotype within this sample, there have been no recorded incidences 
of TGF-PRII microsatellite mutation within patients with effective MMR. None of the 
other 3 microsatellites, BAX, IGFIIR or hMSH3 were mutated in any of the samples. 
These levels of mutation are in line with previous studies; however, as there were 
only 2 patients within the sampling group with MSI, this is too small a sample size to 
draw statistically significant results from. The overall level of MSI in this study is 
2/24 (8.3%); this level correlates with previous studies. This level is at the lower end 
of previously recorded MSI levels in sporadic colorectal cancer and may be a result of 
the sample consisting predominantly of distal colorectal cancers. Despite this bias 
towards distal tumours within the sample population, proximal tumours were shown 
to contain proportionately more microsatellite mutations with 1/6 (16.7%) being MSI 
as opposed to 1/14 (7.1%) distal tumours.
None of the patients with mtDNA MSI had nMSI mutations and, although there was 
only a small number of patients showing nMSI, this data suggests there is no link 
between mtMSI and nMSI, and that these probably occur through different pathways.
Despite the lack of correlation between mtMSI and nMSI, these may still be important 
factors when considering the treatment of the cancers and prognosis for specific 
patients. The more that is known about the differences in types of colorectal tumour, 
the more chance there is of developing treatments which are specific to the cells with 
defects in specific pathways. For example colorectal tumours with defective mismatch 
repair could be treated with chemotherapeutic agents which do not affect normal cells 
where such repair is functional (Parsons et al., 1993). One such pathway specific 
cancer treatment for sporadic MSI-H cancers suggests treating with demethylating 
agents which may reverse the hypermethylation of promoters for MMR genes such as 
hMLHl and either treat or help prevent the development of these colorectal tumours 
(Veigle/a/., 1998).
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Chapter 5
Detection of tumour suppressor gene expression changes with 
tumour progression using array analysis and real time PCR
5.1 Introduction
5.1.1 Gene expression
Gene expression is the term used to describe how different genes within a cell are 
turned on or off to varying extents depending upon the requirements of the cell. It is 
because of differing gene expression patterns that cells from different tissues that 
contain the same DNA are able to take on completely different roles such as the cells 
of the colorectal mucosa and cells of the underlying muscle. Until recently gene 
expression has primarily been analysed by histochemistry with anti-bodies and stains 
defining the proteins expressed. These techniques are still of great value especially 
when examining the localised patterns of expression, for example, by studying the 
varying levels of proteins required for the homeostatic balance between cell 
proliferation and cell differentiation in a single crypt foci of the colonic epithelium. 
Patterns of APC and Rb expression vary within a single crypt foci with higher levels 
of Rb detected at the base of the crypt than at the top of the same crypt, an opposite 
pattern is found for APC which is predominantly expressed at the top of each crypt 
(Ali et al, 1993; Smith et al., 1993). Techniques such as RT-PCR and cDNA arrays 
have now been developed which can analyse the cellular levels of mRNA, the 
precursor to proteins.
5.1.1.1 Gene expression changes in colorectal cancer
As well as adding to the understanding of cancer development, the study of gene 
expression can act as an indicator of prognosis. For example, a lack of expression of 
the cyclin dependent kinase inhibitor p57 in colorectal cancers is linked to poor 
prognosis for the patient (Li et al., 2003). The expression levels of several tumour 
endothelial markers have been associated with colorectal cancer progression and 
nodal involvement and therefore may be useful as prognostic indicators (Rmail etal., 
2005). Gene expression in a specific tumour can also give indications on how a
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particular patient may respond to certain chemotherapeutic agents. For example, colon 
cancer cells with low levels of Bax are resistant to 5-flurouracil, the most commonly 
used drug in colon cancer treatment (Violette et a l , 2002). Gene expression analysis 
of individual patients may also be important in determining the dose of chemotherapy 
for each patient. Irinotecan is an anti-cancer drug which interacts with DNA- 
topoisomerase 1, the effectiveness of this drug in patients varies widely between 
different patients. A recent study of colorectal tumours has shown the expression level 
of the genes CES1 and CES2 which are involved in the irinotecan pathway vary 
greatly between patients. This information can be used to decide not only whether this 
drug would be appropriate in each individual case but also to establish a dosage which 
would have less of a toxic effect on the patient’s normal tissues (Yu et a l , 2005).
5.1.2 DNA Arrays
The advent of array technology has made it possible to examine the levels of gene 
expression of many genes in one experiment. Arrays are now commercially available as 
gene chips with several thousand DNA sequences printed on a glass slide, these require 
expensive and specialist equipment for data reading and further software and expertise 
for the data mining required for such large data sets. Arrays are also available as nylon 
membranes containing between 18 and 96 genes which have advantages over the gene 
chips in terms of being less expensive in terms of consumables and specialised 
equipment needed and allows a more focused approach to gene expression analysis as 
the arrays contain genes which are grouped in terms of function such as DNA repair 
and tumour suppressor genes. The disadvantages of these types of nylon membrane 
arrays are that there can be more background noise in comparison to the glass slide 
arrays and the membrane can become distorted, both of these disadvantages are due to 
the material of the medium on which the genes are printed (Cheung et a l , 1999). These 
negative aspects can be overcome using the software designed for the analysis of these 
specific types of array. The array selected for these experiments is the GEArray 
(Superarray, USA) human cancer/tumour suppressor array which is composed of 23 
genes that inhibit cell or tumour growth including known tumour suppressor genes, 
cyclin-dependent kinase inhibitors and genes which regulate tumour suppressors, these 
genes and their functions listed in Table 5.1. Further details including full gene names 
and Genebank accession numbers are listed in Table 5.2.
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5.1.3 Introduction to genes present on the GEArray tumour suppressor array
Gene Function
APC Regulates epithelial homeostasis processes such as cell cycle progression and apoptosis
BRCA1 Transcription factor, activates genes such as p53 following DNA damage
BRCA2 Transcription factor, involved in the repair of double strand breaks
CBP Modulates DNA damage response by transcriptional activation
DPC4 Involved in the TGF-p signalling transduction pathway
IRF-1 Transcriptional activator and collaborates with p53 to induce cell cycle arrest
MSH2 Mismatch repair gene
NF2 Stabilizes cell membrane
pl8 Cyclin-dependent kinase inhibitor, inhibits cell cycle progression
pl9 Cyclin-dependent kinase inhibitor, inhibits cell cycle progression
p21 Cyclin-dependent kinase inhibitor, inhibits cell cycle progression
p27Kipl Cyclin-dependent kinase inhibitor, inhibits cell cycle progression
p300 Modulates DNA damage response by transcriptional activation
p53 Suppresses cell growth, mediates cell cycle arrest, activates apoptosis inducing genes
p57Kip2 Cyclin-dependent kinase inhibitor, inhibits cell cycle progression
PTEN Encodes a dual-specificity phosphatase
Rb Regulates cell cycle progression from G1 to S-phase
TGF-PRI Acts as a signal transducer after binding the epithelial cell growth inhibitor TGF-P
TGF-(3RII Acts as a signal transducer after binding the epithelial cell growth inhibitor TGF-P
TSC1 Involved in cell cycle control, endocytosis, cell adhesion and transcription
TSC2 Involved in cell cycle control, endocytosis, cell adhesion and transcription
VHL Down regulator of transcription elongation
WT1 Transcription factor involved in growth, differentiation and cell cycle arrest
GAPDH Constitutively expressed housekeeping gene used on this array as a positive control
P-actin Constitutively expressed housekeeping gene used on this array as a positive control. Codes for protein which forms part of the cells cytoskeletal structure
PUC18 Bacterial plasmid used on this array as a negative control
Table 5.1
Brief description of the function of the genes present on the tumour suppressor array 
used in these experiments.
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Abbreviated 
Gene name
Full gene name Genebank
code
APC Adenomatous polyposis coli M74088
BRCA1 Breast cancer 1, early onset U68041
BRCA2 Breast cancer 2, early onset X95177
CBP Human CREB-binding protein U85962
DPC4 Human deletion target in pancreatic carcinoma U44378
IRF-1 Interferon regulatory factor 1 NM_002198
MSH2 MutS homolog 2 (nonpolyposis colon cancer) U03911
NF2 Neurofibromin 2 LI 1353
p 18 Cyclin-dependent kinase inhibitor 2C U 17074
pl9 Cyclin-dependent kinase inhibitor 2D U40343
p21 Cyclin-dependent kinase inhibitor 1A L47233
p27Kipl Cyclin-dependent kinase inhibitor IB U 10906
p300 El A binding protein p300 NM_001429
p53 Tumor protein p53 Ml 4694
p57Kip2 Cyclin-dependent kinase inhibitor 1C U22398
PTEN Phosphatase and tensin homolog U96180
Rb Retinoblastoma 1 Ml 5400
TGF-PRI Transforming growth factor, beta receptor I LI 1695
TGF-PRII Transforming growth factor, beta receptor II D50683
TSC1 Tuberous sclerosis 1 AF013168
TSC2 Tuberous sclerosis 2 X75621
VHL Von Hippel-Lindau syndrome AF010238
WT1 Wilms tumor 1 X51630
GAPDH Glyceraldehyde-3 -phosphate dehydrogenase M33197
p-actin Beta Actin X00351
PUC18 PUC18 bacterial plasmid DNA
Table 5.2
Abbreviations and descriptions of the genes and control sequences on the tumour 
suppressor array used in these experiments.
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5.1.4 Rationale of the study
The previous chapters described experiments designed to detect and evaluate any 
differences between the various stages of colorectal cancers in terms of mitochondrial 
mutations and microsatellite instability. Alterations were found in several of the 
carcinoma samples which were informative in terms of pathways and mechanisms of 
carcinogenesis and therefore possible treatment avenues. However, these mutations 
were present at a late stage and therefore were not useful candidate markers for early 
diagnosis. Rather than look for possible markers and see if these were present early 
on, the experiments in this chapter look at early stage samples and see if there are any 
changes present that may have potential as a molecular marker or may appear 
important in the early stages of progression of carcinogenesis and therefore to add 
data to the Vogelgram of cancer progression from adenoma to carcinoma as well as to 
try to discover why some polyps progress to cancer whilst others do not.
The purpose of this study was to address these issues by exploiting the new 
technologies available to study gene expression of several genes in a single tissue 
sample in one experiment, particularly as some samples were very small, limiting the 
quantity of RNA available for analysis.
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5.2 Materials and methods
5.2.1 Sample collection
16 samples from 5 patients were collected from surgery, resected with the assistance 
of a pathologist and stored at 4°C in KNAlater (Ambion, UK) until use as described in 
Chapter 2, Section 2.2. Tumour samples were taken from patient five from the central 
and peripheral regions of the carcinoma to allow analysis of the clonality of the 
tumour. Table 5.3 lists the patient details for this sample cohort.
Patient
Number Sex Age
Dukes’
Stage
Location of 
tumour
1 67 M C Rectal
2 61 M A Rectal
3 63 M C Sigmoidal
4 57 F A Rectal
5 74 F C Rectosigmoidal
Table 5.3 Patient details for the tissue samples used in the array analysis described in 
this chapter.
5.2.2 RNA extraction and quantification
RNA was extracted from the tissues as described in Chapter 2, Section 2.11.1 and 
quantified as described in Chapter 2, Section 2.11.2. The purity of the RNA was also 
assessed to detect any protein contamination, this is also described in Chapter 2, 
Section 2.11.2
5.2.3 Arrays
The GEArray original series human cancer/ tumour suppressors gene array 
(SuperArray, USA) with 23 tumour suppressor genes was selected for these 
experiments. The genes on this array are listed in Tables 5.1 and 5.2. The location of
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these genes on the array is illustrated in Figure 5.1. Gene expression levels were 
measured for the tumour suppressor and housekeeping genes described in section
5.1.3 utilising nylon membrane arrays using the protocol described in Chapter 2, 
section 2.12.
APC ] (BRAC) (BRAC ( BRAC) BRAC) pUC18APC
IRFl ) (pUC18CBP DPC4 DPC4 IRFlCBP
NF2 B-actinMSH2 ] ( MSH21 NF2 pi 8 p!8
p21 p27 p27pl9p 19 i-actm
P53 P57 P57p300 ] ( p300 ) ( p53 GADPl
TGFB1 ( TGFB} (GADPlRb RbPTEN'I (PTEN
TSC2 ] ( TSC2 \ (GADPlTGFB 
. RI1 j
TGFB) f TSC1
. RH J V ,
TSC1
VHL VHL WT1 WT1 1ADPH GADPH (GADPl
Figure 5.1
Locations of the genes on the tumour suppressor membrane array. Full gene names 
for each abbreviation are listed in Table 5.2.
5.2.3.1 Array analysis
Images of each array were captured as described in Chapter 2, section 12.1. Spot 
intensities were consolidated prior to background subtraction and normalisation as 
described in Chapter 2, section 12.2. Data was filtered to remove results from genes 
being expressed at levels less than 10% of the housekeeping gene p-actin as this is
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lower than can be accurately measured using these arrays. Expression ratios were 
transformed to produce a continuous range of fold changes; this is explained in more 
detail in Chapter 2, Section 2.12.2. Fold changes over ±2-fold are considered 
significant changes in gene expression (Quackenbush, 2002). Arrays from each tissue 
type were analysed independently against the remaining tissue types from the same 
patient, for example the array from the normal mucosa was analysed against that of 
the polyp and the tumour and the array from the polyp was separately analysed 
against the tumour array. This was carried out so that an accurate assessment of the 
gene expression changes at each stage could be determined and genes that were for 
example down-regulated from normal mucosa to polyp but up regulated from polyp to 
mucosa could be detected even though these may give no overall change in 
expression from normal mucosa to tumour.
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5.3 Results
5.3.1 Quantity and quality of RNA extracted
The RNA quality and quantity extracted from each sample depended upon the size o f 
the sample and the sample type. Some adenoma samples measured <3mm and so a 
limited amount o f RNA could be extracted. The tissue ffom the adenoma and 
carcinoma samples was far easier to break up and so a higher amount o f RNA per 
gram o f tissue was extracted with the normal mucosa yielding lower amounts. The 
quality o f the RNA for all the samples used in this study was high as determined by 
spectrophotometry with an A260/A240 ratio o f over 1.8 as described in Chapter 2, 
Section 2.11.2. Repeat array analysis was undertaken where RNA quantities allowed 
RNA quality and quantity values are included in Table 5.4.
Patient
Number
Sample
No Sample Type Ratio
Cone.
pg/ml
1 12 Rectal adenocarcinoma 1.97 1834
15 Polyp 1.89 1595
13 Normal mucosa 1.85 690
2 28 Rectal adenocarcinoma 1.88 2587
31 Large Polyp 1.82 1012
33 Normal mucosa 2.10 716
3 38 Sigmoid adenocarcinoma (Peripheral region) 1.96 1140
39 Sigmoid adenocarcinoma (Central region) 1.93 1364
40 Normal mucosa 1.95 753
42 Polyp 2.00 692
4 16 Rectal adenocarcinoma 1.94 1917
19 Polyp 1.82 687
17 Normal mucosa 1.91 672
5 86 Normal mucosa 1.89 686
88 Rectosigmoid adenocarcinoma 1.90 902
90 Polyp 1.81 840
Table 5.4
Table o f RNA sample details including the A260/A 240 ratio and the concentration of 
RNA extracted for each tissue sample.
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5.3.2 Array analysis and results
For each patient RNA was extracted from normal mucosa, polyp and an 
adenocarcinoma as described in Chapter 2, Section 2.11.1. cDNA was produced and 
used to carry out the array analysis, see Chapter 2, Section 2.12. Analysis of the spot 
intensity data obtained for each gene was carried out as described in Section 5.2.3 to 
give an average result for the two spots per gene on each array, to remove background 
noise levels and to normalise the data against housekeeping gene P-actin to allow for 
meaningful comparisons to be made between each array.
5.3.2.1 Array results from patient one
Patient one was a 67 year old male with Dukes’ stage C rectal cancer. Photographs of 
the array images for this patient can be seen in Figure 5.2 The darker spots on these 
images correspond to genes with comparatively higher levels of gene expression than 
the other genes within the same array. The experiments were repeated and the average 
fold changes between tissue types are listed in Table 5.5 and are depicted graphically 
in Figure 5.3.
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Fold change in gene expression
Normal Normal to Polyp to
Gene to polyp tumour tumour
APC 0.00 0.13 0.00
BRCA1 0.00 1.02 0.00
BRCA2 0.00 1.41 0.00
PUC18 0.00 1.00 0.50
CBP 1.53 3.27* 2.14*
DPC4 -2.75* 0.16 2.96*
ERF-1 0.00 -1.59 0.00
MSH2 0.00 1.23 0.00
NF2 -2.08* -0.12 1.89
pl8 0.00 -3.18* 0.00
GAPDH 1.03 1.08 0.05
pl9Ink4d 0.00 -1.70 0.00
p21Wafl -7.01* -3.64* 2.00*
p27Kipl 1.23 2.31* 1.88
p300 -1.28 2.01* 2.52*
p53 -1.82 0.00 1.86
p57Kip2 -1.30 -6.75* -4.87*
b-actin 1.00 1.00 1.00
PTEN -1.33 1.45 1.87
Rb 0.00 -2.54* 0.00
TGFBR1 -1.37 -0.07 1.29
TGFbR2 -0.05 2.53* 2.64*
TSC-1 0.00 0.12 0.00
TSC2 0.00 -5.31* 0.00
VEIL 0.00 1.76 0.00
WT1 0.00 -5.61* 0.00
Table 5.5
Gene expression fold changes between tissue samples for patient one. A value of 0.00 
has been used where data for the gene was not above 10% of B-actin and is therefore 
not included as this is below the threshold recommended by Superarray, by these 
same recommendations, changes above 2 fold are significant and are marked with an 
asterisk.
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Average fold changes in gene expression for patient
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Figure 5.3
This graph shows the fold changes between the tissue types for the genes where the 
changes in gene expression are over 2 fold. The error bars for each gene indicate +/- 
standard deviation between repeat experiments.
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5.3.2.2 Array results from patient two
Patient two was a 61 year old male with Dukes’ stage A rectal cancer. The average
fold changes between tissue types as determined by array analysis are listed in Table
5.6
Fold change in gene expression
Normal Normal to Polyp to
Gene to polyp tumour tumour
APC -2.69* 0.00 0.00
BRCA1 0.00 0.62 2.18*
BRCA2 0.00 0.00 0.00
PUC18 0.00 0.00 0.00
CBP 0.25 -0.77 -0.59
DPC4 2.09* -1.15 -1.40
IRF-1 -0.95 0.00 0.00
MSH2 -0.94 0.62 1.95
NF2 0.85 -0.63 0.52
pi 8 -2.78* -0.72 2.29*
GAPDH 1.07 -1.31 -1.39
pl9Ink4d -8.18* -0.77 2.96*
p21Wafl -3.96* -2.72* 0.47
p27Kip 1 -0.37 -1.44 -0.11
p300 -1.91 -1.25 1.59
p53 -0.08 0.05 1.24
p57Kip2 -2.27* 0.88 0.61
b-actin 0.00 1.00 1.00
PTEN -11.31* -1.06 2.09*
Rb -5.97* -0.16 4.11*
TGFBR1 -6.98* 1.62 12.90*
TGFbR2 -10.76* -0.75 2.21*
TSC-1 -3.78* -1.51 4.42*
TSC2 0.00 1.35 1.23
VHL 0.00 -0.87 2.85*
WT1 0.00 0.00 0.00
Table 5.6
Gene expression fold changes between tissue samples for patient two. A value of 0.00 
has been used where data for the gene was not above 10% of B-actin and is therefore 
not included as this is below the threshold recommended by Superarray, by these 
same recommendations, changes above 2 fold are significant and are marked with an 
asterisk.
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Average fold changes for patient two
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Figure 5.4
This graph shows the fold changes between the tissue types for the genes where the 
changes in gene expression are over 2 fold. The error bars for each gene indicate +/- 
standard deviation between repeat experiments.
5.3.2.3 Array results from patient three
Patient three was a 63 year old male with Dukes’ stage C sigmoidal cancer. From 
patient three RNA was extracted from normal mucosa, polyp and two samples from 
the same adenocarcinoma, one from the centre o f the tumour and one from the 
peripheral region. cDNA was produced and used to carry out the array analysis. There 
was unfortunately insufficient RNA to carry out a repeat array experiment for the 
peripheral tumour The data recorded in Table 5.6 is the average fold changes 
between the tissue types excluding peripheral tumour, but observations from this 
experiment are discussed in Section 5.4.5.
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Fold change in gene expression
Normal Normal to
Polyp to 
central
Gene to polyp central tumour tumour
APC -2.30* -0.69 0.59
BRCA1 0.00 -0.75 0.63
BRCA2 -0.80 -0.68 0.59
PUC18 1.00 1.00 1.00
CBP -11.48* -3.28* 3.73*
DPC4 -2.26* -3.90* -1.37
IRF-1 -1.62 -1.50 -2.67*
MSH2 -0.84 -2.62* -0.87
NF2 -2.04* -2.92* -1.44
pl8 -0.01 -0.88 -0.68
GAPDH -1.07 0.30 0.40
pl9Ink4d -1.55 -0.95 -0.15
p21Wafl -4.97* -8.44* -1.71
p27Kipl 2.05* 3.70* 1.29
p300 -2.54* -1.92 0.52
p53 0.38 3.24* 2.89*
p57Kip2 -1.33 -0.92 -0.56
b-actin 1.00 1.00 1.00
PTEN -2.56* -2.18* 0.51
Rb -1.31 2.20* 2.39*
TGFBR1 -3.62* -1.30 2.57*
TGFbR2 -2.66* -1.86 1.61
TSC-1 0.00 1.56 -1.43
TSC2 0.00 4.43* 0.00
VHL 0.00 7.80* 0.61
WT1 0.00 3.12* 3.79*
Table 5.7
Gene expression fold changes between tissue samples for patient three. A value of 
0.00 has been used where data for the gene was not above 10% of B-actin and is 
therefore not included as this is below the threshold recommended by Superarray, by 
these same recommendations, changes above 2 fold are significant and are marked 
with an asterisk.
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Average fo!d change in gene expression for patient three
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Figure 5.5
This graph shows the fold changes between the tissue types for the genes where the 
changes in gene expression are over 2 fold. The error bars for each gene indicate +/- 
standard deviation between repeat experiments.
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5.3.2.4 Array results from patient four
Patient 4 was a 57 year old female with Dukes’ stage A rectal cancer. The average
fold changes between tissue types as determined by array analysis are listed in Table
5.8
Fold change in gene expression
Normal Normal to Polyp to
Gene to polyp tumour tumour
APC -1.65 -2.54* -1.54
BRCA1 -2.48* -1.11 2.25*
BRCA2 -2.12* -1.99 0.08
PUC18 0.00 1.00 1.00
CBP -1.88 -2.16* -0.16
DPC4 -3.03* -27.06* -8.95*
ERF-1 -2.53* -4.93* -1.92
MSH2 -1.86 -3.80* -2.04*
NF2 -3.17* -6.75* -2.09*
pl8 -1.28 -2.07* -1.60
GAPDH -1.12 -1.14 -0.01
pl9Ink4d -1.85 -2.68* -0.45
p21Wafl -3.73* -5.07* -1.35
p27Kipl 0.05 -1.66 -1.76
p300 -1.71 -1.91 -0.10
p53 -1.55 -1.93 -0.19
p57Kip2 -15.35* 0.00 -8.99*
b-actin 1.00 1.00 1.00
PTEN -3.33* -8.29* -2.43*
Rb -1.38 -2.56* -1.77
TGFBR1 -3.01* -7.95* -2.74*
TGFbR2 -2.61* -4.40* -1.73
TSC-1 -0.01 1.79 -1.31
TSC2 -0.06 -15.57* -31.76*
VHL 0.50 1.26 -1.65
WT1 -4.56* 0.23 3.17*
Table 5.8
Gene expression fold changes between tissue samples for patient four. A value of 0.00 
has been used where data for the gene was not above 10% of B-actin and is therefore 
not included as this is below the threshold recommended by Superarray, by these 
same recommendations, changes above 2 fold are significant and are marked with an 
asterisk.
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Figure 5.6
This graph shows the fold changes between the tissue types for the genes where the 
changes in gene expression are over 2 fold. The error bars for each gene indicate +/- 
standard deviation between repeat experiments.
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5.3.1.5 Array results from patient five
Patient 5 was a 74 year old female with Dukes’ stage C rectosigmoidal cancer. The
average fold changes between tissue types as determined by array analysis are listed
in Table 5.9
Fold change in gene expression
Normal Normal to Polyp to
Gene to polyp tumour tumour
APC 1.50 -1.98 -2.90*
BRCA1 0.00 -1.93 -3.02*
BRCA2 0.00 0.00 0.00
PUC18 0.00 0.00 0.00
CBP -1.57 -0.47 0.20
DPC4 -1.42 -1.42 0.06
IRF-1 0.00 0.00 0.00
MSH2 -2.28* 0.22 2.65*
NF2 -3.14* -0.09 2.94*
pl8 0.00 0.00 0.42
GAPDH -1.16 -1.32 -1.14
pl9Ink4d -0.10 -1.49 -1.41
p21Wafl -3.58* -3.38* 0.11
p27Kipl -1.18 -0.08 0.13
p300 -1.87 -0.20 1.64
p53 -0.41 3.79* 3.24*
p57Kip2 -1.24 -6.00* -4.25*
b-actin 1.00 1.00 1.00
PTEN -1.48 -3.74* -2.52*
Rb -0.09 2.54* 2.74*
TGFBR1 -2.33* -9.49* -5.13*
TGFbR2 -1.72 -2.96* -1.73
TSC-1 0.28 -1.96 -2.73*
TSC2 0.00 0.00 -2.32*
VHL 2.47* -6.46* -15.75*
WT1 0.00 0.00 0.00
Table 5.9
Gene expression fold changes between tissue samples for patient five. A value of 0.00 
has been used where data for the gene was not above 10% of B-actin and is therefore 
not included as this is below the threshold recommended by Superarray, by these 
same recommendations, changes above 2 fold are significant and are marked with an 
asterisk.
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Average fold change in gene expression for patient five
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Figure 5.7 This graph shows the fold changes between the tissue types for the genes 
where the changes in gene expression are over 2 fold. The error bars for each gene 
indicate +/- standard deviation between repeat experiments.
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5.3.2.6 Overall array results
To obtain an overall picture of the gene expression changes during colorectal
carcinogenesis the mean changes across all the analysed patients for each gene were
calculated. These results are listed in Table 5.10
Fold change in gene expression
Normal to Normal to Tumour to
Gene polyp tumour polyp
APC -1.28 -1.27 -1.12
BRCA1 -1.71 -0.43 -0.09
BRCA2 -1.46 -0.42 0.15
PUC18 1.00 1.00 1.00
CBP -2.63* -0.68 1.33
DPC4 -1.47 -6.67* -1.83
IRF-1 -1.70 -2.68* -1.98
MSH2 -1.48 -0.87 -0.17
NF2 -1.92 -2.10* 0.24
p 18 -1.35 -1.71 -0.68
GAPDH -0.25 -0.48 -0.18
pl9Ink4d -2.92* -1.52 -0.69
p21Wafl -4.58* -4.65* -0.45
p27Kipl 0.35 0.57 0.55
p300 -1.86 -0.66 1.10
p53 -0.70 1.03 1.85
p57Kip2 -4.30* -10.76* -5.30*
b-actin 1.00 1.00 1.00
PTEN -4.00* -2.76* -0.60
Rb -2.19* -0.11 0.83
TGFBR1 -3.46* -3.44* -1.02
TGFbR2 -3.56* -1.49 0.27
TSC-1 -0.66 0.00 -1.83
TSC2 -0.06 -3.77* -11.99*
VHL 1.73 0.70 -4.11*
WT1 0.31 -0.75 2.20*
Table 5.10
Mean gene expression fold changes between tissue samples for all five patients. 
Averages for each gene were taken for data above 10% of B-actin, data below this 
level was excluded as this is below the threshold recommended by Superarray. By 
these same recommendations, changes above 2 fold are significant and are marked 
with an asterisk.
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Average fold change in gene expression for all patients
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Figure 5.8
This graph shows the average fold changes between the tissue types for the genes 
where the changes in gene expression are over 2 fold. The error bars for each gene 
indicate +/- standard deviation between the average results for each patient
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Figure 5.9
This graph shows the number of patients which exhibited alteration in gene 
expression between the tissue types for the genes where the changes in expression are 
over 2 fold once the standard deviations have been taken into account.
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5.4 Discussion
5.4.1 RNA quality and quantity
The quality of RNA extracted across the samples was uniformly high as determined 
by spectrophotometry. The use of RNAJater (Ambion, UK) on ice in the sample 
collection process is likely to be a contributing factor to this as it has been proven to 
be an effective preservative of RNA in solid tissue samples preventing the 
degradation of RNA (Mutter et al., 2004). The logistical aspects of sample collection 
are another factor responsible for the high quality yields despite small sample sizes. 
The adjacent locations of the hospital and university laboratories, as well as co­
operation between the surgical and pathology department staff enabled the resection 
and collection of surgical samples to occur within minutes of the sample being 
removed from the patient.
5.4.2 The control genes and cDNA sequences
5.4.2.1 p-actin
Beta-actin is a housekeeping gene and is therefore constitutively expressed in cells 
and so acts as both a positive control and also enables arrays to be normalised so the 
data from one array can be compared with another. There has though been a paper 
published reporting the expression levels of p-actin in colorectal samples to increase 
as tissues progress through the process of carcinogenesis. Higher levels of P-actin 
were detected in adenomas and metastatic polyps than in normal colonic tissue and 
even higher levels were detected in carcinomas, especially those which were poorly 
differentiated (Naylor e ta l, 1992).
5.4.2.2 pUC18
This is a bacterial plasmid included on the array as a negative control as there should 
be none of this RNA present in a human tissue sample and so blank areas on the array 
for pUC18 confirm there has been no contamination of the array or sample and is
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used in the array analysis to remove background noise from the intensities of the 
cDNA spots.
5.4.3 Gene expression changes detected in patient one
Patient one was male, 67 years of age at time of operation with Dukes stage C rectal 
cancer. A photograph of the array images captured by the ChemiDoc apparatus 
(BioRad, UK) can be seen in Figure 5.2. From this image it is possible to see some of 
spots on the array are darker than other suggesting these genes are expressed at a high 
level. However it is not possible to assess the change in gene expression without 
normalising the data and subtracting background noise. This and further analysis was 
undertaken and the average fold changes detected can be seen in Table 5.5.
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Figure 5.9
This diagram shows the gene changes that were detected in patient one between the 
stages of cancer progression. The red arrows represent down regulation and the green 
arrows indicate up regulation of the genes within each arrow. All the genes included 
had changes of over 2 fold detected.
Table 5.5 lists the gene expression fold changes for all of the genes on the array used 
for patient one. Where the expression level was so low that the spot intensity was 
<10% of the intensity of that of p-actin these results have been removed as an 
accurate reading cannot be obtained below this threshold. For comparisons between
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arrays for these genes the fold change value has been replaced by 0.00. Figures 5.3 
and 5.9 show the genes which had expression level changes of ±2 fold or greater. 
These results are classed as significant using the recommendations applied to array 
analysis where a 2 fold change is the limit of sensitivity of membrane arrays 
(Quackenbush, 2002). These graphical and pictorial representations of the data also 
show at which stage in progression of rectal carcinogenesis these gene expression 
changes occurred. The variation between experiments is represented on Figure 5.3 as 
error bars of ± the standard deviation (SD).
From normal to rectal polyp, p21 was the only gene down-regulated over 2 fold (- 
7.01, 1.21 SD). This change was apparent even by simple observation of the array 
images and as it occurred at such an early stage this may provide an important clinical 
biomarker. cDNA array studies have found p21 to be 6-fold overexpressed in 
mucinous colorectal cell lines but not in non-mucinous colorectal cell lines. These 
increases in expression were not detected in the tissue samples, possibly due to the 
heterogeneity of tumour tissue (Backert et a l, 1999). HNPCC tumours, which are 
frequently mucinous, have also been reported with overexpressed levels of p21 
(Sinicrope et a l, 1998). In contrast, a study has reported p21 expression in non- 
mucinous colorectal carcinoma tissue samples to be down-regulated to around a third 
of that of normal tissue (Matsushita et a l , 1996). The array findings of p21 down 
regulation for this patients studied in this chapter are in line with these studies as the 
patient had non-mucinous non-hereditary colorectal cancer.
The differences in gene expression between rectal polyp and rectal adenocarcinoma 
were predominantly increases in gene expression with the exception of a down 
regulation of p57 (-4.87). Cyclin-dependant kinase inhibitor 1C or p57Kip2, as the gene 
is also known, is an important inhibitor of cell cycle progression. p57Kip2 is 
inactivated in 10-30% of tumours by hypermethylation of the promoter region and 
histone demethylation in various human cancers types such as colorectal, gastric, 
hepatocellular, pancreatic and in cases of myeloid leukemia and is linked to poor 
prognosis (Kikuchi et al, 2002; Li et al, 2003). p57Kip2 is situated in the nucleus of 
colorectal cancer tissues and a low expression of the gene is associated with a large 
tumour size and the presence of tumours in female patients (Noura et al, 2001). In
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contrast to this current study, recent research of colorectal carcinogenesis has found 
p5?K^ p2 expression to increase from normal colonic mucosa to adenoma tissue and 
decrease from adenomas to carcinomas whereas the expression levels remain 
unchanged when primary carcinomas metastasized to lymph nodes (Li et a l , 2003). 
The expression levels between repeat array experiments of p57 varied to the extent 
that further experiments would have to be undertaken to draw conclusions for gene 
expression values for this gene.
The genes which increased in expression from rectal polyp to rectal adenocarcinoma 
with a fold increase of over 2 were CBP (+2.14), DPC4 (+2.96), p300 (+2.52) and 
TGF-PRII (+2.64).
CBP and p300 are very similar proteins which have similar roles within the cell.. 
Human CREB-binding protein is an acetyltransferase enzyme and acetylates proteins, 
including histones, tagging specifically for transcriptional activation. p300 is also a 
hi stone acetyltransferase that functions as a transcriptional regulator for several 
nuclear proteins (Chan and La Thangue, 2001). p300, along with CBP, controls the 
stability of the p53 protein by facilitating p53 degradation (Grossman et a l , 2003). 
p300 also functions as an essential coactivator in p53-dependant transactivation of 
target genes as part of the cells response to DNA damage (Espinosa and Emerson, 
2001). Studies in colorectal cell lines have shown that p300 regulates p53-dependent 
apoptosis after DNA damage and an absence of p300 results in failure to activate p21 
transcription which prevents p21-dependant cell cycle arrest to occur, leading to 
increasing apoptosis in response to DNA damage (Iyer et a l , 2004). This experiment 
suggests that p300 is a key regulator of p53 response and the inhibition of this gene 
could be used to modulate chemotherapy. These findings highlights the importance of 
this gene in colorectal cancer and measuring the expression levels of p300 in 
colorectal cancer patients with wild-type p53 may give insight into how a patient may 
respond to various chemotherapy agents (Iyer et a l , 2004). In this current experiment, 
patient one showed increases in expression from polyp to carcinoma of CBP and p300 
as well as an increase in p21 expression of 2 fold (0.40 SD). This suggests a p21- 
dependant cell cycle arrest response rather than apoptosis of the tumour cells and this 
patient may therefore benefit from p300 inhibition to promote cell death within the 
tumour. As p53 mutations are a late genetic alteration in colorectal carcinogenesis and
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there have been no significant changes in p53 expression for most of the patients in 
this study, the role of CBP, p300 and p21 in the control of cell cycle arrest and 
apoptosis balance is of great importance.
Human homozygous deletion target in pancreatic carcinoma (DPC4) gene, also 
known as smad4, had an increased expression level from polyp to tumour. DPC4 is 
involved in the TGF-13 signaling transduction pathway. This gene is so called as it is 
inactivated in around 55% of pancreatic cancers and is also inactivated in around 15% 
of colorectal cancers either by loss of heterozygosity or mutation (McCarthy et a l , 
2003). The loss of DPC4 expression in colonic adenocarcinomas is reported a late 
event in the adenoma to carcinoma pathway and shows a weak correlation with 
metastatic cancer (Maitra et a l , 2000; Takaku et a l , 1998).
TGF-BRII, which showed no significant change in expression level from normal 
mucosa to polyp, showed a significant rise in gene expression from polyp sample to 
rectal carcinoma with a rise of +2.64 fold (0.35 SD). The TGF-BRII gene is mutated 
in many cancers exhibiting MSI and because of this the gene is also termed HNPCC6 
as it is frequently mutated in the mismatch repair deficient hereditary disease HNPCC 
(Shin et al, 2000). TGF-BRII is inactivated by mutation within an Aio tract which 
disables the receptor and makes the cell resistant to the growth inhibitory effects of 
TGF-B (Markowitz et al, 1995). TGF-BRII mutations are thought to be the earliest 
mutational event in MSI tumours and have been linked with the progression of 
adenomas to cancer (Duval et al, 2001; Markowitz et al, 1995; Young et al, 1995; 
Abdel-Rahman et al, 1999). There have been no expression studies to date of this 
gene in colorectal cancers other than to define the effect of the inactivating mutation. 
The increase of TGF-BRII expression in the progression of the cancer pathway from 
polyp to carcinoma for this patient may increase the cells sensitivity to the growth 
inhibitor TGF-B. This conclusion does assume that the increase in TGF-BRII 
expression correlates with an increase in the level of functional TGF-BRII protein and 
as this gene is frequently mutated in colorectal cancer this is not a safe assumption to 
make. It would be of interest to detect the protein levels of TGF-BRII and TGF-B 
before drawing any further conclusions. The MSI status of this patient is 
unfortunately not known but as the patient had sporadic rectal cancer the tumour is 
unlikely to be MSI positive as these tumours predominantly occur in the proximal
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colon (Thibodeau et al., 1998), but having this confirmed would again be of interest 
as although the mechanisms behind the mutation of this gene and the alteration of 
expression levels are very different it would be interesting to see if these occurrences 
showed any form of correlation. The increase in TGF-BRII expression seen in this 
patient occurred at the stage of carcinogenesis at which TGF-BRII mutations have 
been reported to be pivotal in tumour progression. It may be that in a subset of 
colorectal patients TGF-BRII expression plays a part in tumour progression.
There were also genes that, although showed no significant change in expression 
between stages, changed significantly in terms of expression from normal mucosa to 
rectal carcinoma tissue. These genes were p27 (+2.31, 0.26 SD), TSC2 (-5.31, 2.06 
SD) and WT1 (-5.61, 2.80 SD). All of these genes had low levels of expression which 
typically resulted in larger standard deviations between repeats than genes expressed 
at higher levels. An application of different techniques such as RT-PCR would be an 
appropriate method of further analysing these genes in order to either confirm these 
results or to find if these are merely artefacts.
5.4.4 Gene expression changes detected in patient two
Patient 2 also had rectal cancers and samples of normal mucosa, polyp and carcinoma 
were all taken from this region. The predominant observation for this patient was 
again a general decrease in gene expression of the majority of genes on the array from 
normal mucosa to rectal polyp followed by a general increase in expression of these 
genes between polyp sample and rectal carcinoma. This is a very similar pattern to the 
results seen from patient 1. Both of these patients were male, in their 60s and the 
tumours developed in the rectal region of the colorectum. The carcinoma from patient 
2 was though less advanced and was categorised as Dukes’ stage A whereas patient 1 
had a more advanced carcinoma at Dukes stage C. Table 5.6 lists the gene expression 
fold changes for all of the genes on the array used for patient two. A value of 0.00 is 
used where spot intensity was very low and an accurate reading cannot be obtained. 
Figures 5.4 and 5.10 are graphical and pictorial representations of this data which 
show the genes which had expression level changes of ±2 fold or greater.
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Figure 5.10
This diagram shows the gene changes that were detected in patient two between the 
stages o f cancer progression. The red arrows represent down regulation and the green 
arrows indicate up regulation o f the genes within each arrow. All the genes included 
had significant changes o f over 2 fold detected. There are no genes labelled for the 
development o f a polyp into carcinoma for this patient as there were no significant 
gene expression changes at this stage.
After taking into account standard deviation, the significant gene expression changes 
from normal mucosa to polyp were p i 9 (-8.18, 1.28 SD), p21 (-3.96, 1.84 SD), PTEN 
(-11.31, 3.42 SD), Rb (-5.97, 0.23 SD), TGF-BRI (-6.98, 0.14 SD), TGF-BRII (-10.76, 
5.86 SD) and TSC1 (-3.78, 1.20 SD).
The cyclin-dependant kinase inhibitors p 19 and p21 were both down-regulated in the 
polyp sample compared to the normal mucosa, p 19 functions to regulate the cell cycle 
and apoptosis by blocking the degradation o f the tumour suppressor p53. p i9 
expression has been reported to be down-regulated in murine colonic cell lines with 
truncated (3-catenin which prevents apoptosis from occurring (Wagenaar et al., 2001). 
(3-catenin is mutated in many colorectal cancers (Morin et al., 1997) and it would be 
interesting to know if was functional in this patient. There are currently no published 
studies o f p i9 expression in human colorectal cancer tissues but the findings for this 
patient correspond to those of the study o f mouse cell lines.
Phosphatase and tensin homolog (PTEN) gene contains two (A)g repeats which are 
susceptible to mutation in MSI tumours (Guanti et a l., 2000). Mutations and allelic 
losses o f  PTEN can be found in brain tumours and endometrial cancers (Mutter et al.,
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2000). Germline PTEN mutations can cause Cowden syndrome and Bannayan- 
Ruvalcaba-Riley syndrome, a symptom of both of these conditions is the development 
of juvenile polyps in the gastrointestinal tract (Woodford-Richens et a l, 2000). 
Although there are no published studies of PTEN expression in colorectal cancers, 
PTEN gene expression loss has been detected by immunohistochemistry in primary 
breast cancers and more advanced prostate carcinomas (Perren et a l, 1999; 
McMenamin et a l, 1999). These reports of PTEN down regulation are in agreement 
with the findings of this current study for this patient.
The retinoblastoma 1 (Rb) encodes a protein which regulates cell cycle progression at 
the transition from the Gj to the S phase (Goodrich et a l, 1991). Mutation of this gene 
is rare but when present causes aggressive tumours of the retina. In contrast to this 
current study which found a down regulation of this gene, Rb levels have been found 
to be increased in colorectal cancers (Gope et a l, 1990). The increased levels have 
been detected in adenomatous polyps and increase further in carcinoma tissue; these 
increased levels may protect cells from growth inhibition and apoptosis (Yamamoto et 
al, 1999).
Transforming growth factor-beta receptor I (TGF-BRI) is involved in the signal 
transduction for growth inhibition and was down-regulated by 6.98-fold in the polyp of 
this patient in comparison to the normal colonic mucosa. Cellular release from the 
growth control of TGF-BRI-dependent growth inhibition is an early event in the 
development of many malignancies (Souchelnytskyi, 2002). Increases in TGF-BRI 
expression are correlated to an increased tumourigenicity, invasion and drug resistance 
in many cancer tissues including colon and gastric as well as several breast and prostate 
cancer models (Teicher, 2001). The expression level of TGF-BRI is important when 
deciding upon a treatment for cancer as leukemia cells resistant to the anti-cancer drug 
cisplatin have been found to have impaired TGF-BRI signaling (Stoika etal., 2003).
Tuberous sclerosis 1 (TSC1) was down-regulated in this patient in the polyp tissue 
compared to normal colonic mucosa. Mutations in the genes TSC1 and tuberous 
sclerosis 2 (TSC2) cause the autosomal dominant disease of the same name which is 
characterized by the widespread development of benign tumours. TSC1 forms a 
complex with TSC2 which is thought to control cell cycle, endocytosis, cell adhesion
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and transcription (Gao and Pan, 2001). The exact role of this complex and how 
mutations in these genes cause the development of benign tumours is as yet unknown. 
Biallelic inactivation has not been found in these genes in neurological tumours and 
so the mechanism behind the role of these TSC genes in tumour development may be 
through altered gene expression levels rather than mutation (Parry et al., 2000).
There were no significant changes seen from polyp to the rectal tumour. The only 
significant difference from normal to tumour was a decrease in expression of p21 (- 
2.72, 0.17 SD) however this is a less striking finding than the initial decrease of this 
gene at the early stage from normal to polyp (-3.96, SD 1.84).
5.4.5 Gene expression changes detected in patient three
Patient 3 was a 63 year old male with a Dukes stage C carcinoma situated in the 
sigmoidal region of the colorectum. Samples were taken from normal mucosa, polyp 
and two samples from the carcinoma, from the peripheral region of the tumour and a 
further sample from the central region of the tumour. Table 5.7 lists the gene 
expression fold changes for all of the genes on the array used for patient three. Figures
5.5 and 5.11 are graphical and pictorial representations of this data which show the 
genes which had expression level changes of ±2 fold or greater.
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Figure 5.11
This diagram shows the gene changes that were detected in patient three between the 
stages of cancer progression. The red arrows represent down regulation and the green 
arrows indicate up regulation of the genes within each arrow. All the genes included 
had changes of over 2 fold detected.
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Again there was a general trend of the genes decreasing in expression level between 
normal mucosa and sigmoidal polyp and an increase in gene expression from polyp to 
sigmoidal carcinoma. The changes which were significant after taking into 
consideration standard deviation were all decreases in expression between the normal 
mucosa and polyp samples. These genes with significant changes are listed here 
followed by the fold decreases and standard deviation (SD), CBP (-11.48; SD 0.34), 
p21 (-4.97; SD 1.50), p300 (-2.54; SD 0.04), PTEN (-2.56; SD 0.01) and TGF-0RII (- 
2.66; SD 0.03). All of these genes were also found down-regulated in patient one 
and/or patient two.
As seen in patient one, CBP and p300 were both down-regulated, -11.48 and -2.54 
respectively. It is also noteworthy that these genes appear to be regulated together as 
in patients 2,4 and 5 neither of these genes were down-regulated yet in patients 1 and 
3 CBP and p300 were both down-regulated at the normal mucosa to polyp stage of 
carcinogenesis. This observation is in line with the very similar functions of these 
proteins as discussed in Section 5.4.3 and this may be a gene expression pattern which 
is key to certain pathways of carcinogenesis or a factor important in the further 
development of the polyp to a carcinoma.
The significant changes seen from polyp to the central region of the sigmoidal tumour 
were CBP (3.73, 1.36 SD) and Rb (2.39, 0.26 SD). Both these genes have been 
previously discussed. There were no significant changes in gene expression from 
normal to sigmoidal tumour.
There were unfortunately problems when analysing the peripheral tumour to compare 
with the expression patterns found in the central tumour sample to assess for clonal 
differences arisen from the development of the tumour. These problems were a result 
of arrays being shipped with contamination which was not evident until the end of the 
experiment and as a result there was only sufficient RNA remaining for one array 
experiment with the peripheral region of the sigmoidal tumour. From this one 
experiment slight decreases in expression were seen from the central tumour sample 
to the peripheral region of the same tumour in the following genes, BRCA1 (-2.36), 
VHL (-2.36) and WT1 (-2.36). Increases in gene expression were seen in NF2 (2.63),
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pl9 (2.26) and p21 (2.20). All of these genes were only marginally above the 2 fold 
threshold regarded as significant and without repeat experiments these initial findings 
cannot be considered as anything other than observations of the possibility of 
measurable changes in gene expression within an individual tumour. From this 
conclusion I raise the suggestion that studies of gene expression in solid tumours 
would be more useful if more details about the exact sampling technique were 
provided in publications, especially where small fold changes have been observed. 
Despite this, the changes observed within the tumour were less pronounced than 
between the samples of each different stage but further investigation of genetic 
changes within individual tumours would be worthwhile and provide more insight 
into the development of the occurrence of clonal growth from which tumours develop.
5.4.6 Gene expression changes detected in patient four
Patient 4 was a 57 year old female with a Dukes stage A carcinoma situated in the 
rectal region of the colorectum. Samples were taken from normal mucosa, polyp and 
carcinoma. Table 5.8 lists the gene expression fold changes for all of the genes on the 
array used for patient four. Figures 5.6 and 5.12 are graphical and pictorial 
representations of this data which show the genes which had expression level changes 
of ±2 fold or greater.
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Figure 5.12
This diagram shows the gene changes that were detected in patient four between the 
stages of cancer progression. The red arrows represent down regulation and the green 
arrows indicate up regulation of the genes within each arrow. All the genes included 
had changes of over 2 fold detected.
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From the rectal normal mucosa to the rectal polyp the genes with significant changes 
after taking standard deviation figures into consideration were all decreases in 
expression and are BRCA1 (-2.48, 0.39 SD), DPC4 (-3.03, 0.76 SD), IRF-1 (-2.53, 
0.32 SD), NF2 (-3.17, 0.71 SD), p21 (-3.73, 0.55 SD), PTEN (-3.33, 0.91 SD), TGF- 
BRI (-3.01, 0.98 SD) and TGF-BRII (-2.61, 0.48 SD).
Breast cancer 1, early onset (BRCA1) gene encodes a protein with several functional 
domains with different roles within the cell. The BRAC1 protein functions as a 
transcription factor (Monteiro et al., 1996) and also interacts with the repair protein 
Rad51 (Scully et al., 1997). BRCA1 has been shown to activate the cyclin dependent 
kinase inhibitor p21 in a p53 independent manner in human colon cancer cell lines in 
response to DNA damage (Somasundaram et a l, 1997). BRAC1 facilitates the 
cellular response to DNA repair and is required for appropriate cell cycle arrests after 
ionizing radiation in both the S-phase and the G2 phase of cell cycle. The C terminal 
region contains the transactivation region of the protein and so germline mutations 
that result in a truncated protein are in part responsible for the inherited predisposition 
to ovarian and breast cancers due to loss of function. Loss of heterozygosity of 
BRCA1 is a molecular alteration present in colorectal carcinomas which is linked 
with a poor prognosis for overall survival (Garcia et al., 2003). There have been no 
published studies to date reporting the gene expression levels of BRCA1 in colorectal 
cancers; it would be very interesting to establish a long term study to find out if there 
is a connection with decreased gene expression and poor prognosis. Also, as this gene 
expression decrease has been detected in the progression from normal mucosa to 
polyp, BRCA1 may be important in determining which polyps continue to develop 
into carcinomas.
IRF-1 was found down-regulated in patient 4 from normal mucosa to polyp by -2.53 
fold (0.32 SD). Interferon regulatory factor 1 (IRF-1) has tumour suppressor activity 
as the protein collaborates with p53 to induce cell cycle arrest after DNA damage 
(Tanaka et al, 1996). A raised level of the IRF-1 protein caused by overexpression of 
this gene induces cell cycle arrest whereas a mutant version of the protein which has 
been detected in gastric cancer is unable to induce cell-cycle arrest and has a reduced 
transcriptional activity (Nozawa et al, 1998). A decreased expression level of IRF-1
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found in this patient would reduce the capacity of the cells within the polyp to induce 
cell cycle arrest and therefore may allow mutated cells to divide before repair can 
occur. This is the first report of IRF-1 expression levels to be reduced in colorectal 
polyp samples.
Neurofibromin 2 (NF2) mutations causes the rare familial cancer neurofibromatosis 2 
which results in brain neoplasms. NF2 mutations have also been detected in multiple 
tumour types including melanoma and breast carcinoma and therefore NF2 is thought 
to have a more general role in tumourigenesis than originally surmised (Bianchi et a l, 
1994). There have been studies of NF2 mutations in colorectal cancer samples, one of 
which reports the presence of missense mutations in 2/44 (4.5%) (Arakawa et a l , 
1994) but the majority of these studies have found no NF2 mutations (Sugai et a l, 
2000; Rustgi et a l, 1995). Inactivation of the NF2 gene may therefore be associated 
with a small minority of colorectal cancers; yet it is possible that NF2 is important in 
colorectal carcinogenesis with alterations to gene function or expression occurring 
through mechanisms other than mutation such as promoter hypermethylation. As a 
down regulation was detected in the polyp of this patient in comparison to normal 
rectal mucosa, it seems more likely that if NF2 is involved in colorectal 
carcinogenesis it is through gene regulation rather than mutation.
From the rectal polyp sample to the carcinoma sample the only significant gene 
expression change was DPC4 (-8.95, 0.07 SD). The pattern of gene expression in this 
patient was a general decrease in gene expression from mucosa to polyp but, unlike 
the other four patients, the genes continued to decrease in expression from the polyp 
to carcinoma sample giving high decreases in expression level when comparing 
normal mucosa with carcinoma tissue such as DPC4 which decreased by -27.06 fold 
(6.59 SD).
5.4.7 Gene expression changes detected in patient five
Patient 4 was a 74 year old female with a Dukes stage C carcinoma situated in the 
rectosigmoidal region of the colorectum. Samples were taken from normal mucosa, 
polyp and carcinoma. Table 5.9 lists the gene expression fold changes for all of the 
genes on the array used for patient five. A value of 0.00 is used where spot intensity
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was less than the cut off level and as a result an accurate reading cannot be obtained. 
Figures 5.7 and 5.13 are graphical and pictorial representations of this data which 
show the genes which had expression level changes of ±2 fold or greater.
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Figure 5.13
This diagram shows the gene changes that were detected in patient five between the 
stages of cancer progression. The red arrows represent down regulation and the green 
arrows indicate up regulation of the genes within each arrow. All the genes included 
had changes of over 2 fold detected.
From the normal mucosa to the rectosigmoidal polyp there were 2 genes with 
significant changes after taking standard deviation figures into consideration were 
both decreases in expression and are NF2 (-3.14, 0.01 SD) and p21 (-3.58, 0.26 SD).
From polyp to rectosigmoidal carcinoma there were several genes with significant 
gene expression changes. Those genes with increases in expression were MSH2 (2.65, 
0.03 SD), NF2 (2.94, 0.69 SD), p53 (3.24, 0.25 SD) and Rb (2.74, 0.64 SD). Genes 
which decreased in expression were APC (-2.90, 0.20 SD), BRCA1 (-3.02, 0.47 SD) 
and VHL (-15.75, 6.96 SD).
Human mutS homologue 2 (hMSH2) is a mismatch repair gene that is mutated in 
around 60% of HNPCC cases and is used as a Bethesda marker for MSI (Ward et a l , 
2001, Loukola et al., 2001). In contrast to the increase in expression level seen here,
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immunohistochemical staining of hMSH2 in MSI-H colorectal carcinomas have 
shown a lack of expression of this MMR gene (Stone et al., 2001). hMSH2 is 
frequently inactivated through hypermethylation in the majority of sporadic cases 
(Jass, 2000; Herman et a l, 1998; Cunningham eta l., 1998).
The tumour suppressor p53 is one of the later genes to become inactivated in the 
pathway of carcinogenesis outlined by Fearon and Vogelstein (1990). This gene 
showed no alteration in expression in the polyp tissue compared to normal mucosa in 
any of the patients and was only found to have significantly altered expression at a 
later stage in carcinogenesis in patient 5. p53 is a growth regulator of fundamental 
importance in many cell types and is the gene most often found altered in a wide 
variety of human cancers. Wild type p53 suppresses cell growth whereas mutants 
increase cell proliferation. One role of p53 is to mediate G1 arrest in cells following 
DNA damage with the aim to allow cellular repair to occur before synthesis resumes. 
Another key role for p53 is the activation of apoptosis inducing genes which can 
ensure a cell with a large genetic mutation load to undergo apoptosis so that these 
mutations are not passed on to potential daughter cells. p53 is mutated in 70-80% of 
sporadic colorectal carcinomas; the mutations are thought to be selected for as they 
confer resistance to apoptosis rather than due to an increase in mutation rate. This 
allows tumour cells to survive with an increase in genetic burden as the p53 mutation 
is relatively late in the adenoma-carcinoma sequence. The presence of mutated p53 in 
a tumour predicts a reduction in overall survival of that patient (Inieta et al, 1998).
The adenomatous polyposis coli (APC) gene was down-regulated in this patient from 
the polyp sample to the adenoma. APC regulates the processes involved in colonic 
epithelial cell homeostasis such as cell cycle progression, migration, differentiation 
and apoptosis. It has been shown to be mutated in approximately 80% of FAP kindred 
and in sporadic colorectal carcinomas with over 98% of these mutations resulting in 
the synthesis of a truncated protein (Fearnhead et al, 2001). APC mutations or loss 
are much less frequent or absent in MSI-H colorectal carcinomas (Iacopetta et al., 
1998; Konishi et al., 1996). The APC gene is recognised as one of the first genes 
disrupted in the adenoma-carcinoma pathway in colorectal cancer and has a major 
role in preventing uncontrolled proliferation of the epithelium. APC expression 
increases as the cells progress up the colonic crypt, a pattern which is disrupted by
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APC gene mutation (Smith et al, 1993). As this current study analysed the overall 
gene expression in homogenised tissues rather than examining the localised 
expression of this gene, the scale of alteration of gene expression in this, and the other 
patients, may be masked. Also this technique cannot detect gene mutations which are 
the principle way in which this gene is inactivated, rather than through regulation of 
gene expression.
VHL was decreased in expression by -15.75 fold (6.96 SD) in this patient from polyp 
to rectosigmoidal carcinoma. Von Hippel-Lindau syndrome is caused by loss or 
inactivation of the VHL gene which gives the patient a predisposition to retinal 
angiomas, blastomas of the central nervous system (CNS) and renal cell carcinomas 
(Latif et al., 1993). VHL acts as a tumour suppressor by down regulation of 
transcription by binding to transcriptional elongation complexes and as a result 
suppresses elongation of mRNA and so reduces the transcription of target genes 
(Duan et al., 1995). Although there are currently no reported gene expression studies 
of VHL in colorectal carcinomas, decreases in VHL expression has been detected in 
renal cell carcinoma cell lines using cDNA array analysis (Zatyka et al, 2002). The 
large significant decrease in expression for VHL in colorectal carcinomas seen in 
patient 5 suggests that the role of this gene may be broader than originally thought 
with involvement in cell growth regulation other than CNS and neuronal development 
and renal carcinogenesis. Despite VHL only registering a significant change in 
expression for this patient, the gene expression level was altered in several of the 
patients but due to low expression levels of VHL in all sample types the result was not 
reproducible leading to large standard deviations. Again, as with other such genes it 
would be interesting to study the expression of this gene using RT-PCR.
In addition to these genes, p57 (-6.00, 2.09 SD), PTEN (-3.74, 1.48 SD), TGF-13RI (- 
9.49, 1.10 SD) and TGF-13RII (-2.96, 0.70 SD) were all significantly decreased in 
expression levels from the normal mucosa sample to the rectosigmoidal carcinoma 
sample.
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5.4.8 Gene expression changes detected across all the patients
Table 5.10 lists the gene expression fold changes for all of the genes on the array used 
for all five patients with minus figures representing a decrease in expression and 
positive numbers representing gene expression increases. Figure 5.8 is a graphical 
representation of this data which show the genes which had average expression level 
changes of +2 fold or greater. Figure 5.9 shows the number of patients in which the 
gene expression was altered from normal mucosa to polyp and from polyp to tumour.
A trend seen across all of the patients was a decrease in expression of the majority of 
genes on the array from normal colorectal mucosa to polyp tissue followed by a 
general increase in gene expression from polyp to carcinoma sample. This pattern also 
meant that if just the gene expression changes from normal mucosa to colorectal 
carcinoma were analysed this gene expression decrease followed by an increase 
would be masked and there would appear to be very little alteration in gene 
expression within the process of carcinogenesis.
APC is a tumour suppressor gene which is mutated in patients with FAP and also is 
one of the earliest genes to be altered in the majority of sporadic colorectal cancer. 
There was no significant alteration in gene expression of this gene between the polyp 
and normal mucosa tissues and only a relatively small change (2.90 fold, 0.20 SD) 
was detected between polyp and carcinoma of patient 5. It is not possible from this 
study to know whether the APC protein was functional however it stands to reason 
from the wealth of research of APC mutation in colorectal cancer that it is from this 
mechanism rather than expression levels that the APC gene is involved in initiating 
tumour growth in colorectal cancer.
From Figure 5.9 it can be seen that both TGF-PRII and TGF-pRI were down- 
regulated at the polyp stage in 3/5 (60%) and 2/5 (40%) patients respectively. Both of 
these receptor genes have been reported to be inactivated early on in colorectal 
carcinogenesis and this array study is in agreement with these previous findings. 
TGF-pRII and TGF-PRI have been linked to an improved and reduced prognosis 
respectively (Duval et al., 2001; Teicher, 2001) yet in this study they were both found
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with decreased expression levels in 2/5 (40%) of the patients analysed. It would be 
very interesting to be able to follow this study up over several years in order to assess 
the survival and treatment responses of the patients studied in this chapter.
PTEN was also down-regulated in the polyp sample of 3/5 (60%) of the patients. 
There is currently a lack of expression studies in colorectal cancer for this tumour 
suppressor despite expression loss being detected in both breast and prostate cancers 
(Perren et a l , 1999; McMenamin et al., 1999). These array results show this gene has 
a widespread down regulation in this small group of patients and therefore a wider 
study of this gene would be of interest.
The only gene which was significantly altered in gene expression across all patients 
was the cyclin dependent kinase inhibitor p21. This gene was found to have a 
decrease in expression level from normal mucosa to polyp in all patients regardless of 
polyp location within the colorectum. p21 was the only gene on this array to be 
consistently down-regulated at this early stage in carcinogenesis.
5.4.9 The role of p21 in colorectal cancer
p21 was the only gene on the array to be significantly down-regulated at the polyp 
stage in all 5 patients analysed in this study and therefore has the potential for being a 
biomarker for colorectal cancer. The array findings of p21 down regulation for the 
patients studied in this chapter are in line with earlier studies of non-mucinous non- 
hereditary colorectal cancers where p21 was found to be down-regulated to around a 
third of that of normal tissue (Matsushita et al, 1996).
Progression through the cell cycle is regulated by cyclins and cyclin-dependent 
kinases (CDKs). High intracellular levels of cyclin kinase inhibitor p21 can induce G1 
and G2 arrest and block entry into S phase and M phase respectively by inactivating 
CDKs or by inhibiting activity of proliferating cell nuclear antigen (PCNA) (Bunz et 
al, 1998). p21, located on chromosome 6p21, can be transcriptionally induced by the 
p53 protein and is responsible for the p53-mediated G1 arrest following DNA damage 
(Waldman et al, 1995). When p21 is disrupted in colorectal cell lines the p53- 
determined fate of the cell, as a response to DNA damage, favours apoptosis over cell
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cycle arrest (Polyak et al, 1996). Monitoring levels of p21 gene expression in patients 
may provide a predictor for how a patient may respond to chemotherapeutic agents 
such as 5-fluorouracil which is affected by p53 expression (Violette et al, 2002).
A previous study which found a 6-fold higher level in p21 reported that cell growth 
was not affected by this increase in expression, possibly due to the overexpressed p21 
protein not being functional (Backert et al, 1999). As mutations of p21 are extremely 
rare (Shiohara et a l, 1994), the growth inhibitory effect of p21 may have been 
prevented by a downstream lesion (Backert et a l, 1999). High expression of p21 has 
also been found to be unable to prevent cell proliferation in human brain tumours 
(Jung et a l, 1995).
To understand whether chromosome number was related to the down regulation of 
p21 gene expression in colorectal tissue samples from normal mucosa and polyp 
through to carcinoma samples, FISH was undertaken to assess chromosome number. 
This is described in chapter 6.
5.4.10 Importance of examining each stage
The design of these experiments allowed comparisons of gene expression to be made 
not only from normal mucosa to carcinoma but also from normal mucosa to polyp 
sample and from polyp to carcinoma. This was particularly important as just studying 
the normal mucosa and the carcinoma can hide gene expression changes which occur 
at various stages. For example in patient 1, DPC4 showed a decrease in expression 
level from normal rectal mucosa to rectal polyp however, from polyp to rectal 
carcinoma this gene was up regulated, giving no overall change in gene expression of 
DPC4 from normal mucosa to carcinoma. Being able to detect the changes present at 
each stage may help to explain why some polyps become carcinomas.
5.4.11 Application of this technique for screening purposes
This technique could be used to screen colorectal biopsy tissue samples for alterations 
in gene expression compared to histologically normal colorectal mucosa from the 
same patient. This would provide information about the pathways of carcinogenesis
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through which the patient’s tumour had arisen. This information may be key in 
allowing the treatment of the cancer to be tailored to the individual patient with the 
hope of increasing the effectiveness of the chemotherapy provided. This technique 
may also be useful in determining which polyps will go on to form carcinomas. p21 
was down-regulated in all of the polyps tested in this study of colorectal cancer 
patients. Therefore this gene may be a crucial gene to distinguish between polyps that 
remain benign and though which become cancerous.
The negative aspects of this technique for use as a screening tool are the expense and 
time consuming nature of the experiments. If this was taken up as a screening tool 
then the mass produced nature of the reagents required may well reduce the cost. 
Several modifications to the protocol or automation of the stages would be needed to 
reduce the time required for these tests. Also, this technique can only be carried out 
using tissue samples obtained from a biopsy, which is an invasive procedure. 
Therefore, whilst important information can be gleaned from such a screen the uptake 
would be likely to remain relatively low.
5.4.12 Limitations of this study
An observation I have made using these cDNA arrays is that, whilst they provide a 
rapid and cost effective scan across many genes using minimal RNA quantities, the 
technique is not as accurate for genes expressed only at low levels as for genes 
expressed at higher levels. Genes which had very low expression levels gave 
inconsistent results with large standard deviations between repeat experiments. A 
technique other than cDNA array analysis would be more appropriate for these genes. 
RT-PCR would be an excellent method to measure gene expression changes in these 
low expression level genes, to confirm other results and provide more accurate figures 
for expression changes. Due to financial and time constraints it was not possible to 
carry out a follow up study involving RT-PCR analysis however this would be an 
interesting area of further research. cDNA arrays have been proved to be a valuable 
scanning tool for the design of further experiments relating to gene expression.
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5.4.13 Discussion Summary
cDNA arrays have been shown here to be a useful technique for the rapid screening 
across many genes for the detection of gene expression changes between various 
stages within carcinogenesis. The technique was more reliable for the genes expressed 
at higher levels than those genes with lower levels of expression for which the 
reproducibility of the experiments was limited. cDNA arrays are best used in 
conjunction with RT-PCR, this would be an ideal follow up study to the findings in 
this chapter.
Despite this, the cDNA arrays detected a significant decrease in expression of the 
cyclin-dependant kinase inhibitor p21 at the polyp stage of tumour development in all 
5 patients studied regardless of tumour location, patient sex or age. This gene may 
therefore be critical in determining progression of a polyp into a carcinoma. p21 
expression levels may also indicate which tumours may respond better to certain 
chemotherapeutic agents and also be an indicator of prognosis in colorectal cancer 
patients. To try to understand more about the mechanism behind this gene expression 
decrease of p21, FISH was undertaken of chromosome 6 where the gene is located 
and these experiments are described in Chapter 6.
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Chapter 6
The detection of chromosome 6 and p21 region copy number 
alterations using fluorescent in situ hybridisation
6.1 Introduction
In Chapter 5 I showed that gene expression array analysis detected that p21 
expression was down-regulated in polyps from the early stages of colorectal 
carcinogenesis. The polyps analysed all showed a significant decrease in expression in 
all 5 of the patients analysed. The purpose of this chapter is to analyse the copy 
number of this gene and the chromosome on which it is situated in an attempt to 
establish whether the decrease in p21 expression is an effect of gene dosage due to 
loss of copy number.
6.1.1 Chromosome instability
Two of the most frequently occurring genetic pathways for colorectal cancer are the 
pathologically distinct microsatellite instability (MSI) pathway (as discussed in 
Chapter 4) and the chromosome instability (CIN) pathway which will be discussed 
here. The CIN pathway is thought to be responsible for around 85% of colorectal 
cancers (Chung, 2000) and is the pathway which Fearon and Vogelstein (1990) 
originally described as being the pathway of colorectal carcinogenesis. Since this 
initial description many more genes have been found to be involved in this pathway 
and so their model of colorectal carcinogenesis has been considerably elaborated. A 
diagram of the currently identified genetic changes which occur during the 
development of cancer through the CIN pathway can be seen in Figure 6.1. CIN 
increases the rate at which gross chromosomal changes occur during cell division 
such as chromosome breaks, duplication, rearrangements and deletions (Narayan and 
Roy, 2003).
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Figure 6.1
Diagram o f the chromosome instable (CIN) pathway o f colorectal carcinogenesis 
based on Vogelstein’s model. The red arrows indicate the key changes required for 
cancer progression. Adapted from Narayan and Roy, 2003.
Aneuploidy, which is the loss or gain o f one or more chromosomes, can arise from 
nondisjunction or anaphase lag. Nondisjunction is the failure o f paired chromosomes 
or sister chromatids to disjoin at meiosis I, meiosis II or mitosis. This results in 
conjoined chromosomes or chromatids migrating to one pole, these will be included 
in one daughter cell and the other daughter cell will have a loss o f genetic material. 
Chromosomes can also be lost and gained as a result o f anaphase lag which is the 
delayed movement o f the chromosome during anaphase (Wolman, 1983). As the 
process o f cell division is extremely complex with a great number o f genes playing 
vital roles at each stage, the mutation, change in expression level or the precise timing 
o f this expression o f any one o f these genes can result in aneuploidy. One o f the key 
genes involved in this process is the adenomatous polyposis coli (APC) gene which is 
discussed in Section 6.1.3.
Not all chromosomal abnormalities involve the loss or gain o f complete 
chromosomes. Chromosome breakages can result in the inversion, deletion and 
translocation o f  fragments o f the arms o f chromosomes. Some deletions result in an 
unstable chromosome; if the deletions remove the telomeres the remaining 
chromosome is likely to be degraded or if the centromere is deleted the chromosome 
is likely to be lost at cell division. Deleted regions o f chromosomes can go on to form 
ring chromosomes, if these contain a centromere these may pass through cell division
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but acentric ring chromosomes will be lost. Both inversions and translocations can 
result in the loss of control of the genes in the fragment involved as well as the 
disruption of genes at the point of insertion. The double strand breaks required for 
these chromosome abnormalities to occur are often a consequence of oxidative 
damage or exposure to environmental agents (Gajeka et a l , 1999). Double strand 
breaks are repaired during cell cycle arrest at G2 prior to mitosis but deficiencies in 
the cells ability to either arrest at this stage or repair the damage can lead to 
misegregation of the affected chromosome and leads to chromosomal aberrations 
(Lodish etal., 1995).
6.1.2 Familial adenomatous polyposis (FAP)
Familial adenomatous polyposis (FAP) is an autosomal dominant disease which arises 
as a result of the germline mutation of the tumour suppressor gene adenomatous 
polyposis coli (APC) located on chromosome 5p21 (Bodmer et a l, 1987; Groden et 
a l, 1991). As can be seen in Figure 6.1, APC is one of the earliest recorded changes 
in the CIN pathway, the mutation of which causes normal epithelial tissue to form 
early colorectal adenomas. In FAP patients hundreds to thousands of these adenomas 
develop during adolescence or early adulthood which, if left untreated leads to 
colorectal cancer in patients betweens the ages of 30 - 40 (Bodmer, 1996). This 
disease is further discussed in Chapter 1, Section 1.3.2.
6.1.3 Adenomatous polyposis coli (APC)
APC regulates the processes involved in colonic epithelial cell homeostasis such as 
cell cycle progression, migration, differentiation and apoptosis and is found to be 
mutated in around 75% of sporadic colorectal cancers (Leslie et a l, 2002; Miyaki et 
al., 1994). The APC gene product is a large multifunctional protein which interacts 
with several proteins including p-catenin, end binding protein 1 (EB-1), glycogen 
synthase kinase (GSK), human homologue of the Drosophila discs large tumour 
suppressor protein (hDLG) and the mitotic checkpoint kinases Bub-1 and Bub-3 
(Leslie et al, 2002; Kaplan et al, 2001). Over 98% of mutations of the gene result in 
the synthesis of a truncated protein which lacks the ability to degrade P-catenin which 
then results in increased transcription of many genes including the oncogene c-myc
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(He et al., 1998). Wild type APC also binds to and promotes the assembly of 
microtubules and is involved in chromosome segregation (Smith et al, 1994; Kaplan 
et al., 2001). APC accumulates at the ends of microtubules embedded in kinetochores 
and plays a role in stabilising the ends of kinetochore microtubules and assists in their 
attachment to chromosomes (Kaplan et al., 2001). EB-1 is thought to be involved in 
connecting APC to microtubules and it has been shown that cells with APC protein 
lacking this domain display chromosome instability and defective chromosome 
segregation (Berrueta et al, 1998).
6.1.4 Fluorescent in situ hybridisation (FISH)
The development of fluorescent in situ hybridisation (FISH) in the mid 1980s was an 
important technical advancement which enabled the detailed analysis of chromosomal 
aberrations. Prior to this, histochemical staining methods were used to detect 
chromosomal aberrations, this technique allowed for the recognition of chromosomal 
banding patterns making chromosomal losses, gains and structural changes in tumours 
detectable. A disadvantage of this method was that it required highly skilled 
researchers and the detection of specific changes was extremely time consuming 
(Boland et al., 1998).
FISH is a type of chromosome in situ hybridisation in which the nucleic acid probe is 
labelled by incorporation of a fluorophore which fluoresces when exposed to UV 
irradiation. In situ hybridisation was first developed in the 1960s when probes were 
labelled with radioisotopes, however, to prevent scattering of the signal the isotope 
needed to be very low energy and so required long developing times of several weeks, 
which created high levels of background signal (Jin and Lloyd, 1997). These 
problems were eliminated with the advent of fluorophores which are chemical groups 
which fluoresce by emitting light of a longer wavelength after being excited with a 
shorter wavelength. Fluorophores allow a greater resolution than isotopes and are also 
safer to work with. FISH became an established technique in the early 1990s and 
various probes have now been developed and are commercially available including 
centromeric probes, whole chromosome paints and probes for specific loci.
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6.1.5 Colorectal cancer analysed by FISH
Since the development of FISH there have been many studies using this technique to 
analyse chromosome aberrations in colorectal cancer samples from tissue and cell 
lines. Using cell lines has the advantage of being able to carry out metaphase FISH 
which provides clearer images and allows the detection of translocations. There is 
though always the possibility that alterations seen are an artefact of the 
immortalisation of the cell line as opposed to genetic changes seen in the colorectal 
tumour from which the cell line is derived. FISH using tissue samples eliminates this 
problem but it is only possible to carry out interphase FISH which generally only 
allows the detection of numerical changes of chromosomes and regions. Structural 
rearrangements such as inversions can be detected by using combinations of probes 
for different regions but this requires a detailed knowledge of the affected 
chromosomes and the locations that such rearrangements may occur as well as a 
series of probes for the region being analysed.
Over 90% of all colorectal cancers show chromosomal aberrations (Muleris et al., 
1990). Previous karyotyping and FISH studies of colorectal cancer have detected 
gains of chromosomes 7, 13 and 20 and loss of chromosome 18 in adenomas and 
carcinomas and the losses of chromosomes 17 and Y in colorectal carcinomas 
(Bomme et al., 2001; Herbergs et al., 1996). The most common of these are the loss 
of chromosome 18 and the gain of chromosome 7, with each aberration occurring in 
around a quarter of colorectal tumours (Leslie et al., 2002). As well as these 
alterations in chromosome number, structural rearrangements have also been detected 
such as del(lp), del(8p), i(13q) and del(17p) in adenomas and in chromosomes 1, 8, 
13 and 17 in colorectal carcinomas (Bomme et al., 2001; Di Vinci etal., 1998). Other 
changes have been reported as being specific to types of colorectal cancer such as 
chromosome 8p which is commonly lost in CIN+ cell lines and tumours but is gained 
in MSI+ cancers (Douglas et al., 2004).
6.1.5.1 Chromosome 6 copy number in colorectal cancers
Comparative genomic hybridisation (CGH) is a technique which can be used to 
compare normal cells against cancer cells to investigate copy number changes across
173
the whole nuclear genome. CGH has been used to detect the loss of chromosome 6 in 
colorectal cancer cell lines but this has not been found in primary colorectal 
carcinomas (Douglas et al, 2004). This suggests that this alteration may be a result of 
the immortalisation of the colorectal cell lines rather than a chromosome aberration 
present in colorectal tumours. Other cytogenetic studies of chromosome 6 in 
colorectal adenomas have reported both the loss and gain of this chromosome with 
slightly more reported incidences of gains rather than losses currently in the literature 
(Bardi et a l, 1997; Bomme et a l, 1996; Bomme et a l, 1998). There are also several 
studies karyotyping colorectal adenocarcinomas where both the gains and losses of 
chromosome 6 have again been reported, but unlike with the adenomas, there are 
more reports of losses rather than gains (Reichmann et a l, 1981; Bardi et a l, 1993; 
Bardi et a l, 1995; Bardi et a l, 1997; Parada et al., 1999). These reports are though 
generally case studies analysing the entire karyotype of only a few patients and so it is 
difficult to establish any patterns of chromosome 6 losses or gains in colorectal 
adenoma and adenocarcinoma tissue from these experiments. It is important to realise 
the limitations of the ability of CGH to detect such changes as >50% of the cells must 
show the alterations in order to be recognised by this technique (Manoir et al, 1995). 
Also, the spatial resolution may not be sharp enough to detect some of the smaller 
chromosomal aberrations. Because of these factors, FISH is recommended as a 
superior technique to CGH in the determination of chromosomal abnormalities in 
clinical cancer diagnostics (Liebisch etal., 2003).
6.1.6 p21
In the experiments described in Chapter 5, p21 expression was found to be reduced in 
the histologically abnormal tissues compared to the levels found in the normal 
colorectal mucosa of all five patients analysed. Importantly, p21 expression was 
reduced in polyps, the earliest stage of carcinogenesis studied in these experiments.
6.1.6.1 The role of p21 in colorectal cells
6.1.6.1.1 Cyclin-dependant kinases (CDKs) and CDK inhibitors
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Cyclin-dependant kinases (CDKs) regulate the cell cycle by phosphorylation o f  target 
substrates involved in DNA replication and mitosis. The G l-S  transition o f  the cell 
cycle is regulated by the interactions between CDKs, cyclins and CDK inhibitors. 
CDKs are activated by cyclins, which act as positive regulators and are inhibited by 
CDK inhibitor proteins such as p i 5, p i6, p21 and p27 (Grana and Reddy, 1995), see 
Figure 6.2. CDKs activity is also regulated by kinases and phosphatases (Navaratnam 
et al, 1999; Kamb, 1995).
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This diagram o f the cell cycle shows the positive and negative regulators o f cell cycle. 
Proteins bordered in grey have been found to be defective in some cancer cells. From 
Fred Hutchinson Cancer Research Center www.fhcrc.org
6.1.6.1.2 The Cyclin-dependent kinases inhibitor p21
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Cyclin kinase inhibitor p21 transcription is controlled by p53 and can induce G1 
arrest and block entry into S phase of the cell cycle by inactivating CDKs or by 
inhibiting activity of proliferating cell nuclear antigen (PCNA). In normal cells, p21 
exists in quaternary complexes with cyclin, CDK, and PCNA (Wang et al., 1994). 
Transcription of the p21 gene is activated by both p53-dependent and -independent 
mechanisms. A consequence of a mutation of p53 can be a decreased level of p21 
transcription; this in turn leads to CDKs remaining active which results in cumulative 
DNA damage and premature replication of unchecked DNA (Navaratnam et al, 1999; 
Kamb, 1995). p21 is expressed in terminally differentiating cells of a variety of 
tissues in a p53-independent manner. Over expression of p21 results in G1 arrest and 
has been shown to suppress effectively tumour growth in vitro and in vivo (Gartel and 
Tyner, 2002). Activated APC gene initiated tumour formation is normally suppressed 
by p21 (Yang et al., 2001(a)). In the colon p21 is expressed as cells exit the 
proliferative section of the colonic crypt. Loss of expression of p21 and topographical 
regulation is detected early in colon tumour formation (El-Deiry et al, 1995, Polyak 
et a l, 1996). Decreased p21 expression in colorectal tumours has been reported to be 
a marker of poor prognosis in patients (Zirbes et al., 2000).
Despite the obvious importance of p21 in regulating colon cell maturation, mice 
deficient in p21 exhibit no apparent phenotype and develop normally. From this 
research it appears that the function of p21 under normal circumstances appears to be 
redundant. However embryonic fibroblasts obtained from these mice are defective in 
Gi checkpoint control and the function of p21 has been demonstrated to be necessary 
for p53-mediated Gi arrest following irradiation (Deng et al., 1995). Radiation, the 
short-chain fatty acid butyrate and the nonsteroidal anti-inflammatory drug (NSAID) 
sulindac all stimulate the cell cycle arrest and apoptosis of colon cancer cells and are 
all linked to the induction of p21 (Goldberg et al., 1996; Archer et a l, 1998; 
Waldman et al., 1997; Yang et al, 2001(b); Siavoshian et a l, 2000).
It is thought that although defective p21 is not itself a cause of tumour formation it 
has a significant role in the progression of carcinogenesis of colorectal tumours that 
are initiated by other genetic events, such as mutation of the APC gene (Kinzler and 
Vogelstein, 1996).
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The presence of reduced p21 gene expression levels in the early polyp stages of 
carcinogenesis, as detected in Chapter 5, indicates that p21 expression levels may be 
critical in the development of colorectal tumours. The mechanisms underlying this 
change are not as yet fully understood.
6.1.7 Rationale of the study
Results from Chapter 5 show a reduced level of gene expression of the tumour 
suppressor gene p21 in early stages of colorectal cancer development, present even in 
early polyp stages. To follow up these results and to obtain a clearer insight into the 
mechanisms occurring, FISH was carried out to discover if these findings were a 
result of variation in copy number of chromosome 6 or of a deletion in the region of 
the chromosome coding for p21.
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6.2 Materials and Methods
6.2.1 Sample collection
Ethical approval was granted for the collection of 63 surgical samples from 13 
patients from operations carried out by Mr. Beynon at Singleton Hospital, Swansea as 
described in section 2.2. Samples were taken of normal mucosa from sites close and 
distant from the colorectal tumour, the tumour itself where possible from the centre of 
the tumour as well as the peripheral regions to detect any clonal variation from the 
tumour. Where this was not possible a single sample was taken from the centre of the 
tumour. Also, samples were taken from metastatic lymph nodes and polyps where 
these had developed. Tissues from these sites were also histologically examined by 
the pathology department at Singleton Hospital, Swansea. These include the same 
samples as those used in Chapter 5.
6.2.2 Slide preparation
Cytology brushing samples were spun onto slides to give a single layer of cells as 
described in section 2.2.1 and treated with pepsin to digest cellular proteins as 
described in section 2.14.1. The slides were also coded at this stage to ensure an 
unbiased treatment and count of the sample.
6.2.3 FISH with commercially available probe
The commercially available green centromeric probe for chromosome 6 (Abbott) was 
hybridised to the treated slides; the excess probe was then removed by washing stages 
as in the protocol described in section 2.14.2. The nuclei were then counterstained 
using DAPI as described in section 2.14.2.
6.2.4 FISH with probes made from clones
The general procedure for developing the p21 probe using clones is schematically 
represented in Figure 6.3 and then further described below.
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Figure 6.3
Schematic representation o f the p21 FISH probe generation process.
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The p21 gene is covered by the clone RP3-421A14 but this alone would not give a 
bright enough signal to score so a clone located just before this and overlapping after 
the RP3-421A14 clone were also used. These were RP1-108K11 and RP11-52A1, 
further details including of the length of these clones can be seen in Table 6.1. The 
clones were purchased from Children’s Hospital Oakland Research Institute (CHORI) 
and cultures of the transformed bacteria where grown as described in section 2.14.4. 
The plasmids were extracted as described in section 2.14.5 prior to nick translation 
and purification as in section 2.14.6. The probe was then made by combining the 
purified nick translation product with human Cot-1 DNA and hybridization mix as 
described in section 2.14.7 and 2.14.8. The slides and probe were independently 
denatured and then hybridised overnight following the protocol in section 2.14.9. 
Excess probe was washed off and the nuclei were then counterstained using DAPI as 
described in section 2.14.9. A schematic representation of this protocol can be seen in 
Figure 6.3.
Gene / Clone Length(kb) Location
Type of 
vector Restriction site
p21 8.6 36754465 -  36763087 - -
RP-108K11 145.6 36553478 -  36699093 PAC BamHI
RP3-421A14 195.4 36751257-36946619 PAC BamHI
RP11-52A1 190.2 36788428 -  36978778 BAC EcoRI
Table 6.1
Table giving the details of p21 and the clones used to make the p21 FISH probe. The 
information contained in this table is acquired from www.ncbi.nih.gov/genome/guide.
6.2.5 Slide viewing and image capture
Slides were viewed using an epifluorescence microscope and images were captured 
using charge - coupled device (CCD) camera operated using Mac-Probe 4.1 (Applied 
Imaging) software as described in section 2.14.3.
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6.2.6 Scoring
Slides were scored as described in section 2.14.3 with a minimum of 800 nuclei per 
sample.
6.2.7 Statistical analysis
To be able to establish whether differences seen were statistically significant, X2 test 
was carried out on the actual count data. The resulting p value was then used to 
determine the level of significance using confidence limits o f 95% (p = <0.05), 99% 
(p= <0.01) and 99.9% (p=<0.001).
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6.3 Results
6.3.1 Sample collection
Samples were collected from surgery over a period of 11 months. All the samples 
were used in this study unless there was information relating to these which would 
warrant the exclusion from this study of sporadic colorectal case. For example, patient 
6 had undergone chemotherapy prior to surgery and so was eliminated from this 
current study. Other samples were eliminated where there was insufficient tissue to 
carry out the analysis or there were doubts as to whether the patient had hereditary 
colorectal cancer which was previously thought to be sporadic. For these reasons the 
patient numbers are not consecutive but this is not due to any selection process other 
than that described above.
6.3.2 Chromosome 6 FISH results
A minimum of 800 nuclei were scored from a minimum of 2 slides for each tissue 
from each patient. Where possible 400 nuclei were scored for each slide but this was 
not always possible due to overlapping nuclei, very few cells on the slide or bacterial 
contamination from the colorectal sample. In these cases further slides were scored to 
give a total nuclei count of 800 for each tissue sample. The full details of these counts 
are listed in Appendix II. A summary of the average values for these counts for each 
patient is listed in Table 6.2 below and the overall average data for each tissue type is 
listed in Table 6.3. Figures 6.4 and 6.5 are photographs of various nuclei observed in 
this study and are typical of those scored in this experiment.
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Figure 6.4
Image o f several nuclei from the normal adjacent mucosa o f patient 1. The nuclei are 
counterstained blue with DAPI and the centromere o f both copies o f chromosome 6 in 
each nucleus are hybridised with the green probe.
Figure 6.5
This image shows 2 nuclei, counterstained blue with DAPI, from the polyp tissue o f 
patient 4. The green probe has only bound in one location within each nucleus 
indicating the loss o f one copy o f chromosome 6 in each.
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These are images o f nuclei from the central tumour tissue o f patient 11. Again in each 
picture the nucleus is stained blue with DAPI and the centromeric region o f 
chromosome 6 has hybridised to the green labelled probe. In image A the nucleus has 
an extra copy o f chromosome 6 and in image B the nucleus has 5 copies o f 
chromosome 6.
Patient
No.
Patient
age
Patient
sex
Sample
No. Sample type
Percent o f cells
2
copies
1
copy
3
copies
4+
copies
1 36 F 1 Central tumour 61.9 7.1 30.4 0.6
2 Peripheral tumour 51.2 5.6 39.5 3.6
3 Normal adjacent 78.5 17.2 4.0 0.3
4 Normal distant 53.1 7.0 39.0 1.0
5 Lymph node 63.7 5.1 30.2 1.0
2 80 M 6 Tumour 81.5 15.6 2.6 0.4
7 Normal adjacent 86.9 9.8 3.1 0.1
8 Normal distant 87.7 9.0 3.3 0.0
4 67 M 12 Tumour 73.3 8.5 17.6 0.7
13 Normal adjacent 92.1 5.2 2.6 0.1
14 Normal distant 93.6 4.0 2.5 0.0
15 Polyp 68.4 20.6 10.8 0.2
5 57 F 16 Tumour 66.2 10.0 21.1 2.7
17 Normal adjacent 89.6 6.9 3.4 0.1
18 Normal distant 89.0 7.6 3.1 0.2
19 Polyp 72.9 24.1 2.9 0.1
7 69 F 23 Central tumour 34.6 9.7 40.5 15.2
24 Peripheral tumour 52.7 6.9 21.9 18.5
25 Lymph node 74.2 21.9 3.6 0.4
26 Normal distant 91.2 5.2 3.3 0.2
27 Normal adjacent 89.4 7.5 3.0 0.1
8 61 M 28 Central tumour 85.2 14.3 0.4 0.1
29 Peripheral tumour 44.0 6.2 48.1 1.7
30 Small polyp 80.7 13.9 5.1 0.4
31 Large polyp 83.8 13.9 2.3 0.0
32 Normal distant 92.0 5.3 2.5 0.2
33 Normal adjacent 90.7 6.3 2.7 0.3
10 63 M 38 Peripheral tumour 73.2 11.5 12.4 2.9
39 Central tumour 75.7 12.6 7.2 4.5
40 Normal adjacent 95.1 3.3 1.6 0.0
41 Normal distant 93.8 3.8 2.3 0.0
42 Polyp 59.3 16.4 18.8 5.5
11 64 F 43 Normal distant 93.3 6.0 0.7 0.0
44 Normal adjacent 84.2 6.9 8.2 0.8
45 Peripheral tumour 79.1 13.1 6.3 1.5
46 Central tumour 48.2 16.9 22.0 12.9
47 Lymph node 78.1 19.6 2.2 0.1
13 64 M 52 Central tumour 88.0 10.0 1.6 0.4
53 Peripheral tumour 90.1 8.9 0.9 0.1
54 Normal adjacent 96.2 2.5 1.4 0.0
55 Normal distant 96.8 1.8 1.4 0.0
56 Polyp 89.9 6.4 3.7 0.0
Table 6.2 continued overleaf
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Patient
No.
Patient
age
Patient
sex
Sample
No. Sample type
Percent o f cells
2
copies
1
copy
3
copies
4+
copies
15 85 F 61 Peripheral tumour 82.8 13.8 3.4 0.0
62 Central tumour 84.5 14.5 0.9 0.1
63 Normal adjacent 89.4 6.5 3.9 0.1
64 Polyp 79.5 11.4 7.8 1.3
65 Large polyp 80.2 11.1 7.8 1.0
66 Normal distant 93.6 4.9 1.5 0.0
16 73 F 67 Peripheral tumour 75.1 19.6 4.5 0.7
68 Normal adjacent 92.1 6.2 1.7 0.0
69 Normal distant 96.6 2.6 0.9 0.0
70 Central tumour 75.2 19.3 4.5 0.9
17 58 M 71 Normal distant 95.2 4.0 0.7 0.1
72 Polyp 78.9 20.2 0.8 0.1
73 Normal adjacent 91.6 7.3 1.1 0.0
74 Peripheral tumour 82.2 13.8 3.6 0.4
75 Central tumour 79.5 7.9 10.2 2.4
76 Lymph node 26.5 11.6 22.6 39.3
20 74 F 85 Normal distant 90.5 7.0 2.2 0.2
86 Normal adjacent 90.5 4.4 4.6 0.5
87 Peripheral tumour 83.2 8.7 7.8 0.2
88 Central tumour 74.4 24.1 1.3 0.3
89 Far polyp 84.3 13.5 2.2 0.0
Table 6.2
Table showing the average percent o f cells with the normal number o f chromosome 6, 
only 1 copy, 3 copies and 4 and more copies for each tissue sample from each patient.
Sample type
Number o f 
samples 2 copies 1 copy 3 copies 4+ copies
Normal distant 13 89.7 ± 11.3 5 .2 1 2 .1 4 .9 1  10.3 0.1 1 0 .3
Normal adjacent 13 8 9 .7 1 4 .6 6 .9 1 3 .6 3 .2 1  1.9 0 .2 1 0 .2
Polyp 10 8 1 .2 1 2 .3 14 .013 .3 4.3 1 3 .0 0.5 1 0 .6
Peripheral tumour 10 75.5 1 12.3 1 1 .8 1 3 .9 11 .71  13.7 1 .0 1  1.0
Central tumour 13 7 0 .7 1  17.4 1 3 .6 1 5 .4 11.91 14.2 3 .7 1 5 .6
Lymph node 4 6 0 .6 1 2 3 .5 1 4 .6 1 7 .7 14 .71  13.9 10 .21  19.4
Table 6.3
Table showing the mean percent o f cells with the normal number o f chromosome 6, 
only 1 copy, 3 copies and 4 and more copies for each tissue type. Figures following 
the mean values are ± standard deviation found between the patients for each tissue 
type.
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Sample type
Normal
distant
Normal
adjacent Polyp
Peripheral
tumour
Central
tumour
Lymph
node
Normal distant - N.S.D * * * *** *** ***
Normal adjacent N.S.D - * * * *** *** ***
Polyp * * * *** - ** ** ***
Peripheral tumour * * * ** - N.S.D *
Central tumour *** * * * ** N.S.D - *
Lymph node *** * * * *** * * -
Table 6.4
Table showing the statistical significance o f the levels o f aneuploidy found in the 
sample types using the chi-squared test. N.S.D. represents no significant difference, * 
, ** and *** indicates a significant difference at confidence limits o f 95%, 99% and 
99.9% respectively.
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Figure 6.7
This is a graphical representation of the data in Table 6.3. The error bars show +/- 1 
standard deviation.
Chromosome 6 copy number in each tissue type
□ Normal distant 
d Polyp
■ Central tumour
□ Normal adjacent
□ Peripheral tumour
□ Lymph node
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6.3.3 p21 probe results
6.3.3.1 p21 probe optimisation
Optimisation of the protocol developed by Doak (2004) was needed in order to create 
a probe which bound only in the appropriate region with a strong signal and with 
minimal background noise. A sufficiently large region of the chromosome had to be 
covered by the probe so that there was a strong enough signal to be scored on 
interphase FISH slides where the chromosomes are not condensed as they are at 
metaphase. This was achieved by using a combination of 3 clones obtained from 
Children’s Hospital Oakland Research Institute (CHORI). During the nick translation 
process an incubation of 2 hours was found to sufficiently incorporate the labelled 
bases and also give fragments size of between 200-800bp which has been found to be 
the optimal size for hybridisation. Sufficient human Cot-1 DNA which is enriched 
with repetitive DNA sequences was needed to eliminate background noise and the 
quantity needed for this again required optimisation, adding 15 pi to 600ng of labelled 
probe gave the clearest results. 5 pi of the finished probe was applied per cytodot on 
each slide. The probe was successfully optimised on normal metaphase cells and a 
photograph of the optimised probe hybridised to a normal metaphase spread can be 
seen in Figure 6.8. This photograph clearly shows the probe bound to the correct 
region of both copies of chromosome 6 and, importantly, not bound to any other 
regions.
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Figure 6.8
This image shows the chromosomes from a metaphase cell stained blue with DAPI 
and red probe bound to the appropriate region o f chromosome 6 on both sister 
chromatids for both chromosome 6 copies.
Fortunately, no further optimisation was required when using the probe on interphase 
colorectal cells. Figure 6.9 shows the probe hybridised to chromosomes within the 
nuclei o f an interphase sample o f colorectal normal mucosa.
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Figure 6.9
An image o f  a nucleus from a histologically normal colorectal mucosa sample 
hybridised with the p21 probe. The nucleus is blue as a result o f  DAPI staining and 
the red probe indicates the presence o f 2 copies o f the p21 region.
6.3.3.2 p21 probe results
Due to time constraints it was unfortunately not possible to use this probe with all o f 
the samples used for the chromosome 6 FISH probe. FISH analyses o f the patient 
samples examined by array analysis in Chapter 5 were however analysed using the 
probe for the p21 region. The results for these experiments are in Table 6.5.
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Sample type
No. o f 
Samples 2 copies 1 copy 3 copies 4+ copies
Normal distant 5 90.9 + 2.9 6.3 ± 2 .0 2.5 ± 0 .9 0.3 ± 0 .3
Normal adjacent 5 90.6 + 2.9 5 .9 +  1.9 3 .2 +  1.3 0.3 ± 0 .4
Polyp 6 72 .7+ 10 .4 19.8 + 8.4 6.1 ±7 .5 1.5 + 2 .1
Peripheral tumour 3 64.5 + 22.9 9.6 ± 3 .6 24.1 ± 23.7 1 .8+  1.7
Central tumour 5 71.0+  9.8 11.7 + 3.6 15.0+11 .8 2.3 ± 1.2
Table 6.6
Table showing the mean percentage o f cells with the normal number o f copies o f  the 
p21 region, only 1 copy, 3 copies and 4 and more copies for each tissue type. Figures 
following the mean values are ± standard deviation found between the patients for 
each tissue type.
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Figure 6.10
This is a graphical representation o f the data in Table 6.7. The error bars show +/- 1 
standard deviation
p21 copy number in each tissue type
□ Distant m ucosa
□ Adjacent m ucosa
□ Polyp
□ Peripheral tumour 
■ Central tumour
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6.4 Discussion
6.4.1 Application of p21 probe
Centromeric FISH probes, as their name indicates, bind to the centromeric region of 
the chromosome and although these are useful for detecting chromosome number 
within samples, it is not possible to know whether the entire chromosome is present or 
for example, if there have been deletions from the arms of the chromosome. For this 
reason it was necessary to develop the FISH probe for the region of chromosome 6 
that the p21 gene is situated. Once optimised, the probe for p21 was straightforward to 
hybridise and clear to visualise, allowing for easy scoring. There was no statistically 
significant (using chi-squared test with 95% confidence limit) variation between 
repeat experiments for the same tissue giving indicating the experiments are highly 
reproducible. This technique can also be used to make probes for other regions of the 
genome where clones are available.
Using a combination of both the chromosome 6 centromeric and the p21 region 
probes not only provides information as to whether there is a change in chromosome 6 
number but also, if the counts for each probe are unequal, indicates either the deletion 
of at least this proportion of the chromosome 6 p arm or a translocation of this region 
onto another chromosome.
6.4.2 Levels of aneuploidy present
6.4.2.1 Chromosome 6
As the tissue samples progressed through the pathway of carcinogenesis the levels of 
aneuploidy increased in respect of chromosome 6 copy number as can be seen in 
Table 6.3 and represented in graphical form in Figure 6.7. The statistical significance 
between the proportions of cells with 2 copies of chromosome 6 for each sample type 
can be seen in Table 6.4. There was no significant difference in the number of copies 
of chromosome 6 between the histologically normal mucosa located close to and 
distant from the carcinoma with both these sample types having 2 copies of the 
chromosome in a mean of 89.7% of cells. This shows that there is no localised effect
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upon the surrounding histologically normal colorectal mucosa. This information is 
especially useful for experiments where it is not possible to collect a distal mucosal 
sample. The remaining cells with an abnormal number of chromosome 6 copies had 
an approximately even number of gains and losses.
The proportion of cells with a normal copy number of chromosome 6 was 
significantly lower in the 10 polyp samples than in the normal mucosa samples. 
Interestingly there was less variation between the polyp samples than in the normal 
mucosa samples. These results show that already at this early stage in carcinogenesis 
the cells are losing their chromosomal stability. Patients 6 and 15 both had 2 polyps 
and in both of these patients the polyps showed a high degree of similarity in terms of 
chromosome 6 aneuploidy and there was no significant difference between the paired 
polyps regardless of size. The abnormal cells found in the 10 polyp samples consist of 
a higher proportion of chromosome losses than gains with 74.5% of these abnormal 
cells exhibiting chromosome 6 monosomy. This is in contrast to the proportion of 
colorectal cancer adenoma cases reported which predominantly describe the gain of 
chromosome 6 (Bardi et al., 1997; Bardi et a l, 1993; Bomme et a l , 1998), but these 
generally have limited patient numbers and studies describing chromosome 6 losses 
have also been published (Bomme et al, 1996; Muleris et a l, 1994). Unlike most of 
these previous studies, this current experiment used FISH analysis of a large number 
of individual cells from several patients and was a focused study analysing 
chromosome 6 directly; this allowed the detection of changes which occurred in only 
a small proportion of cells.
There was a relatively large variation between the polyp and carcinoma tissue 
between the patients with both the carcinoma samples from the centre of the tumour 
and the peripheral regions having a higher level of chromosome 6 aneuploidy than the 
polyp tissue. There was no statistically significant difference overall between the 
levels of aneuploidy in the 2 different tumour samples with 70.7% of central tumour 
and 75.5% of peripheral tumour samples having a normal copy number of 
chromosome 6. Unlike the findings for the polyp samples, the aneuploid cells in the 
tumour samples showed an even number of chromosome 6 losses and gains. 
Interestingly, of the 10 patients from which both central tumour and peripheral
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tumour samples were taken, there were 5 patients (see Table 6.7) which showed 
significant differences between these regions of the same colorectal tumour.
Patient
No.
Central tumour % cells 
diploid for chromosome 6
Peripheral tumour % cells 
diploid for chromosome 6
Confidence
interval
1 61.9 51.2 99%
7 34.6 52.7 99.9%
8 85.2 44.0 99.9%
11 48.2 79.1 99.9%
20 74.4 83.2 95%
Table 6.7
Table showing the confidence intervals for the statistically significant differences 
using chi-squared test seen in chromosome 6 copy number between the central and 
peripheral regions of the same colorectal tumour.
Patient 8 had half the proportion of cells with a normal chromosome 6 copy number 
in the peripheral tumour sample than that taken from the centre of the tumour. The 
abnormal cells also showed different abnormalities with the peripheral tumour having 
48% of the cells showing chromosome 6 gains and the aneuploid cells from the centre 
of the tumour being predominantly monoploid for this chromosome. Almost the 
opposite observation was made of patient 11 with only 48% of the central tumour 
cells exhibiting the normal number of chromosome 6 compared with 79% of the 
peripheral tumour cells. This important observation shows the large scale variation 
that can be found within a single tumour and highlights the likelihood that the 
variation between studies, patients and even between tumours from the same patient 
could be simply due to the variation that exists within cells sampled from a tumour. 
The variations did not show a pattern correlating to the location from within the 
tumour from which the sample was taken. This makes it more difficult to remove this 
variation from studies even by applying strict protocols detailing the sampling site 
from each tumour. A great deal of care therefore needs to be taken when reporting 
FISH findings from solid tumours.
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The metastatic lymph nodes showed the greatest level of aneuploidy of all of the 
samples, with only 60.6% of cells having 2 copies of chromosome 6. The alterations 
in copy number not only occurred at a greater frequency than in the other tissue 
samples but also consisted predominantly of chromosome gains with 24.9% of the 
metastatic lymph node cells having gains of chromosome 6 with 10.2% having 4 or 
more copies. This indicates the level of chromosome instability in metastatic tissues 
to be greater than found in the primary carcinomas. There was also the greatest 
variation between these samples from different patients with a large standard 
deviation. It does need to be highlighted that there was only 4 metastatic lymph nodes 
analysed in this study and further samples would need to be examined before any 
sound conclusions can be drawn from this data.
6.4.2.2 Aneuploidy levels detected in the p21 region
Due to the time required for the optimisation of the probe for p21 region, it was not 
possible to apply this probe to all 63 samples from the 13 patients analysed using the 
probe for chromosome 6. The samples from the 5 patients that were analysed in 
Chapter 5 for the gene expression study were all analysed along with any additional 
tissue samples that were not analysed by the arrays. Unfortunately, this cohort of 
samples did not include any metastatic lymph node tissue. These patients are listed in 
Table 6.5 along with the FISH results for both the chromosome 6 and p21 region 
probe. Where there is a statistically significant difference between the copy numbers 
of these probes in the same tissue of each patient these are marked with a number of 
asterisks depending upon the degree of significance.
The number of cells with a normal number of copies of the p21 region decreased as 
the samples progressed through the pathway of carcinogenesis just as was observed 
for the chromosome 6 centromeric probe. For 4 of the 5 patients there was no 
significant difference between the copy numbers of the chromosome 6 centromeric 
probe and that of the p21 region probe. This suggests that, as there was no significant 
increase or decrease in p21 region copy number in comparison to chromosome 6, 
there were no significant levels of translocation or deletion of the p21 region in any of 
the samples of these patients and the changes in p21 copy number were a result of the
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loss or gain of the whole of chromosome 6. A review of DNA copy number losses in 
human neoplasms found that, although 6q losses are some of the most frequently 
reported aberrations, 6p losses are relatively rare (Knuutila et al., 1999). This is in 
agreement with the findings in this current study which found no significant decrease 
in the copy number of this 6p region in comparison to that of the number of 
chromosome 6 copies in most of the patients analysed.
Patient 5, despite showing no significant difference between the chromosome 6 and 
p21 region copy numbers in the normal mucosa samples, did show differences 
between copy numbers of each probe in the tumour and polyp samples. In both of 
these tissue samples the percent of cells with a normal complement of the p21 region 
was approximately 9% lower than seen for chromosome 6. This suggests that in 
addition to whole chromosome 6 aberrations there was also a high level of 6p 
structural alterations. The polyp sample showed an increase in p21 region losses in 
comparison to chromosome 6 copy number indicating that 6p deletions had occurred. 
The tumour sample however showed a comparative gain of this region suggesting that 
this proportion of chromosome 6 had translocated onto another chromosome. There 
are reports of chromosomal abnormalities occurring at band 6p21 in many types of 
cancer, such as renal and ovarian cancer (Argani et a l, 2001; Wake et a l, 1980) and 
these aberrations are especially common in leukemia (Stock and Dennis, 1999; La 
Starza et al., 2002). It is not possible from this study to establish onto which 
chromosome this region of chromosome 6 has translocated nor the size of the 
fragment either translocated or, in the case of the polyp, deleted. Chromosome 
painting techniques would provide some of these answers as well as giving greater 
insight into the overall levels of aneuploidy present and having the advantage of being 
able to detect balanced chromosomal abnormalities, which is not possible in this 
current study. The decrease in expression of p21 as detected in Chapter 5 was greater 
for the polyp sample than for the tumour sample and this correlation therefore may 
indicate that copy number is at least in part an explanation for this. This is further 
discussed in the final discussion in Chapter 7.
Using the type of interphase FISH applied in this study it is not possible to analyse 
very small regions of the genome. In order for the p21 FISH probe to be visible for 
scoring in interphase cells the probe needed to cover a much larger region than the
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8.6kb which make up the p21 gene. A total of 373.lkb was covered by the 3 clones 
used to create the p21 region probe. Therefore these experiments would not be able to 
detect if a small fragment of the chromosome covered by the probe was deleted. For 
example, if the 8.6kb which code for p21 were deleted there would still be a strong 
signal from the remaining probe as such a small proportion of the overall 373kb probe 
would be unlikely to affecting the binding of the remaining probe. These smaller scale 
deletions can be detected using molecular genetic techniques such as PCR and it 
would be interesting to analyse p21 at this level of detail in future studies.
6.4.3 Other genes covered by the p21 region FISH probe
As described above, the p21 region FISH probe had to cover a larger region than just 
the p21 gene itself so that it could be visualised. The clones used to create the probe 
spanned over 373kb and were located on chromosome 6 positions 36553478 -  
36699093 and 36751257 -  36978778. In addition to p21, the probe covered the 
chromosome 6 locations for the genes splicing factor, arginine/serine rich 3 (SFRS3), 
located at position 36670138-36679187, serine/threonine kinase 38 (STK38), position 
36569654-36623225 and a gene for a hypothetical protein located at 36773606- 
3680938.
SFRS3 is involved in the tissue-specific differential splicing by mediating the protein- 
protein interaction within the intron during spliceosome assembly (Jumaa et al., 
1997). There are currently no published experiments examining the role of this gene 
in the development of any form of cancer. STK38 regulates cell division and 
morphology. Despite the role of this gene in cell cycle control there is, as yet, only 
one study published which has analysed this gene in cancerous tissues. This study of 
human extramedullary plasmacytomas found a downregulation of STK38 by 1.8 fold 
(Hedvat et a l, 2003). There is no explanation for this downregulation offered but it 
would be interesting to see if this correlates with the downregulation observed for p21 
as it is possible that these decreases in expression are the result of a common cause, 
such as deletion of this region of chromosome 6p21.3.
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6.4.4 Other cancer development candidate genes on chromosome 6
Although tumor necrosis factor-alpha (TNFa) is located outside of the p21 region 
FISH probe, at position 31651k-31654k, it does map to position 6p21.3 and therefore 
any large scale chromosome aberrations which involve p21 may also involve the 
TNFa gene. TNFa is a cytokine involved in the inflammatory process and has 
cytotoxic and anti-tumour activity (Jong et al, 2002). TNFa has been examined in 
colorectal cancers where an allelic imbalance between normal and tumour DNA was 
reported (Honchel et a l, 1996). Since this study, further research has established that 
various alleles of this gene provide decreased risks of colorectal cancer but that 
another allele increases the risk (Jong et al, 2002). Raised serum levels of TNFa have 
been described in colorectal cancer patients with metastatic disease (Ardizzoia et al., 
1992) again indicating this gene has a potential role in colorectal cancer development. 
It is therefore important not to assume that any changes to tissues with gains or losses 
of chromosome 6p21 are entirely as a result of change of copy number of the gene
p21.
Other candidate tumour suppressor genes on chromosome 6 are glutamate receptor- 
ionotropic-kinase 2 and angiopoietin-1 as these are located within a region which has 
shown high levels of loss of heterozygosity (LOH) in ulcerative colitis-associated 
colorectal cancers (Ezaki et a l, 2003). If these genes are involved in ulcerative colitis- 
associated colorectal cancer development it seems unlikely that these relate also to 
sporadic cases as LOH for this region was not detected in these latter carcinomas.
The study of other forms of cancer may bring to light other genes on this chromosome 
which are also important in the development of colorectal cancer. Retinoblastoma is a 
type of paediatric eye tumour initiated by the inactivation of the gene of the same 
name. These tumours have been frequently found to have gains of chromosome 6p22 
and the increased gene expression of E2F3 and DEK correspond to these DNA gains 
(Grasemann et a l, 2005). Allelic loss of regions of 6q have been reported in breast 
cancer patients, with the genes ESR and IGF2R mapping to this region and therefore 
having the potential to be involved in cancer development (Roy et al., 2001). It is
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possible that these genes may also play a role in the development of other cancers, 
including colorectal carcinogenesis.
6.4.5 Alternative pathways of colorectal carcinogenesis
Although the mean values of copy number for both chromosome 6 and p21 provide 
information regarding the general trends seen in these experiments across the tissue 
types examined, the means also mask some of the findings of this study. There was a 
large variation between a number of the patients in some tissue types. As described 
earlier there was little variation in chromosome 6 and p21 region copy number in the 
normal mucosa and also the polyp samples but between the tumour samples and also 
the metastatic lymph node samples there was a much larger variation. For example, 
the tumour from patient 7 had only 34.6% of the tumour cells with 2 copies of 
chromosome 6 and gains in 55.7% of its cells, whereas the tumour from patient 2 had 
81.5% diploid tumour cells and chromosome 6 gains in only 3% of its cells (see Table 
6.2). Patient 13 also had low levels of aneuploidy in all of the samples from normal 
mucosa through to tumour samples, this may indicate that this tumour has arisen from 
a pathway other than the chromosomal instability pathway, perhaps from the 
microsatellite instability pathway.
6.4.6 The application of these FISH experiments for patient screening
Significant changes were detected for both the chromosome 6 and the p21 region 
probes between normal mucosa and polyp tissue and between poly and carcinoma. 
This shows the potential of using this technique to analyse the various colorectal 
tissue samples from patients. By finding out the extent of the chromosome aberrations 
for each patient it may be possible to establish an accurate prognosis and be able to 
make informed decisions as to which treatment may be the most appropriate for each 
individual case. Unfortunately, as with the array experiments, the downside to these 
experiments as a screening technique is the requirement of tissue samples obtained 
from biopsy. This is therefore unlikely to appeal to any of the population that 
currently does not take up the existing colonoscopy screening programme.
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6.4.7 Discussion Summary
These experiments have shown that it is relatively simple and cost effective to 
produce FISH probes for chromosome regions that are not as yet commercially 
available provided that clones are available.
The results also show that as expected the proportion of cells with abnormal 
chromosome 6 and p21 copy numbers increased with progression of carcinogenesis. 
Comparisons of the copy numbers of chromosome 6 centromeric probe and that of the 
p21 region probe indicated there was no significant difference between the copy 
numbers of these regions. This indicates that the changes in p21 region copy number 
are a result of loss and gain of the whole of chromosome 6 rather than deletions and 
translocations of just the p21 region.
One of the more striking observations made from this study was the level of 
statistically significant variation in the FISH results for chromosome 6 copy number 
from samples taken from different regions of the same tumour. This highlights the 
caution required when reporting FISH data from colorectal tumours.
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Chapter 7
General Discussion
7.1 General background to the hypotheses behind this thesis
Despite the advances made in medicine over the last few decades 70% of patients 
with colorectal cancer will die from this disease (Mella et al., 1997). This is often the 
result of patients presenting with late stages of colorectal cancer as the 5 year survival 
of patients with Dukes’ stage A cancer is 95% whereas once the cancer has 
metastasised the survival drops to only 3% (Rhodes, 2000). Current screening 
techniques such as colonoscopy are risky procedures and the uptake in screening the 
over 50s is still relatively low, thought to be because of the invasive nature of the 
procedure. Colonoscopy is also an expensive procedure considered borderline in its 
cost effectiveness as a screening tool (Brenner and Rennert, 2005). Other screening 
tests such as the faecal occult blood test (FOBT) although are non-invasive are also 
not ideal as these produce large numbers of false positive results which can cause 
alarm and unnecessary colonoscopies. Also, more dangerously, FOBTs also produce 
false negative results as not all colorectal cancers bleed (Rennert, 2003). Faecal based 
DNA tests are emerging as a potential new colorectal cancer screening method. PCR 
based studies have been undertaken to examine faecal samples for DNA containing 
mutations in the adenomatous polyposis coli (APC), p53 and K-ras genes (Osborn and 
Ahlquist, 2005). These, and similar, studies have had a sensitivity of around 52% for 
adenocarcinomas and 15% - 40% for adenomas, with a specificity of 95% (Osborn 
and Ahlquist, 2005; Imperiale et al., 2005). These results show a greater sensitivity 
than FOBTs yet maintain a higher specificity. These studies show the potential of 
these faecal DNA based screening methods yet increasing the sensitivity is obviously 
a goal. These tests are also very expensive and therefore are currently not viable for 
population-based screening (Song et a l, 2004). To reduce these costs it would be 
ideal to find smaller regions of DNA containing hotspots which are mutated in a 
larger proportion of both colorectal adenomas and adenocarcinomas. If such a non- 
invasive test for colorectal cancer could be developed then this could be a very
202
influential factor in reducing the mortality of colorectal cancer as patients may be able 
to be detected earlier where the chances of survival are much greater. Such a test can 
only result from a better understanding of early stages of disease.
There is currently limited understanding of what makes some polyps progress to 
malignancy whilst others remain benign. 25% of the western population over 50 years 
of age and 50% of over 75 year olds will develop colorectal polyps (Greenwald et al, 
1995). Around 10% of these over 1cm will become malignant within 10 years 
(Stryker et a l, 1987). As yet it is not known which of these polyps do progress and 
therefore it would be useful to know which of these polyps were likely to develop into 
cancers and would require more follow up treatment than those which were likely to 
remain benign.
7.2 Overall objectives of thesis
The experiments described in this thesis were designed to explore the various genetic 
pathways of colorectal cancer development by studying surgically removed tissue 
from normal colonic mucosa and intermediate stages of carcinogenesis as well as 
cancerous tissue and, where possible, metastatic lymph nodes from each patient. 
These experiments examined the occurrence of mutations in the mitochondrial 
genome, how these related to the microsatellite status of the nuclear genome, the 
alterations in gene expression and larger scale chromosomal alterations examined 
using fluorescent in situ hybridisation (FISH). The emphasis of these experiments was 
to find mutations, gene expression changes or chromosomal aberrations which occur 
early in the development of colorectal cancer that may allow for the detection of these 
tumours whilst the chance of patient survival is still relatively high.
7.3 Summary of the findings of the experiments
The experiments described in this thesis all used the largest number of patients 
samples that could be obtained over a three year period and totalled 128 tissue 
samples from 37 patients. As these samples were collected on a chronological rather 
than selective basis there were some tissue types, such as metastatic lymph nodes, that 
have a lower number of samples than would be ideal. The sample numbers from this
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study are still frequently greater than many previously published studies within the 
same field and the results provide an excellent stimulus for further research areas and 
larger studies.
The experiments in this thesis are summarised here and the main findings feature in 
Figure 7.1 which also indicates the timing these changes occur within the normal to 
adenoma to carcinoma progression. These changes may not though all occur within 
the same pathway. For example, neither patient with nuclear microsatellite instability 
also had mitochondrial DNA mutations and therefore these may be changes that occur 
in separate genetic pathways o f colorectal carcinogenesis.
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Figure 7.1
This diagram summarises the genetic changes found at each stage in the experiments 
described in this thesis. The changes detected in this thesis are in the red boxes and 
indicate the stages o f colorectal carcinogenesis (as seen in the green boxes) at which 
these were identified. The full names for the genes abbreviated above are 
transforming growth factor, beta receptor II (TGFI3RII), phosphatase and tensin 
homolog (PTEN) and p21 is the cyclin-dependent kinase inhibitor 1 A.
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7.3.1 Summary of the mitochondrial DNA study
Previous studies of the mitochondrial genome found mitochondrial DNA (mtDNA) 
mutations present in the lung lavage fluid, urine and saliva of patients with lung, 
bladder and head and neck tumours respectively (Fliss et a l , 2000). As there are more 
copies of mtDNA per cell than the nuclear genome, these mtDNA mutations could be 
more readily detected in the paired bodily fluids than nuclear mutations. MtDNA 
mutations therefore provide potential for finding a mtDNA mutation screen for 
colorectal cancer from the faeces of affected patients. In Chapter 3, I describe how a 
379 base pair section of the displacement loop (D-loop) of the mitochondrial genome 
was amplified and analysed for mutations in 65 samples from 24 patients with
sporadic colorectal cancer. The D-loop is so called at it contains the origin of
replication for both strands of the mitochondrial genome and when replication occurs 
the strands become displaced and effectively single-stranded during this process. This 
helps to contribute to a higher mutation rate in this region than for the rest of the 
mtDNA and is the reason this region of the mitochondrial genome was selected for 
this study.
Tumour specific mtDNA mutations occurred in 9/24 (37.5%) of patients. Recently 
published studies found very similar levels of mutation with 10/25 (40%) and 142/365 
(38.9%) of colorectal samples containing mutations within the D-loop (Lee et al., 
2005; Lievre et al., 2005). In this current study, no mutations were present in any of
the normal, adenoma and hyperplastic polyp samples suggesting that these
mitochondrial mutations occur at a late stage of colorectal cancer progression. This 
was also indicated as in one patient a mutation was found in metastatic 
adenocarcinoma tissue but not in matched adenocarcinoma tissue. As these mutations 
occur at a later stage they may be therefore useful in differentiating between polyps 
which remain begin and those which become cancerous. It is increasingly likely that a 
panel of markers will be required to detect colorectal cancers and this could include 
early biomarkers which may detect all polyps and later markers which may detect 
polyps which are likely to become cancerous. D-loop mutations have been found at 
high levels in a wide range of human cancers including cervical, endometrial, ovarian, 
breast, Oesophageal, bladder, lung and head and neck tumours (Wang et al., 2005; 
Kumimoto et al., 2004; Fliss et a l , 2000). This shows the potential of this region as a
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biomarker for cancer detection. Importantly, in a study of 365 colorectal patients, D- 
loop mutations have been found to correlate with poor prognosis and a factor of 
resistance to fluorouracil-based adjuvant chemotherapy (Lievre et a l , 2005). This 
may be due to this drug interfering with the mitochondrial function and requiring a 
functional respiratory chain to be efficient. It is becoming increasing likely that 
mtDNA determines the cellular response to some cancer therapeutic agents 
(Costantini et a l, 2000; Singh et al, 1999). These factors all add weight to the 
importance of mtDNA mutation detection in cancer patients. It would be interesting to 
be able to follow up the patients examined in this thesis with regard to assessing their 
response to any chemotherapy undertaken as well as assessing if there is any 
correlation with prognosis in this sample group.
The results from this thesis are also important in the context of elucidating more about 
the different mechanisms in the carcinogenesis of colorectal tumours in different 
locations within the colon. Of the samples analysed, mtDNA mutations were found in 
6/12 (50%) rectal tumour samples and both of the sigmoid tumours but none of the 
transverse or caecal tumour samples. This could be a result o f different mechanisms 
causing cancer in the proximal and distal regions of the colon. Dietary factors may 
play a larger role in colorectal cancer development of the distal regions of the 
colorectum where the faeces are more concentrated and the exposure time to the 
mucosa is longer. This appears to correlate as diet is thought to be responsible for 
80% of colorectal cancers (Bingham, 2000) and around 75% of cancers occur in the 
distal regions of the colon (Mella et al., 1997). From this, it is likely that the mtDNA 
mutations observed were a result of exposure to mutagenic chemicals within the 
faeces.
20% of the mutations detected were transversion mutations, characteristic of the result 
of damage due to reactive oxygen species (ROS) which can damage guanine bases 
and cause these to mispair with deoxyadenosine (Grollman and Moriya, 1993). This is 
described in more detail in Chapter 3, section 3.1.1.4 and in Figure 3.4. Levels of 
oxidative damage are higher in the mitochondrion than in the remainder of the cell as 
this is the site of oxidative phosphorylation (OXPHOS) (Richter et a l, 1988). It is 
thought that the ROS lipid peroxidases produced as a result of OXPHOS 
preferentially damage the D-loop of the mitochondrial genome due to this region
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containing the membrane attachment site and is therefore closest to the location of 
oxidative phosphorylation which occurs on the inner mitochondrial membrane 
(Hruszkewycz, 1978). The frequency of transversion mutations in the portion of D- 
loop studied was lower in this study than for other regions of the mitochondrial 
genome (Lewis et a l, 2002) but this was a study of smokers and so these were likely 
to have higher levels of oxidative damage. Other studies of various cancer types have 
found lower levels with between 8-10% of the mutations found were transversion 
mutations (Polyak et a l, 1998; Kumimoto et al, 2004; Fliss et al, 2000).
4/9 (44%) of the patients with mutations had either deletion or insertion mutations 
within a C-tract within the D-loop. This finding was particularly interesting as around 
12% of sporadic colorectal cancers show microsatellite instability (MSI) in the 
nuclear genome (Ionov et al., 1993). I then designed further experiments to establish 
whether there was a connection between nuclear MSI (nMSI) and mitochondrial MSI 
(mtMSI), described in Chapter 4 and below in Section 7.3.3. Due to the mtDNA 
mutations being predominantly in microsatellites with the mtDNA, these results also 
may add insight into the mismatch repair mechanisms of the mitochondrial genome.
7.3.2 Nuclear microsatellite instability discussion summary
To try to establish any connection between mtMSI and nMSI I have assessed all the 
samples analysed in Chapter 3 for nMSI, this research is the content of Chapter 4. The 
well documented nMSI markers located within the genes BAX, transforming growth 
factor-p receptor II (TGFpRII), human Saccharomyces cerevisiae mutS homolog 3 
(hMSH3) and insulin-like growth factor II receptor gene (IGFIIR) were examined 
(Souza et al., 1996; Rampino et al., 1997; Ikeda et al., 1998; Molenaar et al., 1998). 
None of the samples showed MSI in the BAX, IGFIIR or hMSH3 microsatellites. 
2/24 patients had mutations within the A10 microsatellite in the TGFI3RII gene. This 
gene is mutated in between 90% - 100% of MSI colorectal cancers (Parsons et a l, 
1995; Souza et a l, 1996) and has not been reported to be mutated in any 
microsatellite stable colorectal cancers. This result was therefore interpreted that these 
2 patients were MSI. Although it is possible that there were false negative results this 
is unlikely as TGF13RII alone is a highly sensitive marker of MSI (Parsons et a l, 
1995; Souza et a l, 1996) and in combination with the BAX, IGFIIR or hMSH3
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markers it would be very unlikely that any MSI positive tumours were not detected as 
such. The overall level of MSI in this study is 2/24 (8.3%), this level correlates well 
with previous studies. The level is at the lower end of previously recorded MSI levels 
in sporadic colorectal cancer. This may be due to the high proportion of patients 
within the sample group with distal colorectal cancers; as MSI tumours tend to be 
located in the proximal regions of the colorectum. In this study proximal tumours 
were shown to more frequently contain microsatellite mutations with 1/6 (16.7%) 
being MSI as opposed to 1/18 (5.6%) of the distal tumours. This is though, based on 
only 2 MSI+ samples and therefore can only be considered an observation warranting 
further investigation rather than a result in itself.
7.3.3 Is there a correlation between mtMSI and nMSI?
None of the 4 patients with mtMSI had nMSI mutations and although there were only 
2 patients showing nMSI this data suggests there is no link between mtMSI and nMSI 
and these occur through different pathways. The 2 patients with nuclear MSI had no 
mtMSI. The tumour locations of the mtMSI+ samples were all distal but 93% of 
nMSI+ sporadic tumours occur in the proximal colon (Thibodeau et al., 1998; Ward 
et al., 2001). This indicates that the nuclear mismatch repair mechanism may be 
separate to the repair system responsible for maintaining these repeat sequences in the 
mitochondrial genome. However, the mismatch repair (MMR) protein human 
Saccharomyces cerevisiae mutS homolog 1 (hMSHl) has been found to be involved 
in the maintenance of the mitochondrial genome stability (Mookeijee et a l, 2005). 
This may indicate that the MMR system in the nuclear and mitochondrial genomes 
have at least some common proteins.
7.3.4 Array Discussion summary
The development of array technology has made it possible to examine the levels of 
gene expression of many genes in one experiment. This technique was appropriate for 
this thesis as many of the polyp samples were extremely small and this approach can 
cover many genes at once using minimal quantities of RNA. Although arrays are 
available which cover several thousand genes, these are very expensive and require 
specialist equipment and expertise to extract the data from these experiments (Cheung
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et al., 1999). I therefore chose to use a membrane cDNA array known as the GEArray 
human cancer/tumour suppressor array from SuperArray (USA) which focused on 23 
tumour suppressor genes. These arrays were a useful technique for the rapid screening 
of gene expression changes between various stages within carcinogenesis. The array 
results were more consistent for the genes expressed at higher levels than those 
expressed at lower levels. It was difficult to obtain reproducible results for the genes 
expressed at low levels as the background noise was often higher than the readings for 
these genes. Despite this, cDNA arrays are ideal preliminary scanning tools especially 
where tissue samples are small, yielding only low quantities of RNA.
The cDNA arrays detected a significant decrease in the expression of the tumour 
suppressor genes transforming growth factor, beta receptor II (TGF6RII) and 
transforming growth factor, beta receptor I (TGFBRI) in 60% and 40% respectively of 
the patients analysed. Phosphatase and tensin homolog (PTEN) was also significantly 
down-regulated in the polyp samples of 60% of the patients studied. Down-regulation 
of PTEN gene expression is thought to promote colorectal cancer progression by 
activating nuclear factor-KB and p-catenin causing deregulated growth and resistance 
to apoptosis (Agarwal et al., 2005).
The most notable detected change in expression was of the cyclin-dependant kinase 
inhibitor 1A known as p21 which was decreased at the polyp stage of tumour 
development in all 5 patients studied regardless of tumour location, patient sex or age. 
This gene may therefore be critical in determining progression of a polyp into a 
carcinoma. p21 expression levels may also indicate which tumours may respond 
better to certain chemotherapeutic agents and also be an indicator of prognosis in 
colorectal cancer patients. It has been reported that decreased p21 expression is linked 
with poor prognosis (Zirbes et al., 2000). As this gene was down-regulated in all the 
patients analysed, either all 5 patients had a poor prognosis or perhaps there is a scale 
where those patients with a larger fold-decrease in p21 expression have a poorer 
prognosis than those with only a small decrease in p21 expression. It would be 
interesting to analyse more patients to see if this study is truly representative of a 
wider population. To try to understand more about the mechanism behind this gene 
expression decrease of p21, FISH was undertaken and these experiments are 
described in Chapter 6.
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7.3.5 Fluorescent in situ hybridisation discussion summary
To further explore the gene expression findings of Chapter 5, where the kinase 
inhibitor p21 was found down-regulated in the polyp tissue of all 5 patients examined, 
FISH analysis was undertaken to determine if these gene expression changes were the 
result of gross chromosomal alterations. A probe for the centromeric region of 
chromosome 6, on which the p21 gene is located, was used to detect numerical 
aberrations and a probe specifically for the p21 region was developed to detect 
aberrations at a higher resolution. It was simple and cost effective to produce FISH 
probes for chromosome regions that are not as yet commercially available by labeling 
clones for the chromosome regions. As expected, due to the hostile microenvironment 
within a tumour and the accumulation of genetic damage, the FISH results also show 
that the proportion of cells with abnormal chromosome 6 and p21 copy numbers 
increased with progression of carcinogenesis.
As well as varying from patient to patient, the proportion of cells with abnormal copy 
numbers of both chromosome 6 and the p21 region varied significantly even within 
the same tumour of 50% of the samples studied. This lack of uniformity within solid 
tumours highlights variability and therefore the need for multiple sampling within 
individual tumours. These findings of such variation within a single tumour may 
result in different areas of a single cancerous growth responding differently to 
treatments such as chemotherapy. It would be interesting to further investigate this 
aspect of the results, possibly by establishing cell lines from different areas from 
within a single tumour and exposing these to various chemotherapeutic agents to 
establish any differences in reaction to these chemicals.
1 of the 5 patients analysed using the p21 region probe had a significant difference 
between the chromosome 6 and p21 region number. This patient showed deletions of 
the p21 region in the polyp tissue and an increase in the carcinoma tissue, both in 
relation to the number of copies of chromosome 6. This shows that deletions and 
rearrangements of chromosome arms as well as gross changes in chromosome number 
occurred in this patient.
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The results of this FISH study have shown some interesting findings and this data 
provides an incentive to expand this study to also examine different regions of some 
of the larger polyps as well as the continuing to examine these regional differences 
found within carcinomas. It would also be interesting to examine other chromosomes 
to gauge the overall level of aneuploidy in the cells and how this compares to the 
levels of chromosome 6 alterations. More metastatic lymph nodes need to be analysed 
using FISH for chromosome 6 and also for the p21 region probe.
7.3.6 Correlation between Fluorescent in situ hybridisation results and gene 
expression data
Even at the polyp stage there was a significant reduction in the number of cells with 
normal copy numbers of both chromosome 6 and the p21 region. This may be a 
contributing factor to the reduction of p21 gene expression observed in Chapter 5, 
especially in polyps where those cells that did not have the normal number of 
chromosome 6 and p21 region mainly had losses (74.5% of aneuploid cells) rather 
than gains (25.5%).
In the tumour samples analysed, from both central and peripheral regions, the 
aneuploid cells had a fairly even proportion of losses and gains. Although from a 
smaller sample number of 4 lymph nodes, the trend observed in the aneuploid cells 
from these metastatic samples was a majority of gains of chromosome 6 with 63.0% 
showing gains and of these 41.0% had gains of at least 2 additional copies of 
chromosome 6. Unfortunately no lymph nodes were examined for gene expression 
alterations in Chapter 5 due to low RNA yields but it would be interesting to see if 
this overall increase in chromosome 6 copy number correlates with an increase in p21 
expression.
By comparing the percentage of cells in each sample with chromosome 6 and p21 
region losses with the fold decrease it appears that there is little correlation between 
these figures. For example, patient 20 (array 5) has 13.5% of polyp cells and 24.1% of 
tumour cells with 1 copy of chromosome 6. If the reduction in p21 gene expression 
was thought to be a result of these chromosome aberrations, then it would be expected 
that the fold decrease in expression would be greater for the tumour than the polyp.
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This was not the case with both these tissue samples exhibiting extremely similar p21 
expression levels with fold decreases in comparison to normal colonic mucosa of - 
3.58 for the polyp and -3.38 for the tumour. Whilst patient 4 (array 1) had the highest 
percentage of cells with 1 copy of chromosome 6 in the polyp sample along with the 
greatest fold-decrease in expression, the reverse was true for patient 10 (array 3). This 
lack of correlation indicates that the mechanism behind the decreases in p21 
expression seen is not a result of chromosomal aberrations for this chromosome or 
region.
Other possible mechanisms which could have caused the decrease in p21 expression 
observed in Chapter 5 include mutation or hypermethylation of the gene or promoter 
region or to any other the genes involved within this complex pathway. For example, 
a reduction in expression of functional p53 could cause a reduction in p21 expression; 
however p53 is reported to be a late occurring change in colorectal cancer.
It would be particularly interesting to study metastatic lymph nodes using the p21 
region probe as one previous study of secondary liver tumours has found chromosome 
6p gains to be more common in colorectal cancer metastases than in primary 
colorectal carcinomas (Parada et al., 1999). It is therefore thought that there are genes 
of importance in the metastatic process of colorectal cancer in this region. The tumour 
suppressor gene p21 has been reported to be involved early in the development of 
colorectal cancer and so it is likely that there are further genes which have later roles 
in this pathway which are also situated on chromosome 6p.
To further this study it would be interesting to analyse all the samples using the p21 
probe for the patients that were examined with the chromosome 6 probe. This would 
allow a more accurate assessment of whether translocations or deletions of the p21 
region did play a part in the mechanism behind the decrease in p21 expression levels 
observed in Chapter 5. This would also determine whether the correlation between 
chromosome 6 centromeric and p21 region aberration levels is representative of the 
whole sample group.
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7.4 Discussion of techniques applied in this thesis
A wide range of techniques were applied throughout these experiments covering 
many aspects of genetics from mutation research to cytogenetics. Mutations were 
detected by single-stranded conformation polymorphism (SSCP), fragment analysis 
and sequencing. Whilst sequencing gave more information about the mutations 
detected by both SSCP and fragment analysis, both of these latter techniques were 
proven to be both sensitive and accurate in detecting these mutations and could be 
used for rapid cost effective screening where sequencing all samples is not a viable 
option. Fragment analysis gave neither false positive or negative results and was 
simple to carry out. SSCP also gave no false positive results but one of the mutations 
was not detected using this technique. SSCP does have the advantage that it requires 
no expensive or specialist laboratory equipment or consumables. Sequencing not only 
confirmed the results of these techniques but also provided specific information 
regarding the nature of the mutations and therefore enables the elucidation of the 
mechanism behind these mutations. For example, from sequencing data it was 
possible to determine that the mutations detected in the mitochondrial genome were 
predominantly insertions or deletions in repeat base sequences as a result of 
unrepaired strand slippage.
cDNA arrays were extremely useful for scanning across many genes to detect gene 
expression alterations between different tissue samples. As these experiments often 
relied on small quantities of RNA due to the small size of the tissue sample, 
particularly for polyps, it was useful to be able to detect the changes in 23 tumour 
suppressor genes in one experiment. These arrays were also useful to use in smaller 
laboratories which do not have specialist glass chip array readers or the bioinformatics 
experience required to mine the vast amount of data produced from the arrays which 
have several hundred genes. Despite these benefits of smaller cDNA arrays, there was 
a problem with contaminated arrays being supplied by the manufacturer. Also, for 
genes which were only expressed at low levels, the results were very variable as the 
background noise levels were too high to obtain significant results and therefore this 
was not a suitable technique for analysing these genes. Nevertheless, cDNA 
membrane arrays are an ideal means of screening across large numbers of genes at 
once so that it can be established which genes are expressed at these levels and may
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require further analysis by methods such as reverse transcription PCR and quantative 
real time PCR (Q-RT-PCR). cDNA arrays also allow observations to be made to the 
patterns of expression seen in groups of genes of similar function; for example, a 
pattern was observed in the patients studied that the expression of these genes was 
generally down-regulated from normal mucosa to polyp followed by a general pattern 
of up-regulation from polyp to adenocarcinoma.
Fluorescent in-situ hybridisation (FISH) analysis was used to follow up the results 
from the gene expression studies. FISH allowed the analysis of individual cells from 
each tissue sample. This was carried out using a commercially available centromeric 
probe to determine chromosome 6 copy number. To discover whether there were any 
chromosomal alterations at a micro level, I developed a probe for the p21 region. The 
probe bound exclusively to the p21 region and was clear and easy to score. This was a 
straight forward and cost effective technique which can be used to make FISH probes 
for any region for which clones are available.
By taking samples of mucosa close to and distant from the tumour it was possible in 
all o f these experiments to assess for any differences that may be localised to around 
the tumour site. There were no significant differences found between these 2 normal 
mucosa samples and this result can be used as justification for using only one normal 
mucosa sample in future experiments. In contrast, there were large significant 
differences found in the FISH study between the central and peripheral tumour 
samples from within a single neoplasm. This highlights the need for multiple 
sampling sites within a tumour and may explain the differences seen not only between 
various studies and patients but also from tumours from the same patient and various 
biopsies of the same tumour.
7.5 Future work
One of the most time consuming aspects of the research described in this thesis was 
the collection and processing of surgical samples. Over several months I built up a 
large collection of colorectal tissues, RNA, DNA and cell brushings which can be 
used for future experiments and therefore vastly reduce the time required for further 
studies.
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As well as continuing to build on the sample numbers, especially of polyps, metastatic 
lymph nodes and secondary tumours, for all of the studies described, it would be 
interesting, where necessary, to confirm some of the results already observed using 
additional techniques. For example, Q-RT-PCR could be used to confirm the gene 
expression changes seen in Chapter 5. This could give accurate measures of gene 
expression change not just for those genes found significantly down-regulated in this 
study, such as p21 and PTEN, but also for those genes such as Wilms tumor 1 (WT1), 
that had large fold differences but were not significant due to the low initial levels of 
gene expression. Also, it would be interesting to use immunohistochemistry to 
confirm the MSI status of those patients found with TGFBRII microsatellite mutations 
by staining for the mismatch repair genes hMSH2 and hMLHl.
Given more time it would be possible to follow up these patients to see if any of the 
findings in the experiments described in this thesis correlate with patient prognosis 
and survival. It would be particularly stimulating to continue the research in to the 
mitochondrial genome. Recently, a correlation of D-loop mutations with poor 
prognosis and resistance to fluorouracil chemotherapeutic drugs has been found, 
(Leivre et al., 2005), and it would be interesting to establish whether this is also true 
for the patients studied in this thesis. Mutations in the coding region of the mtDNA 
have recently been found to promote cancer by preventing apoptosis (Shidara et al., 
2005). It would be interesting to see if the patients with D-loop mutations also had 
these mutations in the coding regions where mutations have a clear cancer causative 
affect.
It would also be interesting to know more about the lifestyles of these patients for 
factors such as diet, exercise levels, whether they smoke and if so how much as well 
as alcohol consumption. Although these are all well documented risk factors for 
colorectal cancer it would be interesting to see if some factors affect particular 
pathways more than others. This would need a large sample size due to the number of 
variables within each person’s lifestyle but I believe this may provide more 
information behind the mechanisms of each individual pathway.
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7.6 Final Conclusions
❖ Mitochondrial DNA (mtDNA) mutations have been found to be frequent in 
colorectal tumours and occur during a late stage of carcinogenesis
❖ Transforming growth factor, beta receptor II (TGFI3RII) is an excellent marker 
for nuclear microsatellite instability and levels of sporadic mismatch repair 
deficient tumours within this examined South Wales population are in line 
with those reported in previous studies for the rest of the Western World.
❖ Neither patient with nuclear microsatellite instability had mtDNA mutations. 
This may indicate mtDNA has an independent repair mechanism however 
further studies are needed to confirm this.
❖ Phosphatase and tensin homolog (PTEN) and TGF13RII are down-regulated at 
the polyp stage in 3/5 patients analysed suggesting an early role in the 
development of at least a subset of colorectal cancers
♦♦♦ The cyclin-dependent kinase inhibitor p21 was down-regulated in the polyps 
of all the patients analysed, this gene may be key to the early stage 
development of the majority, if not all, of colorectal cancers
♦> Fluorescent in situ hybridisation (FISH) probes can be relatively easily 
developed at little cost for regions of the genome available from clone libraries
❖ Chromosome 6 aberrations were detected in increasing frequency in colorectal 
tissue samples with increasingly developed tumours.
♦> Chromosome 6 and p21 region aberrations are unlikely to be responsible for 
the down-regulation observed of the tumour suppressor p21
❖ The large variation within a single tumour observed especially from the FISH 
studies show how essential it is that research and diagnostic tests are based on 
either large portions of a tumour or from multiple smaller biopsies.
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Appendix I
Fragment analysis data table
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